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THE PROSTATE
The prostate is a secretory gland that is part of the male reproductive system. It is located 
underneath the bladder and compromises the proximal part of the urethra. Ventrally it is 
attached to the pelvic bone with various ligaments. Dorsally it has a close relation with 
the rectum, which enables medical doctors to exam the prostate digitally via the rectum.
The main function of the prostate is production of fluid, contributing to approx. 30% 
volume of semen. This prostatic fluid contributes to the alkalinity of semen to neutral-
ize the acidity of the vaginal tract, prolonging the lifespan of spermatozoa.1 Epithelial 
cells also produce proteolytic enzymes such as prostate-specific antigen (PSA), which 
contributes in maintaining liquidity and mobility of spermatozoa after ejaculation.
Normally, the prostate has a size between 15-25 cc but with age the prostate can grow 
benignly.2 Four different zones within the prostate can be identified.3 The peripheral 
zone can take up to 70% volume (in young men), the central zone 25%, the transition 
zone 5% and the anterior fibro-muscular zone also approx. 5%. Most of the prostate 
cancers (70-80%) occur in the peripheral zone.
PROSTATE CANCER
In the Netherlands, the yearly incidence of prostate cancer (PCa) is approx. 11,0004 
and therefore, the second most common cancer among men after non-melanoma skin 
cancer. Each year 2800 men die because of PCa. In time, tumor cells can develop in the 
ageing prostate caused by accumulation of mutations in their DNA. These malignant 
cells have the potential to spread and form tumors throughout the body (metastases) 
and eventually lead to incurable disease.
In order to diagnose PCa early and prevent progression of the cancer, biomarkers are 
needed. Luckily, PCa is one of the few solid tumors with a clinically useful biomarker for 
both diagnostics and follow-up after treatment. This protein, PSA, has been considered 
the “gold standard” for the detection of PCa.5 Although PSA has acceptable sensitivity, it 
lacks specificity. Furthermore, PSA-based screening leads to a high risk of overdiagnosis 
and overtreatment based on findings on complementary diagnostic prostate biopsies.6,7 
Therefore, new molecular markers for PCa are needed.
TUMOR MARKERS
A tumor marker in a biomedical setting can be defined as ‘a biological object present 
in human tissue and/or body fluids that is capable to differentiate between normal and 
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abnormal biological conditions’.8 The National Institute of Health added that it should 
be measured objectively and is evaluated as an indicator of pathogenic processes or 
biological responses to a therapeutic intervention. With this definition a wide range of 
characteristics can be used as a tumor marker, such as easily observable skin lesions, 
MRI-scans, or more inconspicuous variables such as proteins or RNA present in tissue, 
serum or urine. Nowadays, the term tumor marker is inextricably linked to molecular 
markers.
So far, different kinds of tumor markers have proven to be a useful diagnostic or prog-
nostic tool for medical doctors when assessing a certain disease, especially within the 
field of oncology. The presence or an elevation of a marker could indicate the existence 
of a malignant tumor. Furthermore, it could also have the ability to predict disease 
development or outcome upon treatment. Also in PCa, tumor markers have been widely 
used in daily clinical practice. This chapter will discuss multiple types of tumor markers 
for the diagnosis and prognosis of prostate cancer and will review a selection of markers 
that have been validated to some extend or are of high interest.
DIFFERENT TYPES OF MARKERS
Tumor markers can be classified into several categories with their own specific purpose. 
The different kinds of markers can describe the chance of getting a disease (risk marker), 
the presence of disease (diagnostic marker, early detection or screening marker), how 
the course of the disease will be (prognostic marker), to estimate the chance of success 
of a certain treatment (predictive marker).9 Furthermore, markers can also be applied to 
observe therapy efficacy during or after treatment (monitoring marker).
t 8IFOVJOHBNBSLFSGSSJLBFNFOUUIFEJFBFJOUFU	DMJOJDBMM
QSFFOUS
cannot be detected with conventional techniques. Such a marker would be mainly 
suitable for life-threatening diseases that are typically diagnosed too late. In addition, 
risk markers can be implemented to identify a subpopulation for regular checkup or 
screening. In recent years, much research has been dedicated to the identification of 
genomic changes using genome-wide association studies (GWAS) to identify single 
nucleotide polymorphisms (SNPs) associated with the development of a disease.10 
For PCa, it is evident that many of such SNPs are linked to disease development, 
although none of them individually have a very strong correlation.11
t %JBHOUJDNBSLFS IBWF UIF BCJMJU U EFUFSNJOF UIF QSFFODF S UQF GNBMJH-
nancy. Such a marker is often used in immunohistochemically examination of tissue 
specimens or in specific protein/mRNA analysis of patient-derived body fluids.
t 1SHOUJDNBSLFS CFDNF WFS VFGVM XIFO JU J QJCMF U USBUJG QBUJFOU JO
groups that have different outcomes. Based on this stratification, the physician can 
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choose a specific therapeutic option in order to individualize treatment. Next to 
the choice of treatment, if aggressive subtypes can be identified, treatment can be 
initiated earlier.12 One of the best prognostic markers for prostate cancer is Gleason 
score, a representation of the organization of tumor glandular architecture.13
t 1SFEJDUJWFNBSLFSBSFVFEUGSFUFMMUIFSFQOJWFOFUSVUDNFGBQFDJöD
treatment. Although some markers have been described that predict the efficacy of 
hormone, radiation or chemotherapy, these markers are not yet utilized in clinical 
practice.
t .OJUSJOHNBSLFSBSFNFBVSFECFGSFEVSJOHBOEBGUFSUSFBUNFOUUEFUFSNJOF
effectiveness of therapy. Prostate specific antigen (PSA) is a highly effective and es-
tablished monitoring marker for efficacy of radical prostatectomy, hormone therapy 
and/or radiotherapy.14
The occurrence, elevation or modification of tumor markers can be caused by several 
biological processes (Table 1). Some endogenous cellular products are produced and 
shed at a greater rate by the abnormal cancerous cells. Also, these markers can be 
released differently due to a higher apoptosis and necrosis rate in cancer. Furthermore, 
markers can reveal themselves when the environment of the cells becomes aberrant. An 
example is PSA, where higher levels in serum are be detected when the blood-prostate 
barrier is affected. In addition, products of newly created genes in cancerous cells, such 
as the TMPRSS2:ERG fusion transcript, are applicable as highly specific markers. Regard-
ing prostate cancer, DNA (genomics), mRNA (transcriptomics), proteins (proteomics) 
and metabolites (metabolomics) have been the biochemical analytes investigated that 
could contribute to a better and more precise diagnosis and prognosis.
BIOLOGICAL MATERIALS FOR TUMOR MARKER ANALYSIS
When searching for new tumor markers it is important to choose which biological 
material to explore. The most logical material is the one for which eventually a clinical 
applicable assay can be generated.15 Therefore, samples derived with minimally-invasive 
techniques and those easily obtainable, such as blood or urine, are the most obvious. 
Table 1. Expression of different kind of markers in healthy tissue as compared to malignant tissue
Healthy tissue Malignant tissue Type of dysregulation Example marker
+ +++ Upregulated in cancer AMACR/PCA3
+ + New distribution due to cancer PSA
- + Mutation, Oncogene TMPRSS2:ERG
+ - Mutation, Tumor suppressor PTEN
+++ + Downregulated in cancer GSTP1
12 Chapter 1
Blood is widely used, mainly because of the traditional availability and of the idea that 
biochemical analytes in plasma might provide important insight in disease specific 
characteristics. Unfortunately, discovery of tissue or cancer specific marker is hampered 
by the abundances of all kinds of different analytes. The abundant proteins are identified 
preferentially and are generally not useful cancer markers. Probably the most interesting 
new tumor markers are present in the low abundance range. Unfortunately, for certain 
technologies such as mass spectrometry, the high abundant analytes overshadow the 
detection of the low abundant ones. This problem is in essence the so called ‘dynamic 
range problem’. As an example, the proteome in blood has shown to consist of 3500 
proteins so far, but many more have to be identified.16 The 22 most abundant proteins 
account for 99% of the measured proteins, so the search for new and low abundant 
tumor markers is like searching for a ‘needle in a haystack’.17
Another issue that arises when using materials such as blood is the origin of the 
marker. Like most clinically applied cancer markers, it is expected that the disease-
specific markers are derived from the cancer cells or organ of origin. When candidate 
tumor markers are identified in serum, it is difficult to determine from which tissue these 
markers originate. It becomes slightly less complicated with the use of urine or prostatic 
fluids/seminal fluids. These materials are more specifically related to the prostate and 
the abundance and variety of analytes is generally much less.
IDENTIFICATION AND VALIDATION OF NEW MARKERS
Discovery phase
Discovery of new markers is often an open and unselective search by which the dif-
ferential expression of specific biochemical analytes between states is first defined.15 
If one wants to identify a specific marker, optionally, two separate states have to be 
compared without the influence of confounding factors (Figure 1). This comparison and 
eventual identification are typically performed with state-of-the-art technologies such 
as mass spectrometry or microarray analysis by using a small training set of samples. 
Drawbacks from this phase are the costs and the limited number of samples that can be 
analyzed. Because of the limited number of samples and the large number of analytes 
tested, many top candidate markers will be false positives and some genuine markers 
will not be significantly different (false negative).15 With statistical calculations for false 
discovery rate and multiple testing corrections, these false positively identified analytes 
can be trimmed down. Eventually, after a list of potential tumor markers is generated, a 
more focused approach has to be taken where the most promising candidate markers 
must be validated.
General introduction 13
Fi
gu
re
 1
. 
Id
en
tifi
 c
at
io
n 
an
d 
va
lid
at
io
n 
of
 n
ew
 m
ar
ke
rs
14 Chapter 1
Validation phase
The validation phase verifies the differential expression between samples and will 
give the opportunity to test the candidate tumor marker in an independent cohort 
(validation set). For this phase an assay has to be developed that is capable of accurately 
measuring the candidate markers. The assay that is preferentially used is based on the 
specific analyte that has been discovered. For example, if a specific protein is identified, 
an ELISA (enzyme-linked immunosorbent assay) is typically a very sensitive and reliable 
test. When RNA is the marker of interest, most likely the assay that will be used is RT-qPCR 
(reverse transcriptase quantitative polymerase chain reaction). Besides these already 
established and widely used tests, novel techniques can be developed in order to more 
easily or more accurately detect the new tumor markers.18,19 Finally, with a specific and 
reliable test available, it has to be administered to larger study cohorts in order to test 
the most promising candidate markers. This cohort has to contain specific variables in 
order to evaluate its restrictions and indicate the exact disease characteristics for which 
this candidate marker is most suitable. These experiments aim at confirming the previ-
ously discovered markers and will show their sensitivity and specificity for the particular 
disease it has been identified for. Eventually, from this validation step, only a few promis-
ing candidate tumor markers submerge. The ones that show a positive correlation with 
disease specific characteristics will be used for the development of a clinical applicable 
assay. Normally, the whole process extends over a time line of at least 5 years, where 
initially 100-1000 analytes are identified in the discovery phase. Unfortunately, only very 
few, if any, will survive the validation phase and reach the clinical implementation phase.
Implementation phase
In this phase the main focus is the further development of a clinical applicable assay 
that can be used to further validate and implement the tumor marker. With the assay 
development it is important to establish reproducibility across independent cohorts 
and laboratories.20 By using this test, its operating characteristics are evaluated and a 
certain clinical cut-off value further tested and adjusted in multi-center prospective 
studies and compared to current practice. Only after this last phase a specific test will 
gain wide acceptance and eventually be applied in a clinical setting.
OBJECTIVE OF THIS THESIS
Since current molecular biomarkers lack specificity or sensitivity for PCa diagnostics, 
new and better markers need to be identified. The main objective of this thesis is the 
identification of novel candidate biomarkers for PCa by profiling extracellular vesicles.
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Chapter 2 provides an overview of known and (clinically) used PCa markers. It de-
scribes the clinical use of PSA, its isoforms and a range of other markers. Because the 
search for new and better biomarkers is hampered by the dynamic range problem, sev-
eral techniques can be applied for selection and enrichment. One of those techniques 
is the isolation of extracellular vesicles. These vesicles contain a selection of proteins 
and/or RNAs that reflect cellular conditions from the cell they were shed. Chapter 3 
introduces extracellular vesicles and explains it potential as a biomarker ‘treasure chest’. 
It also gives an update on the work that has already been performed regarding these 
vesicles within the field of Urology when this thesis was initiated.
In chapter 4 we address the discovery phase of biomarker detection by proteome 
profiling of extracellular vesicles. In collaboration with the Environmental Molecular Sci-
ence Laboratory (EMSL), Richland, WA, USA, we aimed to identify proteins from vesicles 
released by prostate cancer cells and immortal normal prostate cells. Using mass spec-
trometry and various techniques to verify our findings, we identified a series of proteins 
that were more abundant in vesicles from cancer cells as compared to normal prostate 
epithelial cells.
Our second objective was the validation of novel candidate biomarkers for prostate 
cancer on patient tissue samples. In chapter 5 and chapter 6 we describe the use of 
tissue mass spectrometry and an extensive tissue microarray to validate a few markers 
of interest. With these techniques we explored the diagnostic and prognostic potential 
of selected candidate biomarkers for PCa.
Unfortunately, current techniques for isolation and characterization of extracellular 
vesicles are labor intensive and unsuitable for daily clinical practice. Therefore, our third 
objective compromises the development of a clinically usable (high-throughput) assay 
to analyze extracellular vesicles from patient samples (urine or serum). In chapter 7 we 
describe the results of our collaboration with the department of Biotechnology of the 
University of Turku, Finland. Together we developed a fast, highly sensitive and reliable 
immunoassay (TR-FIA) that can be used for clinical implementation.
Finally, in part 3 all findings are summarized, a general discussion is provided and 
future perspectives recited.
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Novel tumor markers for prostate cancer are still needed to improve the ability to detect 
prostate cancer, predict prostate cancer related morbidity and mortality and monitor 
response to treatment. Current markers used in research and even in the clinic remain 
controversial (Table 1).1 The most widely applied biomarker in prostate cancer is PSA. 
Because of its limitations, multiple new markers have been evaluated to compensate for 
these limitations. Unfortunately many of these markers have not made it into the clinic, 
which shows that identification of better markers remains a challenge.2
Table 1. Current tumor markers for prostate cancer
Marker Biological function Biochemical
analyte
Marker ability
PSA Prostate specific antigen Serine protease Protein Screening/
Diagnosis/Prognosis
%fPSA Percentage free PSA Protein Diagnosis/prognosis
PSAD PSA Density Protein Diagnosis/prognosis
PSAV PSA Velocity Protein Diagnosis/prognosis
[-7],[-5],[-4],[2] 
ProPSA
PSA isoforms Protein Diagnosis
hK2/KLK2 Human Kallikrein 2 Peptidase, cleaving proPSA 
to mature PSA
Protein Diagnosis
PCA3 Prostate cancer antigen Non-coding mRNA without a 
functional protein
RNA Diagnosis
ETS E twenty six gene family Chromosomal 
rearrangement without a 
function
DNA Prognosis
TMPRSS2:ERG Trans membrane protein 
serine 2 (TMPRSS2) and 
ETS related gene (ERG)
DNA
Protein
(ERG)
Prognosis
AMACR Alpha-methylacyl 
coenzyme A racemase
Metabolization of fatty acids 
and bile acid biosynthesis
RNA
Protein
Diagnosis/prognosis
GSTP1 Glutathione S-transferase 
pi 1 (methylated)
Detoxification of 
carcinogens
DNA Diagnosis/prognosis
PSMA (FOLH1) Prostate specific 
membrane antigen
Peptidase, hydrolyzing 
peptides in prostatic fluids
RNA
Protein
Prognosis
PSCA Prostate stem cell antigen Membrane based 
glycoprotein
RNA
Protein
Diagnosis/prognosis
CgA Chromogranin A Proteolytic protein Protein Prognosis
B7-H3 Transmembrane protein 
family B7, member H3
Regulation of T-lymphocytes Protein Prognosis
CAV1 Caveolin-1 Molecular transport, 
cell adhesion and signal 
transduction
Protein Diagnosis/prognosis
GOLPH2 Golgi phosphoprotein 2 Sorting and modification of 
proteins through the Golgi 
apparatus
RNA
Protein
Diagnosis
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PSA
Since its discovery in 1970, PSA has revolutionized the diagnosis and management of 
prostate cancer.1 Subsequently, after its application in urological practice it has proven 
to be a valuable tool for (early) detection, staging and monitoring of men diagnosed with 
prostate cancer (Figure 1A).3,4 Especially the use of PSA as a screening tool has increased 
the identification of prostate cancers and also improved curability with treatment.
PSA, also known as KLK3 or hK3, is a member of the human Kallikrein family. This gene 
family consists of 15 members and is described with a distinct nomenclature.5 The first 
three members (hK1, hK2 and hK3) encode for serine proteases that have diverse physi-
ological functions. Expression of PSA and some other Kallikrein members is androgen 
regulated. PSA protein has a half-life of 2-3 days and is secreted by prostatic epithelial 
cells into seminal fluid. Most likely through tissue leakage, PSA can be found in serum, 
but with a concentration of about 106 times less as compared to seminal fluid.
Initially, PSA is produced as a 261 amino acids preproenzym with a 17 amino acid signal 
peptide that is removed during synthesis (Figure 1B).6 After this step, proPSA is formed 
which contains 244 amino acids, from which subsequently 7 amino acids are cleaved so it 
is processed to PSA that contains 237 amino acids. When shed in serum, PSA is unbound 
(free PSA or fPSA, 5-35%) or bound (complexed PSA or cPSA) to complexes with the anti-
proteases α(alpha)1-antichemotrypsin (PSA-ACT), α(alpha)2-macroglobuline (PSA-A2M) 
or α(alpha)1-protease inhibitor (PSA-API) which inactivate its function.7 In seminal fluids 
it functions as a protease that liquefies semen by interacting with semenogelin and fir-
bronectin.8,9 Although PSA is highly specific for prostate epithelial cells, in much smaller 
concentration it can be measured in malignant breast cells, salivary gland, bowel, other 
urological tissues and renal carcinoma cells.10-12 Nevertheless for practical and clinical 
purposes PSA is organ specific because after removal of all prostate tissue PSA values 
become immeasurable in serum. Although PSA is organ specific, it cannot be ascribed 
Table 1. Current tumor markers for prostate cancer (continued)
Marker Biological function Biochemical
analyte
Marker ability
CRISP3 Cysteine-rich secretory 
protein 3
Unknown RNA
Protein
Diagnosis/Prognosis
Sarcosine Metabolite produced 
after enzymatic transfer 
of a methyl group from 
S-adenosylmethionine to 
glycine
Protein
(metabolite)
Prognosis
Exosomes Nano-sized vesicles, 100 
nm in diameter containing 
RNAs and proteins
Intercellular communication, 
part of degradation pathway
RNAs and
Proteins
Diagnosis/prognosis
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as prostate cancer specifi c because other urological conditions such as benign prostate 
hyperplasia (BPH), prostatitis or mechanical damage also contribute to aberrant PSA-
values in serum.13 It is noteworthy that the production of PSA by prostate cancer cells 
is not higher than benign prostate epithelial cells, but higher serum values is a result of 
an altered prostate-blood barrier.14 In fact, production of PSA by prostate cancer cells is 
generally lower.15
Figure 1. A. Diff erent measurements contributing PSA including PSA dynamics. B. Processing of PSA to its 
subforms.
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Large studies showed that 97% of all men older than 40 years have PSA serum levels 
lower than 4 ng/mL, which gave rise to the idea that this value should be the threshold 
when it is used in a diagnostic setting.16 Furthermore, it was shown that PSA serum 
values could increase when prostate cancer is present.17,18 Initially PSA was used as a 
reliable marker to prove residual disease or progression after radical prostatectomy for 
prostate cancer.19 Patients with lower values preoperative had higher rates of organ-
confined disease.20,21
In a screening setting it has been shown that PSA can increase the detection rate of 
prostate cancer in men without symptoms.22 By using PSA, the percentage of men who 
were found with metastases at diagnosis was reduced from 16% to 4%, but also late-
stage disease and prostate cancer related mortality was observed to be less.23 During 
the last decades it is shown that with the use of PSA the detection of prostate cancer has 
increased dramatically, but that prostate cancer mortality was only reduced with 20%. 
Therefore it was concluded that using PSA for the detection of prostate cancer results in 
a substantial overdiagnosis and overtreatment.24
As a diagnostic tool PSA has a high sensitivity but low specificity for prostate cancer, 
where the positive predictive value (>4.0 ng/mL) is limited to 25%.25,26 Serum PSA levels 
are influenced by tumor grade, volume and site of origin (primary tumor or metastases) 
and it is capable to predict pathological features.13 On the other hand, in 15% of men 
with low PSA levels, prostate cancer is present.27 So, in order to improve identification of 
prostate cancer and gain specificity, changes in variant forms of PSA have been investi-
gated and introduced into the clinic.
FREE PSA
The proportion of free PSA (%fPSA) is lower when compared to total PSA in healthy 
men or men with BPH.28-30 Therefore, %fPSA has been suggested as a marker for prostate 
cancer.31 The exact cause for this occurrence is not fully understood, but it is thought 
that in patients with prostate cancer PSA ‘escapes’ proteolytic activity and stays bound 
to ACT, A2M or API. An extensive meta-analysis that compromised 66 studies showed 
that %fPSA and cPSA have better diagnostic potential compared total PSA (tPSA) in the 
intermediate range of 2-10 ng/mL.32 In studies where %fPSA is combined with serum 
PSA levels between 2.5 and 4 ng/mL, more specificity can be obtained in diagnosing 
prostate cancer.33 The use of %fPSA could contribute to a more reliable diagnosis and 
therefore maybe reduce biopsies by 20% and lessen the overdiagnosis.34 Furthermore, a 
better stratification could be made of patients who are more eligible to undergo active 
surveillance and therefore decrease overtreatment.
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As a prognostic marker, high %fPSA correlated with smaller and lower grade prostate 
cancer.34 Vice versa low %fPSA resulted in a more aggressive form of prostate cancer, 
even when measured up to 10 years before diagnosis.35 Prostate cancers with Gleason 
scores of >7 and extra capsular extension also showed a correlation with low %fPSA.36,37
PSA DENSITY
In a majority of men with slightly elevated PSA levels, the main contributor is probably 
BPH and only in a small percentage of men, prostate cancer.36 To differentiate better be-
tween these two condition a method was introduced that compensated for the increase 
of serum PSA levels by prostate enlargement.38 This measurement, PSA density (PSAD) 
where serum PSA is divided by prostate volume (>0.15), has shown to have a direct 
relationship with the probability of having prostate cancer, especially with intermediate 
PSA levels and no abnormalities on DRE (digital rectal exam).39,40 Although these primary 
reports embrace promising results, this measurement has shortcomings. When PSAD 
was compared to PSA it was not able to enhance the predictive value of PSA alone.41 
Furthermore, PSAD in not sensitive enough for prostate cancer detection, almost 50% 
of all cancers are missed.42 The most plausible interpretation of these conflicting results 
is most likely the heterogeneity of prostate volumes in prostate cancer and BPH. Be-
cause PSAD is influenced by prostate volume, the number of epithelial cells has to be a 
correction for these factors. Correction for transition zone size has shown to be a very 
specific and sensitive technique to detect prostate cancer, but because of the variability 
of ultrasound measurements it has not gained wide acceptance in daily practice.43 Also 
as prognostic marker, increased PSAD values were correlated with Gleason scores >7 
and a greater risk of organ confined disease.44
PSA VELOCITY
Another approach for detecting prostate cancer in the intermediate range of serum PSA 
is by using PSA velocity (PSAV), where the rate of PSA change between two separate 
measurements is taken into account.45 As a diagnostic tool, an increase of 0.75 ng/mL 
or more per year is correlated with the presence of prostate cancer, which has a high 
specificity with PSA values between 4-10 ng/mL (up to 90%).45,46 To obtain a reliable 
PSAV result, the interval between the two separate measurement should be at least 18 
months.46 This interval seems not to be optimal for clinical daily practice because it can 
cause a delay in treatment. Furthermore, based on the characteristics of this marker, its 
use is limited. When initial PSA values are less than 4 ng/mL the sensitivity and specificity 
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is dramatically reduced.47 As a prognostic marker, increased PSAV is significantly related 
to aggressiveness. One study showed that preoperative PSAV values of >2.0 ng/mL per 
year resulted in a nine times higher chance of prostate cancer related mortality after 
prostatectomy or external beam radiotherapy.48,49 A recent study revealed that even a 
PSAV of >0.35 ng/mL per year correlated with a significant higher chance of biochemi-
cal progression.50 On the other hand, when values of <0.4 ng/mL per year were used, 
it increased the likelihood of insignificant prostate cancer.51 Besides these promising 
results, the exact role of PSAV in the stratification and characterization of specific sub-
groups of prostate cancer patients remains not fully elucidated. More research has to be 
performed to maximize its potential as a tumor marker and to establish the most ideal 
cutoff PSAV value for diagnosis and determining prognosis.
PSA DOUBLING TIME
Closely related to PSAV, PSA doubling time (PSADT) could also harbor some interesting 
capacities as a tumor marker. PSADT is defined as the time that serum PSA levels are 
doubled. As a diagnostic tool, so far no reports have been published. Nevertheless, the 
predictive abilities of this tumor marker has been the focus of multiple research efforts, 
but their results show no relationship between pretreatment PSADT and post treatment 
outcomes.52 As a prognostic marker it has mainly been measured post prostatectomy 
and was correlated with survival results. The first study showed that fast PSADT values 
(<10 months) correlated with lower metastasis-free survival.53 Others showed that if 
PSADT was <3 months within a period of 24 months after radical prostatectomy there 
was an associated with lower cancer specific survival.54
PSA ISOFORMS
ProPSA is an inactive precursor of PSA that is cleaved by hK2 or hK4, converting it into 
its active form.55 The precursor form of PSA contains a 7 amino-acid proleader peptide 
and is therefore named [-7]proPSA. Incomplete cleavage of proPSA results in other sub-
forms, such as [-2], [-4] or [-5]proPSA. Elevated levels of proPSA and its truncated forms 
were observed in prostate cancer tissue.56,57 A possible explanation for this finding was 
the observation that proPSA is higher expressed in the peripheral zone of the prostate.57
Mainly in the intermediate range (2.5-10.0 ng/mL) of PSA, ProPSA could early detect 
more prostate cancers.58-60 Even when these isoforms were used, it could avoid 59% of 
all biopsies taken, as compared to 33% when only %fPSA was used. Unfortunately, in a 
prognostic setting proPSA does not seem to be superior to %fPSA, but when combined 
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it is correlated with higher Gleason scores and non-organ defined prostate cancer.61 All 
the single sub-isoforms of proPSA have been investigated and showed no better corre-
lation in diagnosing or determining prognosis as compared to total proPSA or %fPSA.60
KLK2
Human Kallikrein 2 (hK2 or KLK2) is also a member of the Kallikrein family and shares 
80% homology with PSA. It functions as a peptidase, cleaving proPSA to mature and ac-
tive PSA.62,63 Like PSA, it is highly and specifically expressed in the prostate and is andro-
gen regulated. hK2 levels show a distinct expression pattern on immunohistochemical 
analysis, which was also observed in serum. These findings indicated that this marker 
could be indicative, independent of PSA.64,65 The first studies on hK2 showed no correla-
tion of this marker with prostate cancer.66-68 Nevertheless, a review that also included 
all studies on hK2 performed in a later stage, revealed a significant higher expression of 
hK2 in serum from prostate cancer patients.60 Especially for the intermediate elevated 
PSA values, it showed a better discrimination as compared to %fPSA. As a prognostic 
marker hK2 is capable of differentiating between low and high Gleason scores and also 
for extra-prostatic growth, even prior to radical prostatectomy.69-71 Unfortunately, when 
this marker was analyzed in a multivariate model it had a very limited improvement 
on prognoses as compared to Gleason score alone.72,73 One study revealed that hK2, 
together with other variables, was significantly predictor of biopsy outcome.74
URINARY PSA
In almost all reports, PSA as a tumor marker for prostate cancer was measured in serum. 
In contrast to serum PSA, also urinary levels of PSA were evaluated as a potential tu-
mor marker for prostate cancer.75 Although the first report was published in 1985, less 
is known about this PSA measurement. Just as serum PSA it was shown that elevated 
urinary PSA after radical prostatectomy was correlated with disease recurrence and 
therefore was suggested as a monitoring marker.76 In a diagnostic setting, when a ratio 
was taken of urinary and serum PSA expression it was shown that it produced higher 
sensitivity and specificity as compared to serum PSA alone, especially in the intermedi-
ate range.77,78 Unfortunately, reports on urinary PSA levels are few and more research is 
needed to fully elucidate if urinary PSA has any potential as a marker for prostate cancer.
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PCA3
The PCA3 transcript (prostate cancer antigen 3) was discovered in the late 90s as a new 
promising candidate marker for prostate cancer.79 The PCA3 gene is located on chromo-
some 9q21-22 producing a (non-coding) mRNA that does not encode a protein.80,81 After 
its discovery it was named DD3 (differential display clone 3) as a result of a differential 
display analysis that was used to compare mRNA expression between healthy prostate 
tissue and prostate cancer tissue.82 95% of prostate cancer specimens highly expressed 
PCA3, compared to no expression in normal prostate, BPH or other types of cancerous 
tissues. High grade PIN also revealed higher expression, up to 96% of the cases.83,84 PCR 
on similar samples showed a 66-fold increase in PCA3 expression in prostate cancer 
samples with a sensitivity of 94% and specificity of 98%.85,86 Furthermore, the expression 
of this marker is not influenced by age, prostate volume and infections.82 The current 
PCA3 test is mRNA based and the outcome is a ratio between PCA3 mRNA and PSA 
mRNA multiplied by a 1,000.86 This test is preferentially performed on urine samples that 
are collected after digital rectal examination or prostate massage.87 When this test is 
performed on serum, it has less accuracy.88
Initially, the PCA3 test was launched to predict presence of PCa after negative 
biopsies. Subsequent reports on the urine test showed a sensitivity of 54-82% with a 
specificity of 66-83%, where PSA has a sensitivity of only 22-47% for the diagnosis of 
prostate cancer.82,84,86,88-90 Multiple studies have shown that increased PCA3 is statistically 
significantly correlated with more tumor volume.91-93 PCA3 also outperformed the diag-
nostic accuracy of %fPSA. This diagnostic accuracy can even further be increased when 
PCA3 is combined with other (clinical) variables such as PSA, physical characteristics 
during digital rectal examination, age and family history.94 In a screening setting, PCA3 
was capable of improving the performance characteristics and identification of serious 
disease compared with PSA.95
Although many reports describe the relation and prognostic features, such as histo-
pathological outcome, generally no correlation could be observed between PCA3 and 
Gleason score and pT staging.96 With these data it was suggested that PCA3 could be 
applied to predict histopathological outcome after biopsy, especially in patients with 
elevated PSA and a negative biopsy.90,96,97 Furthermore, it was suggested that PCA3 
could be used to determine multifocality of prostate cancer lesions and patients that are 
candidates for active surveillance.82,98-100 The exact role of PCA3 in determining diagnosis 
and prognosis of prostate cancer remains to further investigated. Since the PCA3 detec-
tion assay is RT-PCR (reverse transcriptase PCR) based, the assay needs to be performed 
by expert labs and is much more expensive than protein-based ELISAs.
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ETS
In prostate cancer, chromosomal rearrangements affecting the ETS (E twenty six) 
gene family members are common events; around 60-70% of all cases exhibit such an 
alteration.101,102 In a majority of the rearrangements there is a fusion between the genes 
TMPRSS2 and ERG, the so called TMPRSS2:ERG fusion gene, which is unique for prostate 
cancer. Both TMPRSS2 and ERG genes are located in the same orientation on the long 
arm of chromosome 21. They are spaced by approx. 3 million base pairs and a deletion 
of this interstitial region can cause fusion of the two genes. Because the TMPRSS2 gene 
is androgen regulated, a fusion of this gene with ERG results in the androgen regulated 
and high expression of ERG. So far, this fusion is never observed in normal tissue and 
unique to prostate cancer.103
Multiple gene fusion partners that are related with either the TMPRSS2 part or the ERG 
part have been identified.104 Other fusions of the TMPRSS2 gene occur in fewer cases 
with ETV1, ETV4 and ETV5. Although the TMPRSS2 gene is most often involved, other 
fusion partner such as the SLC45A3, ACSL3, HERV-K, FOXP1, EST14, KLK2, CANT1, DDX5 
genes can rearrange with ETS family members.105 All these gene fusions are unique to 
prostate cancer and seem to play an important role in the biogenesis and development 
of this disease. Therefore they could function as marker for diagnosis and prognosis. 
Recent studies showed that the fusion of TMPRSS2 to ERG is present in the precursor 
lesions PIN (prostatic intraepithelial neoplasia) and therefore must be an early event 
in cancer development.106,107 Multiple studies that address the prognostic value of this 
marker have been performed, with several opposing conclusions.102,105 Two studies ex-
amined 114 and 150 prostates after radical prostatectomy and revealed that expression 
of ERG or TMPRSS2:ERG correlated with a reduction of biochemical progression.108,109 
Gleason score are thought to be lower when TMPRSS:ERG is present.110 No correlation 
was observed by other five studies that compromised similar sized study cohorts.106,111-114 
Also the presence of ETV1 rearrangements failed to correlate with progression of dis-
ease.115 Most reports reveal an unfavorable correlation of gene rearrangements with 
outcome after treatment (radical prostatectomy). These studies showed an increased 
rate of biochemical recurrence, formation of metastases or even death.114,116-124 Interest-
ingly, one study showed that ERG rearrangement alone was associated with low grade 
prostate cancer, present with seminal vesicle invasion there seemed to be a poorer 
prognosis.105,122 Expression of the TMPRSS2:ERG fusion gene was shown not to be able 
to predict response to endocrine treatment in hormone dependent and lymph node 
positive prostate cancer.125,126
Rearrangements of genes from the ETS family are potentially very useful diagnostic 
markers due to their prostate cancer specific occurrence if they can be measured in 
serum or urine. Like for PCA3, a test has been developed to measure fusion transcripts in 
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urine. For prognostic or predictive purposes, fusion gene-based tumor markers remain 
controversial.
Because measurements of the fusion transcripts and genes are performed with RT-PCR 
or FISH (fluorescent in situ hybridization) techniques, implementation in daily clinical 
practice is hampered. Recently, an antibody against the ERG protein was generated that 
can be used for immunohistochemistry.127,128 Although the antibody has some cross-
reactivity with FLI1, it gives the opportunity to easily and quickly assess thousands of 
retrospective and prospective patient samples. All three techniques (ERG antibody on 
protein level, RT-PCR on mRNA level and FISH on DNA level) provide their own unique 
information on the status of the fusion event and are likely complementary in their 
diagnostic and prognostic value.
AMACR
AMACR (alpha-methylacyl coenzyme A racemase) is an enzyme that is encoded by the 
P504S/AMACR gene. In cells, this protein is located in the mitochondria and peroxi-
somes and although the function has not been revealed completely it is related to the 
metabolization of fatty acids and bile acid biosynthesis.129-131 The AMACR transcript and 
protein are known to be highly expressed in a variety of cancers with a very high (up to 
nine times higher) expression in 86% off all prostate cancers.132-134 In 2002, AMACR was 
introduced as a new marker for prostate cancer.135 A meta-analysis of multiple mRNA 
expression arrays revealed that AMACR is over expressed in prostate cancer with high 
sensitivity and specificity.136,137
In a diagnostic setting, the use of the AMACR protein on immunohistochemical 
analysis of prostate biopsy samples has been limited to a valuable complement to 
other known markers.138 Unfortunately, samples that did not contain prostate cancer 
also had AMACR expression, but generally lower compared to the cancer samples.139 In 
18% of the prostate cancers, AMACR is false negative.140 When unusual histopathological 
subgroups of prostate cancer had to be identified, the increased expression was only 
limited to 62-77%.132,141
In a prognostic setting it has been shown that untreated metastasis and hormone-
refractory prostate cancers were strongly positive for AMACR. In this specific prostate 
cancer stages, AMACR has a sensitivity of 97% and a specificity of 92-100%.135,142 Fur-
thermore, decreased expression of AMACR has been shown to have prognostic value in 
predicting biochemical recurrence and prostate cancer related death.143
In order to assess this marker in non-invasive derived patient materials (not biopsies) 
such as serum or urine, expression of AMACR mRNA could also be identified in 69% 
of the cases. Unfortunately, AMACR is not specific to cancer of the prostate, because 
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serum levels can also be elevated in other urological disorders like BPH or auto-immune 
diseases.144 When used in a diagnostic setting as an additive to PSA, sensitivity and 
specificity can be increased when measured in urine, especially when the PSA is in the 
midrange (4-10 ng/mL).145-147 Unfortunately, when AMACR mRNA was normalized to PSA 
mRNA, AMACR did not accomplish to be a statistically significant predictor of prostate 
cancer.148 New promising serum tests for prostate cancer which comprehend the AMACR 
gene are evaluated. With these tests a ratio is calculated between the expression of the 
AMACR gene and the PSA gene.131 Until now, one report has been published were it was 
shown that the AMACR protein is detectable in serum with an ELISA, but elevation of 
this protein was not specific for prostate cancer.149 Although more research has to be 
performed, it is also shown that circulating antibodies against the AMACR protein in 
combination with PSA could function as a useful tool for diagnosis.146,150
GSTP1
During aging, DNA damage occurs as a result of oxidative stress, exposure to chemical 
substances or ionizing radiation.151 These damages can result in mutations or alterations 
of oncogenes and tumor suppressor genes. In healthy cells the cytoplasmic enzyme 
glutathione S-transferase pi I (GSTP1) plays an important role in detoxifying the cell from 
carcinogens. GSTP1 is a member of the glutathione S-transferase family, which contains 
four different classes. All these classes are expressed in prostate tissue.152 Although GSTP1 
expression is increased in various cancers, in prostate cancer GSTP1 is down regulated.153 
This is caused by hypermethylation of the GSTP1 promoter, a mechanism well known in 
cancer to decrease expression of tumor suppressor genes. Hypermethylation of GSTP1 
was observed in all stage of prostate cancer, from high grade PIN to metastases.154,155 
Such methylation was not observed in benign prostate epithelial cells.151 Based on these 
findings and the presence of methylation in 90% of prostate cancers and 67% in high 
grade PIN, it was concluded that GSTP1 methylation might function as a tumor marker 
for prostate cancer.156,157 Subsequently, methylation of this gene could be observed in 
serum, urine and ejaculate of prostate cancer patients when analyzed by methylation 
specific PCR, which gave rise to the idea that it could even be applied in a clinical set-
ting.158-161
As a diagnostic marker it was shown that GSTP1 DNA methylation in urine has a sen-
sitivity of 75% (after DRE) and a specificity of 98% for prostate cancer and is comparable 
to its expression in biopsy specimen.162 Similar values for sensitivity and specificity were 
observed in other studies. It is notable that sensitivity in urine is increased by collection 
directly after digital rectal exam or prostate massage and functions independent of 
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PSA.163-165 To increase sensitivity even more, a relative ratio of GSTP1 methylation over 
methylated MYOD6 can be determined.153
For prognostic purposes, 100% of the locally advanced or metastatic tumors showed 
hypermethylation. Biochemical recurrence after prostatectomy seems to appear more 
and faster when the epigenetic alteration is present.166 In a small study cohort it was 
shown that methylation of GSTP1 is a statistically significant predictor for time to recur-
rence.167 Androgen deprivation therapy does not seem to influence GSTP1 methylation 
in 87% of the cases.168 Unlike other genetic alterations, methylation of this gene is re-
versible after therapeutic intervention. Because no reports have been published which 
describe this effect, more research is needed.
Methylation of GSTP1 seems to function very well as a diagnostic and prognostic tool, 
but because the number of reports describing this marker is lacking, we should be care-
ful in jumping to conclusions. As more results are being published, more allusions are 
made regarding the use of a set of hypermethylated genes for optimal diagnosis and 
determining prognosis in prostate cancer patients.
PSMA
PSMA (Prostate specific membrane antigen), or also known as FOLH1, is a androgen 
regulated gene that encodes a type II transmembrane glycoprotein. PSMA belongs to 
the M28 peptidase family and has a intracellular and extracellular domain.169 Its function 
is limited to hydrolyzing peptides in prostatic fluid and generating glutamate and also 
acts as a folate hydrolase.170,171 This protein is expressed in a number of tissues such as 
prostate, nervous system and kidney.172,173 Furthermore, it has been shown to have a 
higher expression in prostate cancer. This finding could possibly be related to its enzy-
matic activity and thus invasiveness growth of prostate cancer.174,175
In the field of prostate cancer, PSMA has been the focus of many research groups. It 
has mainly been suggested as a prognostic tool.176 Immunohistochemical analysis in a 
group of 232 patients showed higher expression in prostate cancer (79.3%) and metas-
tases (76.4%) as compared to benign prostate tissue (46.2%).177 Other studies showed an 
increased expression in progressive prostate cancer and hormone independent prostate 
cancer.178-183 In serum from prostate cancer patients, the PSMA protein is increased, with 
a higher expression in advanced stages of cancer.184-186 Nevertheless, contradicting stud-
ies show that PSMA is not prostate cancer specific and does not discriminate between 
localized prostate cancer and advanced disease.187 A possible explanation for these dif-
ferent findings could be the fact that in those studies different types of antibodies have 
been used in various assays. Also studies that investigated the expression of PSMA mRNA 
have shown varying and inconclusive results, probably because of different assays used. 
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The sensitivity of diagnosing prostate cancer with PSMA mRNA is more or less similar 
to that of PSA mRNA.174 As a prognostic marker no correlation was observed between 
PSMA mRNA and Gleason score, pT staging and serum PSA. In a study on patients with 
clinically localized prostate cancer, a combined PSMA/PSA mRNA analysis in peripheral 
blood samples showed that this could be an independent predictor to biochemical 
progression after radical prostatectomy.188
Although PSMA seems to be not prostate and prostate cancer specific, there is an 
upregulation of PSMA in prostate cancer and probably more in its aggressive forms. 
Therefore its function as a marker for prostate cancer is limited. A more promising fea-
ture of PSMA is its application in tissue targeted therapy such as prostate specific cancer 
vaccine therapy or radioimmunotherapy.189,190
PSCA
Prostate stem cell antigen (PSCA) is a gene that encodes for a membrane based glyco-
protein. PSCA has been found to be relatively highly present in prostate, but also in other 
cell types such as bladder, placenta and gastrointestinal tissues.191 The expression is also 
elevated in malignant tissues such as prostate cancer, bladder cancer and gastrointesti-
nal cancers.192,193 In prostate the expression of the PSCA mRNA is influenced by puberty, 
androgen deprivation and androgen restorement.194 Although the exact involvement of 
PSCA in prostate cancer is fairly unknown it was shown that PSCA protein and mRNA are 
higher expressed from high grade PIN through all stage of prostate cancer.195,196 Never-
theless, knockout of the PSCA gene in mice resulted in a normal urogenital development 
without an increased risk of prostate cancer.197
As a diagnostic or predictive marker it was shown that expression of PSCA in negative 
biopsies before TURP (transurethral resection of the prostate) is associated with higher 
risk of having prostate cancer in the TURP specimen. Especially when serum PSA levels 
>4.0 ng/mL or with a suspicious DRE.198
In a prognostic setting, immunohistochemical analysis showed that expression of the 
PSCA protein was present in 94% of all tumors and was significantly associated with ad-
verse prognostic features, such as high Gleason score and extra-capsular extension.199,200 
Furthermore, PSCA was identified in bone metastases and lymph node metastases.201,202 
These findings suggest that there is a positive correlation of the PSCA protein with 
advancement of disease status in prostate cancer. When PSCA mRNA was measured in 
peripheral blood it corresponded with a reduced disease free survival time.203 Compared 
to PSA and PSMA it was noticed that specificity and independent prognostic value were 
very high.203 Unfortunately this transcript could only be identified in 13.8% of the pa-
tients, which limited its ability to differentiate between benign and malignant prostate 
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tissue. When this marker was investigated for its post-treatment monitoring value, it 
was shown that after EBRT PSCA mRNA is decreased.204 Therefore it was proposed as in 
interesting marker for follow-up after treatment.
Besides the properties of being a possible diagnostic or prognostic marker for prostate 
cancer, it has also been found that PSCA is a possible target for prostate specific virus 
therapy.205,206 When PSCA is used, it was possible to inhibit tumor growth and formation 
of metastases.
CHROMOGRANIN A
Chromogranin A (CgA), is a gene that encodes for a proteolytic protein that is a member 
of the chromogranin/secretogranin family of neuroendocrine secretory proteins. CgA is 
one of the most frequently produced proteins in neuroendocrine cells in the prostate 
and can be easily measured by a radioimmunoassays.207 Serum levels of Chromogranin 
A could reflect neuroendocrine activity of prostate malignancies, therefore it holds an 
interesting potential to function as a marker for prostate cancer and especially for neu-
roendocrine differentiation.208,209 Unfortunately, Chromogranin A is not prostate specific, 
it is also elevated in various neuroendocrine tumors and neuroblastomas.210-213 The exact 
function of Chromogranin A in prostate cancer is unknown, but it has been shown that 
it influences the growth of prostate cancer cells.214
Despite conflicting results as a diagnostic tool, when measured in serum, high Chro-
mogranin A levels seem to correspond with the presence of (organ confined) prostate 
cancer. 216 In combination with PSA a better diagnostic accuracy could be established.215 
An interesting report showed that Chromogranin A is able to predict conversion of hor-
mone naïve prostate cancer to hormone refractory disease and the presence of hormone 
independent prostate cancer itself.216,217 A small prospective study on 50 prostate cancer 
patients showed that high Chromogranin A serum levels prior to radical prostatectomy 
were able to predict higher Gleason scores, extra capsular extension and eventually 
treatment failure.218-220 Especially in patients with hormone independent prostate cancer 
this marker correlates with adverse outcomes and decreased overall survival.221 Further-
more, this marker could function as a predictor for chemotherapy response in hormone 
independent prostate cancer.222 In a prognostic setting, high levels of CgA correspond 
with factors such as a higher Gleason score, advanced pT stage and metastases.223,224 Im-
munohistochemical analysis showed similar results.225,226 No decrease in Chromogranin 
A serum levels were observed after radiotherapy or hormone therapy, Therefore the use 
of this marker in as a monitoring tool seems not to be sefull.227,228 Specific antibodies 
against Chromogranin A can suppress its function through apoptotic pathways, leading 
to programmed cell death. Therefore Chromogranin A antibody mediated apoptosis was 
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suggested as an alternative treatment for prostate cancer.214 A derivate of this marker, 
Chromogranin A velocity was introduced as a marker for predicting time to androgen 
independence after hormonal treatment.228
B7-H3
The transmembrane protein family B7 has gained publicity with its role in regulation of T 
lymphocytes.229 Subsequent reports showed that a total of four subtypes (B7-H1, B7-H2, 
B7-H3 and B7-H4) could be identified in cancers and might play a role in the mechanism 
by which human malignancies evade host immune responses.230-232 Higher expression 
of some of these subtypes are correlated to more aggressive behavior and poor clinical 
outcome.233,234 The B7-H3 has also been identified in healthy placenta and malignant 
tissues.235 Although there was expression in benign tissue, the expression in cancerous 
lesions was significantly higher.230
B7-H3 could be identified as an independent prognostic factor in 338 patient samples 
after radical prostatectomy that were followed with a median of 3.9 years. The patients 
which showed elevated B7-H3 expression had a shorter time to cancer progression.236 
This indicated that B7-H3 could function as a prognostic marker. Furthermore, B7-H3 
expression is higher in metastases and hormone refractory prostate cancer. The expres-
sion is not hampered by hormone treatment.237 Also, this marker could have prognostic 
value for biochemical recurrence after salvage radiotherapy, especially with low primary 
TNM staging, low Gleason score and low pre-radiotherapy PSA.238 Because this marker is 
membrane-bound in cells it also harbors a function in targeted therapy. Chemotherapy 
or radionucleotide therapy that is directed against B7-H3 makes it possible to specifi-
cally engage prostate cancer cells.
CAV1 (CAVEOLIN-1)
Caveolin-1, is a major structural component of caveolae. These caveolae are specialized 
membrane invaginations that are abundant in adipocytes, endothelium and smooth 
muscle cells. Caveolae are involved in molecular transport, but also in cell adhesion and 
signal transduction.239,240 Caveolin-1 has been linked to prostate cancer since the late 
90s, where it was identified as a marker.241 The exact relation of caveolin-1 and pros-
tate cancer remains unclear, but it is known that caveolin-1 in prostate acts as a tumor 
suppressor by keeping Akt dephosphorylated in the Akt-pathway.242 Subsequently it 
was shown in in vitro experiments that downregulation of the expression of this gene 
resulted in cells turning from androgen-independent to androgen-dependent.243 This 
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implicated that there is a role for Caveolin-1 in the development of castration resistance. 
It is also known that this protein plays a role in the malignant characteristics of prostate 
cancer cells by changing the microenvironment and promoting angiogenesis.244 Studies 
showed that Caveolin-1 is also expressed in normal prostate stromal cells, but minimally 
expressed in normal epithelial cells.245 The protein expression of Caveolin-1 is higher in 
prostate cancer cells compared to normal prostate epithelial cells.241 The expression of 
this marker in epithelial cells upregulates when prostate cancer grading increases.245 
Furthermore, the protein Caveolin-1 also has higher serum values in patients with pros-
tate cancer, which makes it possible to measure it with a very sensitive and reproducible 
ELISA.246 Median serum Caveolin-1 levels are significantly higher in localized prostate 
cancer compared to men with BPH.
Caveolin-1 levels could harbor a predictive potential in men undergoing radical 
prostatectomy.247 Higher expression of Caveolin-1 was correlated with an increased 
risk of developing aggressive recurrent tumors after surgical treatment. Pre-operative 
high Caveolin-1 serum levels resulted in a 2.7 fold higher risk of developing biochemical 
recurrence.248
When Caveolin-1 was investigated as a prognostic tool, in samples retrieved after radi-
cal prostatectomy it was shown that a positive immunohistochemical staining correlates 
with a significant worse prognosis.249 In patients with lymph node negative prostate 
cancer, Caveolin-1 expression is an independent prognostic factor for a Gleason score 
>7, extra prostatic extension, positive surgical margins. When combined in a multivari-
ate model with other variables such as Gleason score it is possible to more accurately 
predict the chance of biochemical recurrence. Unfortunately, another study showed in 
1458 cases no correlation between high post-operative Caveolin-1 values in serum and 
aggressiveness of prostate cancer or adverse prostate cancer events.250
GOLPH2
GOLPH2 (Golgi phoshoprotein 2), also known as GOLM1 or GP73, is a type II Golgi 
membrane protein and involved in the sorting and modification of proteins that are 
exported from the endoplasmatic reticulum through the Golgi apparatus. Recent find-
ings suggest that changes in structure and function of the Golgi apparatus may play 
an important role in the development or behavior of malignant cells. This protein has 
already been shown to be elevated in liver diseases as a result of viral infections, but also 
as a potential marker for hepatocellular carcinoma.251,252 Immunohistochemical experi-
ments on prostate cancer samples revealed that the GOLPH2 protein also is upregulated 
in prostate cancer.253,254 An interesting finding was that this specific marker is present, 
even when AMACR is negative. Therefore it was mainly introduced as an additive protein 
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marker for prostate cancer, next to other known markers. Preceding mRNA profiling 
studies, research already showed that GOLPH2 mRNA is upregulated in prostate cancer 
tissues.255,256 When this gene transcript is used in a marker profile to detect prostate 
cancer in urine, it seems to be capable to outperform PSA measured in serum.148
MYO6 (MYOSIN IV)
Myosin IV is a Golgi apparatus-associated protein that is involved in intracellular vesicle 
and organelle transport and is required for the structural integrity of the Golgi apparatus. 
Furthermore the protein has been suggested as an important factor for cell migration 
and even cancer invasion.257-259 Based on a microarray experiment it was discovered that 
the MYO6 mRNA is upregulated in prostate cancer, next to GOLPH2.260 Interestingly, 
expression of the transcript goes down in androgen-independent and more aggressive 
prostate cancers.260 With Immunohistochemical analysis it was shown that a strong 
protein expression is present in a PIN, the majority of prostate cancer cells, and weak or 
absent expression in neighboring benign prostate cells.254. In a prognostic setting, no 
differences were observed between the different Gleason scores or other pathological 
indicators for aggressiveness.260 Based on these results, the transcript could be used as a 
diagnostic marker, but further research has to be performed to reveal the true potential 
of this marker and to assess its possible role in prognosis.
CRISP3
Cysteine-rich secretory protein 3 (CRISP3), also known as specific granule protein 28 
(SGP28), has recently been implicated as potential marker in prostate cancer. Relatively 
little is known about its function and role in prostate cancer. The CRISP3 mRNA has shown 
to be present in high concentrations in salivary glands, pancreas and prostate.260-262 Fur-
thermore, its expression has been shown in secretory epithelium in the male urogenital 
tract, including the epididymis and the ampullae of the ductus deferens.263 Regarding 
prostate cancer, multiple studies have shown that the expression of the CRISP3 mRNA 
is high264er (20-300 times) in prostate cancer as compared to healthy prostate tis-
sue.262,265,266 Also on the protein level, CRISP3 was shown to be higher expressed.267 The 
protein also has been identified by ELISA in multiple bodily fluids, such as serum, saliva 
and seminal plasma.268 Unfortunately, serum concentrations were not different between 
prostate cancer samples and healthy controls.
As a prognostic marker, immunohistochemical analysis of prostate cancer specimen 
showed an increase in expression when Gleason scores increased. Expression in normal 
38 Chapter 2
prostate epithelial cells was weak of absent. A similar analysis on radical prostatectomy 
samples revealed that expression of CRISP3 eventually positively correlated with bio-
chemical recurrence.269 In a multivariate analysis this protein was still associated with 
recurrence. Nevertheless, when this marker was added in a model with other known 
markers, such as PSA, no improvement was observed. With the results acquired so far, 
CRISP3 does not seem to be a good prognostic marker for prostate cancer.264,270
An interesting observation was the decrease of CRISP3 after ochiectomy in some 
patient samples. This could reflect that CRISP3 could be partially androgen regulated 
and might function as a monitoring marker.
SARCOSINE
The discovery of Sarcosine as a marker for prostate cancer has only recently been made. 
Since a large number of research groups are exploring changes on the level of genom-
ics, transcriptomics and proteomics, changes in the metabolomic field are novel and 
few. Sarcosine is a metabolite that is produced by the enzymatic transfer of a methyl 
group from S-adenosylmethionine to glycine. This reaction is catalyzed by the enzyme 
glycine-N-methyltransferase (GNMT), which is highly expressed in prostate, liver 
and pancreas. The first report on Sarcosine in prostate cancer showed that Sarcosine 
stimulates malignant growth of prostate cancer cells and has prognostic value.271 With 
mass spectrometry they analyzed blood, urine and tissue samples from different well 
characterized prostate cancer patients and explored them for metabolites. In a relatively 
small patient cohort a total of 1126 metabolites were identified. Sarcosine was highly 
increased during prostate cancer progression to metastasis and could easily be iden-
tified in urine.271 Subsequently they showed a decrease in disease progression when 
glycin-N-methyltransferase was knocked down.
Although these results look very promising, subsequent reports showed that Sarco-
sine as prognostic marker is debatable. On tissue samples the expression in cancerous 
samples was 7% higher compared to benign prostate samples. Unfortunately no sta-
tistical differences were seen regarding prostate cancer progression.272 A drawback of 
this study was the fact that metastatic samples were not included. Also Sarcosine as a 
urine marker, normalized to creatinine, could not reproduce the original finding that 
Sarcosine functions as a prognostic marker. 273 When compared to PSA, urine derived 
Sarcosine was not able to outperform serum PSA on itself. When added to an algorithm 
with PCA3 or %fPSA diagnostic performances could be improved.274
Although Sarcosine was promoted as a promising new marker for prostate cancer, its 
exact clinical value and applicability is unclear. The conflicting reports are mostly based 
on a limited number of samples with limited follow-up and different technologies to 
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measure this metabolite. In order to resolve these contradictions we need to control 
some of the variables, such as the study cohort and tumor marker assays.275
EXOSOMES
Exosomes are small vesicles (50-150 nm) that are shed by almost all cell types in the 
human body into almost all body fluids. Initially, exosomes were discovered during 
studies on the loss of the transferrin receptor loss in sheep reticulocyte maturation.276 
Exosomes are formed by inward budding of the cellular membrane which results in the 
formation of a large endosome. After formation of the endosome it is subjected to a 
second step of inward budding. During this second step, cytoplasmic content is taken 
up in small vesicles. When the endosome (now referred to as multivesicular body) is 
filled with small vesicles it fuses with the cellular membrane and the small vesicles, or 
so-called exosomes, are shed in the extracellular space.277,278 Because of this biogenesis 
pathway, exosomes contain proteins and RNA that are specific for the cell from which 
they are derived and thus represent the state of the cell.279 By isolating prostate (cancer) 
derived exosomes one is able to search for new and specific tumor markers for prostate 
cancer. The reports on exosomes in prostate cancer are limited. One of the first clinically 
related studies showed their potential. The quantity of exosomes isolated from urine is 
higher in prostate cancer patients as compared to healthy controls.280 Unfortunately, in 
this study nothing was reported about differences in exosomal content. RNA expression 
analysis revealed that known markers of prostate cancer such as the TMPRSS2:ERG fu-
sion mRNA and PSA mRNA could be identified in exosomes.279 This finding emphasizes 
their function as tumor marker containing structures.277,281
Although the reports are limited, the study populations are very small and the 
variation in number of exosomes, exosome research in prostate cancer could accelerate 
tumor marker discovery. Because they are present in body fluids, noninvasive technique 
can be applied to isolate exosomes and use them for diagnose or monitor the course 
of prostate cancer.282 Unfortunately, when isolating exosomes from serum or urine no 
distinction can be made between the different tissues from which the exosomes are de-
rived. Therefore more research has to be done to specifically isolate and profile prostate 
(cancer) derived exosomes.
SUMMARY
Currently, PSA is the best and most widely accepted prostate tumor diagnostic and 
monitoring marker we have available for daily medical practice. Nevertheless, its limita-
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tions cause a need for new and more accurate markers. From the many discovery en-
deavors, there seems to be an inexhaustible source of new potential tumor markers that 
are being explored. Unfortunately, most of these candidate tumor markers still need 
to be evaluated more thoroughly to validate their diagnostic or prognostic value and 
demonstrate their added value over current practice.
Because of the heterogeneity of prostate cancer there is a fairly good chance that the 
use of single tumor marker will not cover all aspects of the disease and a combination of 
two or more markers is needed. In addition, multiple markers will be needed to address 
the different types of relevant clinical decision points, ranging from risk assessment, 
diagnosis and personalized therapy.283 Importantly, different technologies including 
mass spectrometry and microarrays are being introduced into the clinical to measure 
novel markers and extend the types of markers from the typical proteins to metabolites, 
DNA and RNA.
Despite the large efforts invested in prostate cancer marker research in the past 
decade, the number of clinically valuable markers is very limited. We have learned that 
open and unselective searches in a discovery phase, generally result in many new can-
didate markers, but also that most of these are not validated in independent and larger 
cohorts. It has become painfully clear that the complexity of body fluids and tissues, a 
selection bias and inadequate number of samples for discovery and the variation be-
tween individuals are some of the major hurdles in the ongoing quest for novel markers. 
Despite these challenges, more accurate and reproducible technologies, more focused 
explorations and the growing number of samples in (consortium) tissue banks, improve 
the essential steps of excluding false positive candidates in an early stage and robustly 
validate novel markers.
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ABSTRACT
Context
Although progress has been made in respect of types of markers (protein, DNA, RNA and 
metabolites) and the implementation of improved technologies (mass spectrometry, ar-
rays, and deep sequencing), the discovery of novel biomarkers for prostate cancer (PCa) 
in complex fluids, such as serum and urine, remains a challenge. Meanwhile, recent stud-
ies have reported that many cancer-derived proteins and RNAs are secreted through 
small vesicles, known as exosomes.
Objective
This narrative review described recent progress in exosome research, particularly focus-
ing on their potential role as novel biomarkers for PCa. The purpose of this review was to 
acquaint the clinicians and researchers in the field of urology with the potential role of 
exosomes as biomarker treasure chests and their clinical value.
Evidence acquisition and synthesis
Medline and Embase entries between 1966 and September 2010 were searched using 
the key words of exosomes, microvesicles, prostasomes, biomarkers, prostate cancer 
and urology. Leading publications and articles constructively contributing to exosome 
research were selected for this review.
Conclusions
Exosomes are small vesicles (50 to 100 nm) secreted by almost all tissues; they represent 
their tissue origin. Purification of prostate (cancer)-derived exosomes will allow us to 
profile exosomes, providing a promising source of protein and RNA biomarkers for PCa. 
This profiling will contribute to the discovery of novel markers for the early diagnosis 
and reliable prognosis of PCa. Although the initial results are promising, further investi-
gations are required to assess the clinical value of these exosomes in PCa.
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INTRODUCTION
Prostate cancer (PCa) is one of the few solid tumors with a clinically useful biomarker 
for both diagnostics and follow-up after treatment. This biomarker protein, prostate-
specific antigen (PSA), has been considered the “gold standard” for the detection of PCa.1 
Although PSA has acceptable sensitivity, it lacks the specificity for discriminating benign 
prostate diseases (e.g., benign prostatic hyperplasia (BPH) and infection), indolent PCa 
and aggressive PCa. It has also been shown that PSA-based screening leads to a decrease 
in the prevalence of advanced PCa and a reduction of PCa-related mortality by 20%.2,3 
However, this screening is also associated with a high risk of overdiagnosis and over-
treatment based on findings on complementary diagnostic prostate biopsies. Therefore, 
new molecular markers for PCa are needed to more specific, to prevent unnecessary 
prostate biopsies and to help the urologists to decide the most optimal treatment.4
Searching for novel biomarkers has been the focus of many research groups, and the 
studies have become more extensive and sophisticated. Although exciting progress 
has been made in respect of novel technologies, such as mass spectrometry analysis or 
RNA-based arrays, discovering new biomarkers in serum and urine remains a challenge. 
Particularly, proteomic profiling from complex body fluids is hampered by several prob-
lems. One of these problems is that a few high-abundance proteins (albumin, immuno-
globulins, transferrin, complement factors, fibrinogen, and so on) make out 97% of body 
fluids, whereas low-abundance proteins are generally the most promising candidates 
for biomarker discovery.5 As indicated, this dynamic range of protein concentrations is 
very large (e.g., serum contains 7.5 X 105 nmol/L albumin and 10-1 nmol/L PSA (3 ng/ml), 
meaning that for every single molecule of PSA, 7.5 million molecules of Albumin are 
present. Mass spectrometry has made large-scale proteomics analysis feasible; however, 
the high-abundance proteins reduce the detection sensitivity of this technology.6 Most 
likely, promising marker proteins are probably present at the concentration of 10-3 to 10-5 
nmol/L. The sensitivity of mass spectrometry has a detection limit of up to 102 nmol/L.7 
Due to the dynamic range issue, identification and quantification of the low-abundance 
proteins remains a great challenge. Therefore, even with current “state-of-the-art” tech-
nologies, discovering novel biomarkers is still like searching for a needle in a haystack.
This dynamic range problem can be partially tackled by several methodologies. For 
example, high-abundance proteins can be depleted by chromatography or by precipi-
tation. Moreover, fractionating the samples into many different portions, for instance, 
by isoelectric focusing, mass separation or affinity chromatography, can improve the 
identification of low-abundance markers. Unfortunately, fractionation increases the 
number of measurements and, consequently, the time to process an individual sample. 
The detection sensitivity can increase approximately 100-fold by combining these two 
methods; however, it is still not enough to identify the low-abundance markers.8
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Another option that may contribute to the better identification and detection is spe-
cific enrichment. An obvious problem with this approach is that in a discovery setting, 
it is not known what the protein or RNA marker of interest is. However, recent findings 
have revealed that small tissue-derived vesicles, the so-called exosomes, are present in 
serum and urine and contain a wide range of proteins and RNAs 9,10 that represent their 
tissue origin. These vesicles also express tissue-specific transmembrane proteins that 
can be used for specific isolation of the vesicles from the complex fluids. Enrichment of 
cancer-derived vesicles from complex body fluids may solve the dynamic range problem 
and allow the identification of novel biomarkers.
OBJECTIVE
Since the last decade, exosome research has been rapidly expanded, and the number 
of coherent publications has been gradually increasing. Therefore, it is necessary to ac-
quaint the clinicians and researchers in the field of urology with this biological concept. 
The main objective of this narrative review was to describe recent progress in exosome 
research, especially in the field of urology, particularly focusing on their potential role as 
novel biomarkers for PCa.
EVIDENCE ACQUISITION AND SYNTHESIS
All entries between 1966 and September 2010 in Medline and Embase were searched 
to identify original studies and review articles. Leading publications and original articles 
constructively contributing to exosome research were included. For focusing the exo-
some research in the field of urology, the search was conducted using the following 
key words: (exosome* OR microvesicle*) AND (prostate cancer OR urology). The search 
was limited to the publications written in English with the full text available. Initially, 
we reviewed titles and abstracts for clinical relevance. A total of 25 manuscripts were 
reviewed, from which five were selected. Because the term of exosome has also been 
used in literature for a RNA-degradation complex, we manually excluded the articles 
describing such complex to prevent confusion.
Biogenesis and secretion of small vesicles
Exosomes (50 to 150 nm in diameter) were first described in sheep reticulocyte matura-
tion in 1983.11 In studies on transferrin receptor loss during reticulocyte development, it 
has been noticed that this plasma membrane receptor is shed through small vesicles.12,13 
The biogenesis of these vesicles starts from the internalisation of cellular membrane that, 
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thereby, forms an early endosome. During the formation of this endosome, cytoplasmic 
content is taken up by inward budding of endosomal membranes, resulting in exosome 
formation. When exosomes are formed, the endosome is called a multivesicular body 
(MVB). When the MVB fuses with the cellular membrane, the vesicles are secreted (Figure 
1).14
The exact mechanisms involved in exosome biogenesis are not fully elucidated; 
however, some factors have been reported to play a role. First, specific lipids and 
transmembrane proteins are grouped in the cellular membrane.15 These groups form 
separate microdomains, the so-called lipid rafts. These lipid rafts are enriched with 
glycosphingolipids and contain transmembrane cross-linked proteins.15,16 Although 
the exact role of lipid rafts in exosome formation is not clear, they seem to exert an 
important regulatory effect. Second, for sorting and encapsulating cellular content 
into exosomes, protein complexes, such as “endosomal sorting complex responsible for 
transport (ESCRT)”, and the process of protein ubiquitination are involved.17 The function 
of these protein complexes is regulated by Vps4.18 Third, exosome secretion is partially 
regulated by multiple Rab proteins, which control intracellular transport pathways by 
regulating vesicular trafficking. Especially, Rab27A, Rab27B and Rab35 have been shown 
to be important regulators in vesicle secretion.19
Although we only partially understand biogenesis of exosomes, we do know that they 
contain cytoplasmic content (proteins and RNAs) that is encapsulated by a cholesterol-
rich phospholipid membrane consisting of a host of transmembrane proteins.20,21 
Exosomes probably represent the transmembrane and intracellular conditions of their 
cell origin. Furthermore, the process of the biogenesis and shedding of exosomes has 
been shown in many mammalian cell types, including malignant cells; it is an indepen-
dent pathway, compared to the secretion of signal peptide proteins (such as PSA) that 
are processed through the classic consecutive route (Figure 1). Therefore, profiling the 
exosomes derived from specific tissues may contribute to the understanding of the 
pathogenesis of tissue-related diseases.
Exosomes and their functions
Exosome shedding is a process with a wide range of important regulatory functions. 
Their discovery in sheep reticulocyte maturation gave rise to the idea that exosomes 
may function as a trash bin for unnecessary and redundant proteins. Therefore, it could 
be an alternative pathway for lysosomal degradation.22 Nevertheless, most attention 
has been paid to their role in the immune system. Functional experiments have shown 
that exosomes affect the immune system by expressing and processing antigens.23 First 
of all, exosomes are enriched with specific antigens, compared to whole cell lysates.24 
Second, exosomes from antigen-presenting cells (APC) contain large amounts of major 
histocompatibility complex (MHC) class I and II molecules.21,25 When APC-derived exo-
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somes are incubated with donor cells, MHC could be re-expressed in these cells.26 These 
results indicate that there is an exchange of membranes or membrane proteins between 
exosomes and cells, and that, exosomes, therefore, harbour a communicative function. 
Aside from the membrane transfer, exosome content, such as proteins and RNAs, can 
also be shuttled between cells through exosomes.27 By transferring RNAs, exosomes 
are capable of transferring genetic information that can be translated into functional 
proteins in target cells.28
In the field of cancer research, there is an ongoing debate regarding their exact role 
as pro- or anti-tumor effectors. Experiments in mice have shown that cancer-derived 
exosomes can induce protective anti-tumor immune responses.29,30 It has been demon-
Figure 1. Schematic overview of different secretion mechanisms. (A) Secretion of signal peptide proteins 
through the classic consecutive route and processed through the rough endoplasmic reticulum and Golgi. 
(B) Merocrine secretion pathway. Cellular membrane buds inward and forms an early endosome. After the 
formation of such an endosome, cytoplasmic content is internalised into small vesicles (100 nm), the so-
called exosomes. When exosomes are present inside the endosome, the endosome forms a multivesicu-
lar body (MVB). The MVB fuses with the cellular membrane, and the exosomes are released. (C) Apocrine 
secretion pathway. Proportionately larger vesicles (500 to 1000 nm), such as oncosomes, are formed by 
membrane shedding.
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strated that exosomes isolated from malignant effusions are an effective source of tumor 
antigens to be presented to CD8+ cytotoxic T cells.31 In vitro-derived exosomes can even 
function as cell-free vaccines and lead to a decrease or stabilisation of tumor growth.32 
A possible explanation might be that exosomes initiate immune-mediated cell death. 
Nevertheless, these scenarios look promising in vitro under stress conditions 33 but do 
not seem to be well-applied to clinical settings.24 Opposite to the anti-tumor responses 
are other in vitro studies reporting a potential role of promoting tumor cell growth.34 
Particularly, the transfer of miRNAs through glioblastoma exosomes may induce tumor 
growth in a benign cell line.35 Because the effects and content of exosomes can be ver-
satile, it is not surprising that both pro- or anti-tumor effects have been described and 
that the role of exosomes might change during cancer progression.
Exosomes, prostasomes and other vesicles
Many types of vesicles have been described in literature. These vesicles are heteroge-
neous in terms of size, content and origin; therefore, they have different names. Unfor-
tunately, the differences in nomenclature lead to confusion. It is still unclear if all of the 
different vesicles are unique in biological function, or if they represent a sliding scale 
of one entity. Based on their biogenesis, however, vesicles could be generally divided 
into two classes: merocrine (inward budding and exocytosis, such as exosomes) and 
apocrine (surface shedding) synthesis (Table 1).
Studies on small vesicles in the field of urology mainly used the terms of prostasomes 
and exosomes. Usually, the vesicles isolated from seminal/prostatic fluids are called 
prostasomes. Confusion starts with vesicles isolated from prostate (cancer) cells cul-
Table 1. Characteristics of different types of vesicles secreted by prostate or PCa cells.33,45
Vesicle Size 
(nm)
Known protein 
markers
RNA marker
examples
Synthesis 
pathway
Function Reference
Exosomes 50 - 
150
CD9, CD63, CD81, 
CD82, Annexins, 
and RAB proteins
PCA-3,
TMPRSS2:ERG
Merocrine Antigen presentation, 
immune regulatory, 
and metastatic activity
10,45-47
Prostasomes 50 - 
500
CD13,CD46, CD55, 
CD59, Annexins, 
and RAB proteins
- Merocrine 
and 
apocrine
Immunosuppressive 
and sperm cell motility 
improving
36-39
Oncosomes 50 - 
500
Signal transduction 
proteins
DIAPH3 Apocrine ND 48
Microvesicles 100 - 
1000
Integrins, selectins, 
and CD40 ligand
EGFRvIII Apocrine Procoagulation and 
anticoagulation
35,49
Ectosomes
(microparticles)
50 - 
1000
CR1 and proteolytic 
enzymes
- Apocrine Procoagulation and 
anticoagulation
50,51
ND: Not Defined
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tured in vitro or grafted in mice. Currently, both prostasomes and exosomes are used. 
Therefore, the questions are whether prostasomes are prostate-derived exosomes, and 
whether the prostasomes from seminal fluid are the same as the vesicles secreted by 
cultured cells.
Prostasomes have a pure prostatic gland origin and are present in high concentrations 
in seminal/prostatic fluid.36 These vesicles are suggested to be shed through exocy-
tosis after their formation in a MVB (merocrine), such as exosomes, and possibly also 
by membrane shedding (apocrine).36 Compared to exosomes, they are enriched with 
cholesterol, sphingomyelin, Ca2+, GDP and many transmembrane proteins (CD13, CD46, 
CD55 and CD59).37-39
Electron microscopy (EM) showed that prostasomes are round and have a mean 
diameter of 150 nm (50 to 500 nm). This description is highly similar to the exosomes 
derived from prostate epithelial cells that are also round-shaped and have a diameter of 
100 nm (50 to 200 nm).10 A striking difference is that exosomes usually contain a lipid 
bilayer membrane, whereas prostasomes usually contain a cholesterol-rich lipid multi-
layer membrane.40 In terms of their functions, prostasomes have mainly been implicated 
in human reproduction by exhibiting a specific and favourable effect on the motility 
of spermatozoa 41 and by delaying acrosomal reaction.42 Potential immunosuppres-
sive activities of prostasomes have been demonstrated and are suggested to protect 
spermatozoa from phagocytosis by cells of the female immune system.43 The protein 
content of prostasomes is comparable to that of the exosomes derived from prostate 
cancer cell lines. Most of the identified proteins are well-characterised intracellular pro-
teins, including annexins, Rab proteins, heat shock proteins 70 and 90 (HSP70/HSP90) 
and signal transduction proteins.43,44 The identification of biomarkers for PCa, such as 
PSMA (FOLH1) that is also present in exosomes, suggests that prostasomes may be a 
valuable source for novel biomarkers. So far, no reports have been published assessing 
prostasomal RNAs.
According to their marginal differences in size, morphology and content, the two 
types of vesicles are similar. Only their functions and potentially their lipid composi-
tion differ. Nevertheless, we hypothesised that prostasomes are exosomes derived from 
prostate tissue in a biological setting. Experimental comparison between exosomes 
and prostasomes may help differentiate their specific prostasomal properties from the 
more general characteristics and clarify their similarities and differences in biogenesis, 
content and function.
Isolation and visualisation of exosomes
Isolation
For morphological and biochemical characterisation, exosomes are usually isolated by 
differential ultracentrifugation. This well-developed isolation method has been shown 
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to be effective and can process up to 250 ml of samples. Unfortunately, this method is 
time-consuming (approximately 6 hours) and, therefore, is unsuitable for daily clinical 
practice and might affect RNA and protein quality due to degradation. Therefore, faster 
and simpler isolation methods, such as filtration, precipitation and immunoaffinity puri-
fication, are needed. Filtration techniques have already been established and can rapidly 
enrich exosomes from complex fluids.47,52-55 Because it is particularly useful for smaller 
volumes, it could be easily implemented in a clinical setting.
When isolating exosomes from body fluids, it is impossible to distinguish exosomes 
derived from different tissues, which is a problem when searching for content in a subset 
of exosomes derived from a specific tissue or cell type. In this situation, immunoaffinity 
purification using beads or columns coated with an antibody directed against a tissue-
specific transmembrane protein can be applied.56, and unpublished work
Visualisation
Because of the small size of exosomes, EM is the most suitable technique for morphologi-
cal characterisation (Figure 2).48,57 Using gold-labelled immune electron microscopy, it is 
possible to investigate whether exosomes express certain proteins on their membrane.58 
Another way of visualisation is to use confocal microscopy (CM), with the membrane 
of exosomes fluorescently labelled.59 Although unlabelled exosomes are too small to 
be visualised by standard confocal microscopy, the lipophilic fluorescent dyes in their 
membranes is easily detected. Also, CM can be used to visualise exosomes isolated by 
antibody-covered magnetic beads (Figure 3). Another advantage of this technique is the 
possibility of studying the functions of exosomes and their interaction with host cells.60
Quantification of exosomes
Counting exosomes in a sample remains a challenge. The number of exosomes is gener-
ally estimated by measuring the amount of protein.47 The technology of fluorescence-
activated cell sorting (FACS) is capable of counting exosomes; however, individually 
measuring each exosome (relatively tiny compared to a cell) in a flow system is difficult 
Figure 2. Electron microscopic image of an exosome. Close-up view 
of an exosome derived from the PC346c cell line. The diameter of the 
vesicle is approximately 100 nm, and the membrane is a lipid bilayer.
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due to the resolution of the laser. These visualisation techniques (EM and CM) are not 
quantitative for determining the exact number of exosomes in a fraction but can be 
used to examine morphology and to determine transmembrane properties.
One study reported the successful use of a sandwich ELISA assay for exosome quanti-
fication.61 In this assay, two different transmembrane proteins present on all exosomes 
are used. In theory, when such an assay is developed using one general transmembrane 
(capture) protein and one tissue- or cancer-specific transmembrane (detection) protein, 
the number of exosomes derived from a specific tissue can be measured.
Exosomes as biomarker treasure chests
The molecular content of exosomes is dependent on their cell origin and strongly as-
sociates with the original cellular conditions.62 Therefore, the identification of tissue- or 
disease-specific exosomal proteins and RNAs will enable us to use these vesicles as a 
source of new biomarkers. Since the late 90s of last century, an increasing number of 
studies have investigated the protein content of exosomes and their potential diag-
nostic and prognostic values in various types of cancer, resulting in a comprehensive 
database consisting of 64 papers and a total of 2,400 different proteins.63 All of these 
protein identifications have been obtained by mass spectrometry. In terms of RNAs, the 
first study on exosomes was performed in 2007.28 Using microarray technology, they 
have shown that exosomes from mouse-derived bone marrow cells contain mRNAs and 
miRNAs. An increasingly number of papers, using microarrays as well, have described 
the potential role of proteins and miRNAs as diagnostic and prognostic tools.64-66
Until 2002, exosomes had been predominantly isolated and analysed from in vitro cell 
lines. More recent studies have showed that these vesicles can be isolated from body 
fluids, such as blood, urine, semen, amniotic fluid, malignant and pleural effusions, bron-
choalveolar fluid, synovial fluid, saliva, and breast milk. These findings demonstrate that 
exosomes are present in all body fluids and can be used for determining health status.67
Figure 3. Exosomes attached to an immunoaffinity bead and visu-
alised by confocal microscopy. These 4,500-nm size beads with anti-
bodies directed against the exosomal membrane protein CD9 are in-
cubated with fluorescently labelled exosomes derived from urine (100 
nm). This close-up view of one bead shows that it contains multiple 
(red) exosomes. The green mark indicates a single exosome attached 
to the bead.
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Exosomes as a diagnostic and prognostic tool for PCa
In terms of PCa, the reports on exosomes are very few. One of the first studies reported 
no apparent differences between exosomes of benign origin and malignant origin, 
regarding their synthesis, storage and release.68 Most likely, these vesicles may differ in 
biochemical properties. Unfortunately, so far, no high-throughput techniques, such as 
mass spectrometry and microarray, have been used to evaluate the differences between 
exosomes of benign origin and malignant origin to identify new biomarkers. Four stud-
ies used mass spectrometry to profile exosomes derived from PCa cell lines, xenografts 
and metastases. To search for PCa-secreted proteins, serum from PCa-xenografted mice 
was analysed by mass spectrometry. All of the identified proteins were screened for 
human-specific sequences by extensive database searching. The proteins containing 
human-specific sequences were of PCa origin. Interestingly, the subcellular localisation 
of most of these proteins is cytoplasmic, supporting the idea that these proteins are 
secreted in mouse blood through exosomes. Indeed, proteomic profiling of exosomes 
derived from human PCa cell lines confirmed the presence of almost all of the previous 
identified serum proteins.[26] Two other studies analysed vesicles from prostate cell lines 
and vertebral prostate cancer metastases by mass spectrometry; they identified pro-
teins related to angiogenesis, signal transduction pathways and cancer progression 48,69, 
including caveolin-1 (Cav-1), Akt, pyruvate kinase M2 (PKM2), programmed cell death 6 
interacting protein (PDCD6IP) and poly(A)-binding protein 1 (PABPC1). Subsequent in 
vitro functional assays (such as migration and proliferation assays) demonstrated that 
these vesicles can influence cancer microenvironment and promote cancer progression. 
Although these findings are promising, further investigations are needed to fully eluci-
date the role of PCa exosomes in cancer development.
Aside from these biological studies, exosomes and exosomal content from patient 
samples have also been evaluated for their potential as potential biomarkers. Urinary 
exosomes from 10 organ-confined PCa patients undergoing hormonal therapy prior to 
radical radiotherapy were analysed.58 Other than a considerable variation in the quantity 
of total exosomal proteins, no difference was observed between healthy men and PCa 
patients. Although these results do not specify which proteins are present in exosomes, 
it emphasises the technical feasibility of assessing exosomal proteins to evaluate the 
clinical status of PCa. However, better sample preparation, such as immunoaffinity isola-
tion, and more robust technical approaches are needed to define significant differences 
with such a huge variation.
RNA expression analysis of urine-derived and PCa cell line-derived exosomes revealed 
that the known RNA-markers for PCa, such as the TMPRSS2:ERG fusion gene and PCA3, 
can be detected in exosomes by RT-PCR.10 The TMPRSS2:ERG fusion transcripts were de-
tected in urinary exosomes from two patients with high Gleason scores but not in those 
from two patients with low Gleason scores.47 PCA3 mRNA was detected in exosomes 
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derived from all patients. Interestingly, none of the hormone-treated patients showed 
detectable levels of TMPRSS2:ERG or PCA3 RNAs, suggesting that the response to treat-
ment might reduce the size of PCa tissue and, thereby, decrease the expression levels of 
these androgen-responsive genes.
Exosomes in other urological malignancies
Very few studies on exosomes in other urological malignancies are available. One group 
(Welton et al.) published a report on the profiling of exosomes from a bladder cancer cell 
line.70 They measured exosomes derived from a single bladder cancer cell line by mass 
spectrometry and identified a set of protein biomarkers associating with bladder cancer, 
such as multiple tetraspanins and alfa-6 integrins . In respect of renal cell carcinoma, 
Zhang et al. evaluated the effects of exosomes as an immunotherapy tool by express-
ing GPI-IL-12 on exosomal membranes.71 Implementation of this protein in exosomes 
significantly promoted T cell proliferation, contributing to an enhanced cytotoxic effect 
of these T cells. This effect may improve tumor rejection, therefore suggesting that 
exosomes may have potential application in immunotherapy.
Considerations
The studies on small vesicles in PCa describe the first step in developing new methods 
and identifying novel markers for the diagnosis and prognosis of PCa. Although the ini-
tial results are promising, further investigations are required to assess the exact clinical 
values and the biological functions of exosomes.
To investigate prostate- or PCa-derived exosomes from complex body fluids, current 
isolation protocols (such as ultracentrifugation) are not optimal. Procedures according 
to these protocols result in a heterogeneous sample of exosomes derived from several 
different organs. Organ-specific isolation can be achieved by immunoaffinity capture 
beads coated with antibodies directed against organ- or cancer-specific proteins. Ex-
periments using latex or magnetic beads have been successfully used to achieve specific 
purification.47
For biomarker discovery from body fluids, it is important to decide which type of fluid 
to use. To search for markers from the prostate, serum, urine and semen are the obvious 
options. Collecting urine is less invasive, compared to drawing blood through venipunc-
ture, and urinary exosomal proteins are generally more stable because the proteolytic 
activity in urine is lower than that in serum.6 When urine is collected for prostasome/
exosome study, the procedure is preferentially performed after prostate massage to 
increase the quantity of exosomes.58
Evaluation of exosomal content from retrospective samples with different tumor 
characteristics and a generally long follow-up may provide us novel diagnostic and 
prognostic biomarkers for PCa. To use retrospective biobank samples, the knowledge 
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of collection, storage, and processing conditions of urinary and plasma serum samples 
is essential. Storage without multiple cycles of thawing and freezing of whole urine at 
-80 degrees Celsius does not seem to affect exosomal content 6. Exosomes can resist en-
dogenous proteolytic activity in urine for at least 18 hours at 37 degrees Celsius. These 
findings indicate that exosomes are quite stable in complex body fluids.
CONCLUSIONS
Exosomes are small vesicles (50 to 100 nm) secreted by almost all tissues, representing 
their tissue origin. By isolating these exosomes, several problems of biomarker discov-
ery from complex body fluids can be largely solved. Therefore, purification of prostate 
(cancer)-derived exosomes will allow us to profile the exosomes, providing a promising 
source of protein and RNA biomarkers for PCa. This profiling will contribute to the dis-
covery of novel markers for the early diagnosis and reliable prognosis of PCa. Although 
the initial results are promising, further investigations are required to assess the clinical 
value of these exosomes in PCa.
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ABSTRACT
Background
Current markers for prostate cancer, such as PSA lack specificity. Therefore, novel 
biomarkers are needed. Unfortunately, the complexity of body fluids often hampers 
biomarker discovery. An attractive alternative approach is the isolation of small vesicles, 
i.e. exosomes, ~100 nm, which contain proteins that are specific to the tissue from which 
they are derived and therefore can be considered as treasure chests for disease-specific 
biomarker discovery.
Materials and Methods
Exosomes were isolated from 2 immortalized primary prostate epithelial cells (PNT2C2 
and RWPE-1) and 2 PCa cell lines (PC346C and VCaP) by ultracentrifugation. After 
tryptic digestion, proteomic analyses utilized a nanoLC coupled with an LTQ-Orbitrap 
operated in tandem MS (MS/MS) mode. Accurate Mass and Time (AMT) tag approach 
was employed for peptide identification and quantitation. Candidate biomarkers were 
validated by Western blotting and Immunohistochemistry.
Results
Proteomic characterization resulted in the identification of 248, 233, 169, and 216 
proteins by at least 2 peptides in exosomes from PNT2C2, RWPE-1, PC346C, and VCaP, 
respectively. Statistical analyses revealed 52 proteins differently abundant between PCa 
and control cells, 9 of which were more abundant in PCa. Validation by Western blotting 
confirmed a higher abundance of FASN, XPO1 and PDCD6IP (ALIX) in PCa exosomes.
Conclusions
Identification of exosomal proteins using high performance LC-FTMS resulted in the 
discovery of PDCD6IP, FASN, XPO1 and ENO1 as new candidate biomarkers for prostate 
cancer.
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INTRODUCTION
Prostate Specific Antigen (PSA) is a clinically useful protein biomarker for diagnostics and 
follow-up after treatment for prostate cancer (PCa). Nevertheless, PSA-based screening 
was shown to have a high risk of overdiagnosis and overtreatment because it lacks speci-
ficity.1,2 In order to differentiate more accurately between benign prostate diseases and 
(different forms) of PCa, prevent unnecessary prostate biopsies, and support the urologist 
in recommending optimal treatment, new molecular biomarkers are urgently needed.
In the past few decades, a tremendous amount of research has been performed to 
find new and better biomarkers for PCa, often using state-of-the-art mass spectrometry 
technologies, but the discovery of novel low abundance protein has been generally 
hampered by the complexity of serum or urine.3 Isolation of exosomes from body fluids 
represents an attractive approach to bypass these limitations and enable detection of 
candidate (low abundant) biomarkers.
Recent findings in the search for new biomarkers have revealed that small exosomes 
(50-150 nm), are present in serum and urine.4 By isolating exosomes from body fluids 
it should be possible to overcome the dynamic range challenge and facilitate charac-
terization of tissue/cancer-derived proteins that might more accurately represent cel-
lular conditions. Therefore exosomes could be useful for determining individual tumor 
characteristics.5
In this study, our goal was to determine the presence and significance of exosomal 
proteins as novel candidate biomarkers for PCa by comparing exosomes from non-
cancerous prostate cell lines to exosomes from PCa cell lines.
MATERIAL AND METHODS
Cell culture and isolation
Two human immortalized prostate epithelial cell lines (PNT2C26 and RWPE-1) and two 
PCa cell lines (PC346C7 and VCaP8) were cultured in 10 T175 (175 cm2) culture flasks 
(Greiner Bio-One, Frickenhausen, Germany) up to 80-100% confluency. The PNT2C2 and 
VCaP cell line were cultured in RPMI 1640 (Lonza, Verviers, Belgium) and supplemented 
with 5% and 10% FCS, 500 U penicillin and 500 U streptomycin (Lonza, Verviers, Bel-
gium). The RWPE-1 cell line (ATCC-LGR, Wesel, Germany) was cultured in Keratinocyte 
Serum Free Medium (Invitrogen, CA, USA) and supplemented with 5 ml Pen-Strep and 
a commercial kit containing Bovine Pituitary Extract (BPE, 0.05 mg/ml) and Epidermal 
Growth Factor (EGF, 5 ng/ml). The PC346C cell line was cultured in Dulbecco’s modified 
Eagle’s medium-Ham’s F-12 medium (Lonza), supplemented with multiple additives as 
described by Marques.9
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After reaching 80-100% confluency, the cells were incubated with 25 ml serum free 
medium. After 48 h, the supernatant was collected and subjected to centrifugation 
steps of 400 xg (10 min), 3000 xg (20 min), and 10,000 xg (30 min) to remove cellular 
debris. Exosomes were then pelleted at 64,000 g (110 min), and at 100,000 g (Sucrose 
gradient) for 1 h.10 At least two separate exosomes isolations from each of the four cell 
lines were pooled. Total amount and concentration of exosomal proteins of the pooled 
samples was measured with a BCA-assay (Pierce, Rockford, IL, USA).
Electron Microscopy (EM)
5 µL of exosomes were spotted onto Formvar-coated grids (200 mesh) and fixed in 
2% paraformaldehyde. After fixation the exosomes were negatively stained using 4% 
uranylacetate. Grids were examined by a Philips CM100 electron microscope at 80 kV.
Sample preparation for Mass Spectrometry
TFE (2,2,2-Trifluoroethanol) (Sigma-Aldrich) was added to the samples to a final con-
centration of 50%. The samples were sonicated in an ice-water bath (Branson 1510, 
Danbury, CT) for 2 minutes and then incubated at 60 0C for 2 h with constant shaking 
(300 rpm). For protein disulfide bridge (S-S) reduction, DTT (Dithiothreitol) (Sigma-
Aldrich) was added at final concentration of 2 mM, followed by sonication for 2 min. 
The samples were spun down and incubated at 37 oC for 1 h with shaking (300 rpm). 
The samples were diluted, 5-fold with 50 mM ammonium bicarbonate (pH 7.8) prior to 
adding sequencing grade modified trypsin (Promega, Madison, WI) for protein diges-
tion (1:50 w/w trypsin-to-protein). The samples were shaken (300 rpm) over-night (16 
h). Rapid freezing of the samples in liquid nitrogen quenched the digestion. All samples 
were concentrated down in Speed-Vac SC 250 Express (Thermo Savant, Holbrook, NY).
Mass spectrometry
Proteomic measurements were performed using a nanoLC-MS at the Environmental Mo-
lecular Science Laboratory (EMSL), Richland, WA, USA. The analytical platform consisted 
of an on-line constant pressure (5000 psi) reversed-phase (C18) liquid chromatography 
(RPLC) system [150 µm i.d. × 360 µm o.d. × 65 cm capillary (Polymicro Technologies Inc., 
Phoenix, AZ)] coupled to an LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific, 
San Jose, CA) via an electrospray ionization (ESI) source manufactured in-house.11 Briefly, 
full MS were acquired over m/z range of 400-2000 at resolution of 100,000, followed by 
data-dependent LTQ MS/MS for the top six most abundant ions in each full MS scan, us-
ing a collision energy setting of 35% and dynamic exclusion time of 60 s. An exponential 
HPLC gradient of 100 min (from 0 − 70% B) was used for each analysis, with mobile 
phases consisting of 0.1% formic acid in water (A) and 0.1% formic acid in ACN (B). Each 
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sample was analyzed in triplicate, with approximately 5 µg of total peptide consumed 
(i.e., loaded on the column) in each analysis.
Mass Spectrometry Data Analysis
The resulting MS data was analyzed using the PNNL developed Accurate Mass and Time 
(AMT) Tag pipeline.12 SEQUEST software13 was used to search tandem mass spectra 
against the UniProt human database (download on April 5 2011). Confidently identified 
peptides (Suppl. Table 1) were assembled into an exosome-specific AMT tag database. 
For comparative analyses, LC-MS features were matched against AMT tags for identifica-
tion and relative MS-peak intensities were used to derive change in abundance. AMT tag 
approach facilitated quantitation of many more peptides than spectral counting alone. 
As long as a peptide was identified in at least one sample/analysis (by tandem MS), it 
could be quantified in all datasets where it was detected, even if the LC-MS feature was 
not abundant enough to be fragmented in that particular analysis. VIPER software14 was 
used to correlate AMT tag entries (identified peptides) with LC-MS features relying on 
high mass measurement accuracy (MMA <2 ppm) and normalized elution time accuracy 
(NET ~2.5%). Consequently, each LC-MS feature matched back to a single peptide (AMT 
tag) thereby giving a peak intensity value (or relative abundance) for that peptide. For 
redundant peptide identifications in the case of a single peptide matching multiple 
proteins (typically protein isoforms) a representive protein was chosen; therefore, each 
reported peptide matches back to a single protein. No peptide identifications were 
made on mass alone.
For the 263 identified proteins, the Human Protein Reference Database (HPRD) and 
Ingenuity Pathway Analysis (IPA) were used to determine subcellular location and bio-
logical function.15
Selection of potential protein biomarkers for prostate cancer was performed using 
two independent approaches. First, proteins were selected that were present in both 
PCa cell line derived exosomes and absent in both non-PCa exosomes. With the second 
approach, DAnTE software16 was used to convert peptide peak intensity values to a log2 
scale and assess them at a protein level using Rrollup (reference peptide based scaling) 
parameters where peptides were excluded from scaling if they were not seen in at least 
three datasets and no minimum peptide presence was required. Proteins presented in 
this manuscript were identified by at least two peptides. ANOVA pairwise comparisons 
between each PCa and control cell line were also performed in DAnTE where the mini-
mum number of data points per factor level was set at three, so that in order for a protein 
to show statistically significant changes it would have to be identified in all three repli-
cates. Significant difference was determined as a p-value and q-value lower than 0.05. 
DAnTE generates p-values and estimates their q-values. The q-value of a test measures 
the proportion of false positives incurred (called the false discovery rate) when that par-
84 Chapter 4
ticular test is called significant. Only the significantly different proteins were selected for 
unsupervised hierarchical clustering. TreeView software was used to log transform and 
mean center expression values, and subsequently cluster all the proteins based on their 
expression. To further select the most promising proteins, a ≥1.5 log2 fold change cutoff 
was applied along with a requirement that each protein showed significant change in at 
least two of the four comparisons listed in Table 1. Table 1 lists the resulting 52 proteins, 
9 of which showed increased (and 43 decreased) abundance in exosomes derived from 
the PCa cells.
To further select the most promising proteins from the two approaches, proteins 
were scaled based on prostate preferentiality. Five different human gene expression 
atlases17-21 based on microarray expression data were combined in SRS22, to determine 
protein-corresponding gene expression. Eventually, prostate preferentiality was deter-
mined as 1.5 fold higher expression in prostate tissue compared to kidney and bladder 
tissue using gene expression microarray data.23
Table 1. Proteins with significant abundance changes (>1.50 log2 fold) between prostate cancer and im-
mortalized primary prostate epithelial cell lines.
Protein Description (UniProt Accession #) gene_
symbol
PC346C/
PNT2C2
PC346C/
RWPE
VCaP/
PNT2C2
VCaP/
RWPE
Programmed cell death 6-interacting protein(Q8WUM4)* PDCD6IP 1.64 3.28 1.95 3.59
Elongation factor 1-alpha 2(Q05639) EEF1A2 1.92 3.18   1.83
Fatty acid synthase(P49327)* FASN 1.67 4.06   2.52
Ubiquitin-60S ribosomal protein L40(P62987) UBA52   2.44 1.98 3.03
Vacuolar protein sorting-associated protein 28 
homolog(Q9UK41)
VPS28 2.22 3.14   2.13
Actin-related protein 3B(Q9P1U1) ACTR3B   5.71   5.27
Basal cell adhesion molecule(P50895) BCAM     1.95 1.95
CD9 antigen(P21926)* CD9   4.13   2.58
Polyadenylate-binding protein 1(P11940) PABPC1 2.89   3.24  
14-3-3 protein beta/alpha(P31946) YWHAB -4.88 -4.11 -2.42 -1.64
Annexin A2(P07355) ANXA2 -7.86 -5.10 -5.60 -2.84
Sodium/potassium-transporting ATPase subunit alpha-
1(P05023)
ATP1A1 -3.23 -2.87 -3.38 -3.01
Sodium/potassium-transporting ATPase subunit beta-
1(P05026)
ATP1B1 -3.68 -3.03 -3.52 -2.87
Sodium/potassium-transporting ATPase subunit beta-
3(P54709)
ATP1B3 -2.79 -2.04 -2.33 -1.58
Basigin(P35613) BSG -2.90 -3.56 -4.62 -5.28
Chloride intracellular channel protein 1(O00299) CLIC1 -5.03 -2.85 -4.34 -2.16
Integrin alpha-6(P23229) ITGA6 -2.34 -4.84 -2.21 -4.72
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Table 1. Proteins with significant abundance changes (>1.50 log2 fold) between prostate cancer and im-
mortalized primary prostate epithelial cell lines. (continued)
Protein Description (UniProt Accession #) gene_
symbol
PC346C/
PNT2C2
PC346C/
RWPE
VCaP/
PNT2C2
VCaP/
RWPE
Junctional adhesion molecule A(Q9Y624) F11R -1.56 -1.58 -2.15 -2.17
Actin, aortic smooth muscle(P62736) ACTA2 -3.61   -3.97 -1.83
Potassium-transporting ATPase alpha chain 2(P54707) ATP12A -3.67 -2.32 -2.89  
Catenin beta-1(P35222) CTNNB1 -5.02 -1.73 -2.90  
Alpha-enolase(P06733)* ENO1 -3.63 -1.82 -2.18  
78 kDa glucose-regulated protein(P11021) HSPA5 -3.86   -3.56 -2.08
Importin subunit beta-1(Q14974) KPNB1 -5.13 -2.02 -2.15  
Pyruvate kinase isozymes M1/M2(P14618) PKM2 -4.02 -2.88 -2.19  
Triosephosphate isomerase(P60174) TPI1 -3.67 -2.19 -1.62  
14-3-3 protein epsilon(P62258) YWHAE -3.70 -2.73    
14-3-3 protein theta(P27348) YWHAQ   -3.17   -1.85
4F2 cell-surface antigen heavy chain(P08195) SLC3A2 -4.01 -5.90    
ADP-ribosylation factor 1(P84077) ARF1 -3.81   -3.12  
CD151 antigen(P48509) CD151     -4.41 -3.12
Coxsackievirus and adenovirus receptor(P78310) CXADR -2.70   -1.96  
EH domain-containing protein 4(Q9H223) EHD4 -2.77 -2.18    
Prostaglandin F2 receptor negative regulator(Q9P2B2) PTGFRN   -1.91   -2.76
Putative heat shock protein HSP 90-beta 2(Q58FF8) HSP90AB2P -3.60 -1.87    
Putative heat shock protein HSP 90-beta-3(Q58FF7) HSP90AB3P -4.05   -2.35  
Hemoglobin subunit beta(P68871) HBB   -5.21   -5.19
Ras GTPase-activating-like protein IQGAP1(P46940) IQGAP1 -5.14   -4.40  
Keratin, type I cytoskeletal 9(P35527) KRT9 -1.54 -1.88    
Keratin, type II cytoskeletal 2 epidermal(P35908) KRT2 -1.64 -1.92    
Lactadherin(Q08431) MFGE8 -2.02 -2.19    
Protein DJ-1(Q99497) PARK7 -1.80 -2.37    
Phosphoglycerate kinase 1(P00558) PGK1 -2.28   -2.13  
Peroxiredoxin-1(Q06830) PRDX1 -2.43   -2.14  
Ras-related protein Rab-10(P61026) RAB10 -3.10   -3.11  
Ras-related protein Rab-1A(P62820) RAB1A -2.93 -2.11    
Ras-related C3 botulinum toxin substrate 1(P63000) RAC1   -1.63   -2.42
Ras-related protein Rap-1A(P62834) RAP1A -3.01   -2.95  
Adenosylhomocysteinase(P23526) AHCY -1.97 -1.68    
Tubulin alpha-1A chain(Q71U36) TUBA1A -3.42   -1.80  
T-complex protein 1 subunit epsilon(P48643) CCT5 -2.72 -2.85    
UDP-glucose 6-dehydrogenase(O60701) UGDH -3.58   -3.13  
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Western blotting
From every exosome sample 5 µg of protein was mixed with Laemmli sample buffer 
(1:1), heated at 950C for two minutes and loaded onto 10% one-dimensional SDS-PAGE 
gels. Subsequently, proteins were transferred onto Protran nitrocellulose membranes 
(Whatman’s Hertogenbosch, the Netherlands) and blocked (1h) at room temperature 
with 5% nonfat dry milk in Tris-Buffered Saline with 0.1% Tween-20. Then, the gels 
were incubated overnight at 40C with antibodies against: PDCD6IP (1:500 dilution, 
Sigma-Aldrich), FASN (1:500 dilution, Sigma-Aldrich), XPO1 (1:200 dilution, Santa Cruz 
Biotechnology, Heidelberg, Germany), ENO1 (Clone H300, 1:1000 dilution, Santa Cruz 
Biotechnology), GAPDH (Clone 7B, 1:500 dilution, Santa Cruz Biotechnology), CD9 
(Clone 209306, 1:500 dilution, R&D Systems, Abingdon, UK), PSA (Clone A0562, 1:500 
dilution, DakoCytomation, Heverlee, Belgium). Secondary antibodies (HRP-conjugated 
Goat anti Mouse/Rabbit, 1:10,000 dilutions, DakoCytomation) were incubated for 1 h. 
BM Chemiluminescence Blotting Substrate (POD, Roche Applied Science, Almere) was 
used to initiate the oxidation by HRP.
Immunohistochemistry (IHC)
IHC expression analysis of candidate biomarkers was performed on: normal prostate 
tissue (NAP, n=2), PCa Gleason score 3+3=6 (n=2), and PCa Gleason score 5+4=9 (n=2). 
Tissues slides were mounted on aminoacetylsilane coated glass slides (Starfrost, Berlin, 
Germany), deparaffinised in xylene and dehydrated in ethanol. Endogenous peroxi-
dase activity was blocked with 0.3% hydrogen peroxide in PBS for 20 min. Microwave 
pretreatment was performed for 15 min in tris(hydroxymethyl)aminomethane-EDTA 
(pH 9.0). After pretreatment, the slides were incubated with the PDCD6IP (1:400), FASN 
(1:50), and XPO1 (1:50) antibodies, overnight at 4 0C. Subsequently, the EnVision DAKO 
kit (DAKO, Glostrup, Denmark) was used for chromogenic visualization. After staining 
the slides were counterstained with hematoxylin, washed, dehydrated and mounted in 
malinol (Chroma-Geselschaft, Körgen, Germany).
RESULTS
Isolation and characterization
Electron Microscopy (EM) of the purified exosome samples revealed that vesicles derived 
from four cell lines are reasonably homogeneous in size, with an approximate diameter 
of 70-200 nm (Figure 1). LC-MS/MS analyses after tryptic digestion, identified 1494 non-
redundant peptides (Suppl. Table 1), corresponding to 496 proteins by at least 1 peptide 
(Suppl. Table 2). 263 proteins were identified by at least 2 peptides, and specifically 248, 
233, 169, and 216 proteins were identified in the PNT2C2, RWPE-1, PC346C and VCaP 
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cell lines, respectively (Suppl. Table 3). Unsupervised hierarchical clustering of these 263 
proteins resulted in a clear distinction between cancer and control cell lines (Figure 2).
The identifi ed exosomal proteins in the 4 cell lines showed similar subcellular localiza-
tion patterns (Figure 3A). When compared to all proteins included in the IPA database, 
exosomes contain, relatively speaking, more cytoplasmic proteins and almost no extra-
cellular proteins. A majority of proteins detected within exosomes relate to tumorigen-
esis, cell death, protein synthesis, cellular growth and proliferation (Figure 3B).
Figure 1. Electron microscopic (EM) images of purifi ed exosomes derived from the PNT2C2, RWPE-1, 
PC346C and VCaP cell lines. All exosome samples contain multiple vesicles with a size in the range of 70-200 
nm. The darkness of the vesicles refl ects the diff erence in density of exosomes between samples.
Figure 2. Unsupervised hierarchical clustering of diff erentially abundant proteins (n=263 proteins with 
>2 peptides) based on their MS-peak intensity values. Each exosome sample was analyzed in triplicate. 
Results were mean centered and log-transformed. Relative protein abundance is colored-coded with red 
corresponding to a relatively high abundance, green r corresponding to a relatively low abundance, and 
grey indicating missing abundance values.
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Selection of potential biomarkers
To select proteins that show signifi cant change in abundance between the PCa exo-
somes and non-PCa exosomes we used ANOVA pairwise comparisons (i.e., p-value and 
q-value <0.05, presence in all analyses, ≥ 2 peptides).16 Supplemental Tables 5-8 contain 
results obtained for the PC346C (PCa) vs. PNT2C2 (control), PC346C (PCa) vs. RWPE-1 
(control), VCaP (PCa) vs. PNT2C2 (control), and VCaP (PCa) vs. RWPE-1 (control). To further 
improve confi dence, we required that each protein was determined to be signifi cantly 
changing in abundance in at least 2 comparisons; this further reduced our list to 52 
proteins (Table 1).
Figure 3. A. Subcellular assignment of the proteins identifi ed within the diff erent samples. Exosomes 
from all four cell lines (PNT2C2, RWPE-1, PC346C, VCaP) contained 60% of cytoplasmic proteins and 25% of 
transmembrane proteins. B. The top seven functions of exosomal proteins according to Ingenuity Pathway 
Analysis. Fisher’s exact test was applied to calculate signifi cance (p-value < 0.05).
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Our proteomic analysis indicated PDCD6IP, FASN, CD9, and ENO1 to have significant 
change in abundance between two conditions, while XPO1 did not pass our stringent 
filtering criteria and was therefore considered unchanged in abundance in the VCaP vs. 
RWPE-1 comparison (Suppl. Table 8). Even so, we chose to validate XPO1 because of its 
higher abundance in VCaP exosomes compared to the RWPE-1 control and the availabil-
ity of a high quality antibody suitable for Western blotting and immunohistochemistry.
Exploration of novel candidate biomarkers
For FASN and XPO1, strong signals were observed in whole cell lysates as compared 
to the exosomes and there appears to be relatively higher abundance within the VCaP 
exosome sample (Figure 4). The protein PDCD6IP is enriched in exosomes and shows 
higher abundance in both PCa-derived exosome samples as depicted in Figure 4 and 
Table 1. Based on the MS analyses, FASN is significantly higher in the PC346C exosomes 
compared to both controls and in VCaP exosomes compared to RWPE-1 control. This 
higher abundance of FASN in PC346C is confirmed by the Western blot. CD9 is highly 
enriched in exosomes and shows relatively high abundance in the PC346C exosomes. 
XPO1 exhibited higher abundance in the VCaP exosomes compared to controls. MS data 
characterized ENO1 to be significantly decreased in abundance in PC346C compared 
to both controls and in VCaP compared to the PNT2C2 control. Western blotting of 
ENO1 revealed an additional band (approximately 30 kDa) within the two PCa-derived 
exosome samples. As expected, based on the difference in PSA-secretion and exosome 
formation, PSA is predominately present in the two cancer cell samples and absent in 
exosomes. Supernatants that were collected after exosomes were pelleted during ultra-
centrifugation, did not contain any of the exosomal proteins, except ENO1 and GAPDH 
uniquely in VCaP medium.
Validation on clinical samples
PDCD6IP showed strong luminal and basal epithelial cytoplasmic staining in normal 
adjacent prostate (NAP), with no alteration in protein expression in PCa tissue with 
different Gleason scores (Figure 5). In NAP, FASN is moderately to highly abundant in 
epithelial cells. Nevertheless, when Gleason scores increases, staining becomes stronger. 
Regarding XPO1, there is a strong nuclear abundance in NAP and a weak cytoplasmic 
staining. Within PCa cells, the cytoplasmic abundance increases with Gleason scores. 
Nuclear staining remains equal among all PCa tissues.
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Figure 4. Validation of protein expression by Western blotting. All four exosome samples and their cor-
responding cell lines were used for validation. Furthermore, supernatant from the pelleted exosomes was 
used as a control. The selected proteins FASN, XPO1, CD9 and PDCD6IP, were tested with ENO1 and GAPDH 
as controls. PSA was tested to confi rm it is secreted through alternative secretion pathway and therefore 
not present within exosomes. The nearest protein marker (kDa) is indicated for each blot.
Figure 5. XPO1, FASN and PDCD6IP abundance by immunohistochemistry on normal adjacent prostate 
(NAP), low-grade prostate cancer (Gleason score 3+3=6) and high grade prostate cancer (Gleason score 
4+5=9). Representative pictures of the staining from 2 independent samples per group.
Proteomic profiling of exosomes 91
DISCUSSION
Comparison of exosomes derived from cancerous and non-cancerous cell lines provides 
a powerful tool to overcome the dynamic range challenge and identify novel low 
abundant cancer-derived biomarkers. This unique approach within exosomal protein 
research, combined with state-of-the-art LC-MS analyses facilitated identification of 
novel candidate biomarkers for PCa. So far, this manuscript is the first that describes 
expression amongst multiple PCa cell lines, but also analyses exosomes from multiple 
non-malignant prostate epithelial cell lines. This comparison enables us to identify PCa 
specific candidate biomarkers more properly. Also this paper is the first that describes 
validation of the expression of candidate protein markers on clinical patient samples, 
implying their true value as biomarkers.
The total number of unique proteins we identified in this study (496 by ≥1 peptide, 
263 by ≥2 peptides), is comparable with previously published exosome proteomic 
reports.24-28. Assignment of a subcellular localization revealed that a large proportion of 
exosomal proteins normally locate in the cytoplasm or nucleus of cells. After compar-
ing this to a database containing a vast majority of all proteins (~20,000), we noticed 
that exosomes have a relatively comparable abundance of nuclear proteins, higher 
Figure 6. Comparison of proteins identified by Hosseini-Beheshti et al., Sandvig et al. and this manuscript 
visualized by a Venn diagram. Every area represents the logical relations all identified proteins.
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abundance of cytoplasmic proteins and a substantially lower abundance of extracellular 
proteins. This fits the current theory of exosome formation.4 Exosomes display an over-
representation of transmembrane and cytoplasmic proteins, such as CD9 and PDCD6IP, 
as shown by Western blots. This finding agrees with the theory that biogenesis and 
selection of exosomal content is not a random procedure, but at least partly the result 
of a selective sorting process.4
Two recent proteomic studies revealed exosomal proteins related to prostate can-
cer;28,29 Sandvig et al. performed LC-MS analysis on a single prostate (cancer) cell line, 
were Hosseini-Beheshti examined five PCa cell lines and one non-malignant prostate 
epithelial cell line. They both reported 266 and 220 proteins, which is similar to the 
number we revealed. Interestingly, Sandvig et al. reported a different protein subcellular 
distribution and correlation with biological processes as compared to our data. Sandvig 
et al. proposed CDCP1 and CD151 as candidate markers, were Hosseini-Beheshti sug-
gested ANXA2, CLSTN1, FLNC, FOLH1 and GDF15. Hosseini-Beheshti et al. also showed 
FASN to be an exosomes-derived candidate biomarker (in agreement with our results). 
When we compare their identified proteins (by >2 peptides) we noticed an overlap of 
only 9 proteins, respectively CD9, ANXA1. ACTB, PGK1, RAN, EPCAM, HSPB1, PDCD6IP 
and PRDX1 (Figure 6).
These proteins have been published previously in multiple articles and are consid-
ered to be present in almost all exosomes. PDCD6IP has also been identified by both 
researchers, but has not been found to be marker for PCa. A total of 199 proteins have 
uniquely been found in our dataset, which contains our proposed and most promising 
candidate biomarker XPO1. The relative majority of overlap is with Hosseini-Beheshti 
et al (42 proteins in total), most probably because we analyzed exosomes from similar 
cell lines. Interestingly our data also has an overlap with Sandvig et al (45 proteins), but 
the overlap between them and Hosseini-Beheshti et al is relatively less. The large dif-
ference of proteins identified between all groups could be explained by different mass 
spectrometry techniques and data-analysis approaches.
We identified PDCD6IP as being enriched in exosomes, especially in PCa exosomes. 
PDCD6IP, also known as ALIX, is a cytoplasmic protein that is known for its role in 
apoptosis and is shown to be involved in the pathway of selected sorting by ESCRT-
complexes.30 PDCD6IP has been used as a general marker to prove the presence of 
exosomes.31 However, no association was made with a higher abundance in cancer-
derived exosomes. A possible explanation for high PDCD6IP abundance in PCa-derived 
exosomes could be that PCa cells have an altered production of exosomes, where they 
are unable to regulate the sorting of exosomal content properly anymore. It is also pos-
sible that cancerous cells attempt to remove the PDCD6IP protein by exosome secretion 
to (partially) suppress apoptosis. To complement this theory, other non-PCa related 
studies have shown that overexpression of PDCD6IP correlates with cell death.32 Using 
Proteomic profiling of exosomes 93
IHC, we did not find any difference in PDCD6IP abundance between normal prostate 
epithelium and PCa tissue.
Both FASN and XPO1 have a higher abundance in PCa exosomes derived from VCaP 
cells. FASN catalyzes the formation of long chain acids from acetyl-CoA, malonyl-CoA 
and NADPH and has already been suggested as a marker for PCa.33,34 Recent studies 
showed that FASN is primarily expressed in hormone-sensitive cells, promote cell pro-
liferation and that the inhibition of FASN effectively and selectively kills cancer cells.33 
However, these studies were all performed in vitro. The VCaP cell line used herein is 
hormone-sensitive, which could explain the higher abundance of FASN in VCaP-derived 
exosomes. Cancer cells produce more FASN, likely because it promotes cell proliferation, 
which could lead to higher incorporation into the exosomes. In agreement with previ-
ous results,35 we also observed a significantly increased abundance in PCa as compared 
to NAP.
XPO1 has been suggested as a prognostic marker for other types of cancer.36 XPO1 is 
a nuclear protein known to be involved in nuclear-cytoplasmic export of signal-bearing 
(NES) proteins, which play a role in relevant tumor signaling pathways, such as P53, AKT1, 
HDAC5, the androgen receptor (AR) and the EGFR.37-39 Our findings indicate that XPO1 
could be a potential biomarker for PCa. When this protein is validated on whole section 
PCa samples with IHC, we observe a strong nuclear expression and a very weak cytoplas-
mic expression. Interestingly, within cancer cells, this protein seems to translocate into 
the cytoplasm. When Gleason score increases, cytoplasmic XPO1 expression increases. 
Why this process occurs remains unclear. In a normal cell, XPO1 has to be transported 
from the cytoplasm back in the nucleus in order to function as a chaperone protein. 
If this relocation process is inhibited in cancer, cytoplasmic XPO1 will accumulate and 
more XPO1 might get incorporated in exosomes.
As published previously, an additional protein band (approximately 30 kDa) appears 
with Western blotting when using an antibody directed against ENO1 in the PC346C 
cell line.40 Here we show that this band is also present in VCaP exosomes and absent 
in exosomes from two non-PCa cell lines. The origin of the additional band could be a 
non-specific antibody cross-reaction to another protein, an alternative spliced ENO1, a 
translated fragment or a breakdown product from the original protein. A known protein 
isoform called MBP-1 (c-myc promoter-binding protein-1) is produced form the ENO1 
gene.41 MBP-1 is identical in sequence to ENO1 but lacks the first 93 or 96 amino acids. 
With a calculated molecular mass of 36 kDa, MBP-1 is unlikely the estimated 30 kDa ad-
ditional band. The observation that this additional band occurs only in both cancerous 
samples could indicate that it might have a relation to PCa.
Unfortunately, all previous published studies28,29 were discovery-based, and no cor-
relation was made to clinical samples. This report is the first that shows validation of 
exosomal proteins as prostate cancer biomarkers on patient samples. A recent report 
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by Principe et al showed the first identification of more than 900 proteins in exosomes 
derived from human prostate secretion from patients with low grade PCa and healthy 
men.42 When we compared their unique protein expression (presence of >2 peptides) 
only 31 proteins overlap, from which are multiple annexins (ANXA1-7), peroxiredoxins 
(PRDX1-6), PDCD6IP and general transmembrane proteins (CD9/CD242/CD44). All these 
proteins are thought to be present in almost all exosomes.
The new markers we identified came from cell line derived exosomes. It would be 
interesting to investigate whether these proteins could be identified in exosomes 
derived from urine samples43 or even tissue samples.44 As we showed, some candidate 
biomarkers could harbor clinical potential value for PCa and therefore should be tested 
on large cohorts of patient samples to fully elucidate their role as a biomarker for this 
disease. An option for validation could be a tissue micro-array, containing large numbers 
of prostate (cancer) tissue. Unfortunately, this assay does not assess exosomal proteins 
anymore but looks at cellular protein expression. In order to test exosomal proteins 
on large cohorts of patient samples it would be interesting to develop an assay which 
could measure exosomal proteins directly from urine of tissue samples. An ELISA-assay 
could be an option for this comprehensive task, where you can capture prostate-derived 
exosomes very easily from urine and subsequently perform protein detection assays. 
The ELISA-assay can be performed in two ways. The first is by using a detection anti-
body directed against exosomal transmembrane proteins. This technique enables us to 
identify these transmembrane proteins but also estimate the number of exosomes. The 
second potential use for this technique is capturing exosomes in the assay, disrupt the 
membrane by using a detergent and subsequently measure the released intra-exosomal 
proteins. So far the number of reports on exosome-based ELISA-assays is minimal. More 
research has to be performed to establish such an ELISA-assay which enables us to 
measure exosomal proteins.
CONCLUSION
Prostate (cancer) cells secrete exosomes that can be used to identify novel candidate 
biomarkers for PCa. Identification of exosomal proteins by high performance LC-FTMS 
resulted in the discovery of PDCD6IP, FASN, XPO1 and ENO1 as new candidate biomark-
ers for PCa. In the next phase, all proposed candidate biomarkers will be evaluated on 
patient samples (tissue, serum or urine) to fully elucidate their potential clinical value.
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ABSTRACT
Although many patients are cured from prostate cancer (PCa) by surgery only, there 
are still patients who will experience rising prostate-specific antigen (PSA) levels after 
surgery, a condition known as biochemical recurrence (BCR). Novel protein prognostic 
markers in PCa tissue might enable finding better treatment for those patients experi-
encing BCR with a high chance of metastasis. In this study, we aimed to identify altered 
proteins in prostate cancer tissue, and to evaluate their potential role as prognostic 
markers. We used two proteomics strategies to analyse 34 prostate tumors (PCa) and 
33 normal adjacent prostate (NAP) tissues. An independent cohort of 481 samples was 
used to evaluate the expression of three proteins: AGR2, FASN and LOX5 as prognostic 
markers of the disease. Tissue microarray immunohistochemical staining indicated that 
a low percentage of positive tumor cells for AGR2 (HR (95% CI) = 0.61 (0.43-0.93), and 
a low percentage of positive tumor cells for LOX5 expression (HR (95% CI) = 2.53 (1.23-
5.22) are predictors of BCR after RP. In contrast, FASN expression had no prognostic value 
for PCa.
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INTRODUCTION
Prostate cancer (PCa) remains to date the most commonly diagnosed cancer in men in 
the Western world.1 Although many patients are cured from this disease after radical 
prostatectomy (RP),2 one third of patients will show an increment in serum PSA levels 
-also known as biochemical recurrence (BCR).3 For those patients, more frequent follow-
up and adjuvant therapies are often required to limit progression of the disease,3,4 There 
is a high need for robust molecular markers that can distinguish indolent cases of PCa 
from those that will recur after initial treatment.3,4
Small molecules, such as metabolites and lipids, have been associated with the 
progression of different types of cancer, including PCa.5 In our previous study, using a 
LC-MS/MS-based targeted metabolomics method, we found lower concentrations of 
arachidonic acid (AA) in serum from PCa patients in the most aggressive stage of the 
disease.6 In addition, serum levels of hydroxyeicosatetraenoic acid (HETE) metabolites, 
which are produced by lipoxygenase-type enzymes from AA, were elevated in serum 
of part of the patients within the same group of advanced PCa.6 At tissue level, it has 
been reported that levels of AA in PCa were significantly lower compared to benign 
prostate tissues.7 In addition, Yang et al. analysed PCa core biopsies and they found that 
the 15-LOX-2 metabolite 15-HETE, was higher in PCa than in the normal cores.8 These 
findings suggest that the AA pathway might play an important role in PCa development 
and progression. However, analysis of proteins of the AA pathway in PCa, as well as their 
role in the prognosis of PCa is still unknown. In this study, we used two complementary 
mass spectrometry approaches to identify differentially expressed proteins in PCa tissue 
that could be used as prognostic markers for this disease. Protein signatures were vali-
dated in an extended cohort using immunohistochemistry on archival PCa tissue and 
an available tissue microarray. The expression of the selected proteins was evaluated for 
prediction of biochemical recurrence after radical prostatectomy.
MATERIALS AND METHODS
Clinical Specimens
Discovery set: The protein fractions from tissue RNA isolation of 67 samples (33 NAP tis-
sues and 34 PCa tissues) were analysed (MEC-2004-261); PCa samples were previously 
published (GSE41408),9 as well as additional cancerous and control samples, accessible 
via GEO accession number GSE59745.10 Clinico-pathologic characteristics of the samples 
used for proteomics profiling are presented in Supplementary Table 1.
Tissue Microarray (TMA)- Evaluation set: A Tissue Microarray (TMA) was constructed 
including 481 patients diagnosed with PCa from the European Randomized Study of 
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Screening for PCa (ERSPC).11-13 All patients had undergone RP in Erasmus MC between 
1987 and 2010, without previous radiation or hormonal therapy. Clinical follow-up was 
recorded after each control visit at our outpatient clinic, and data were transmitted to a 
central study database. Post-operative biochemical recurrence (BCR) was defined as an 
increment of 0.2 ng/mL in serum PSA after two consecutive measurements, with at least 
three months between measurements. Clinico-pathologic characteristics and follow-up 
for patients treated by RP are also summarized in Supplementary Table 1.
Sample preparation
Proteomics
The protein interface from tissue RNA isolation with RNA-Bee of 67 PCa tissue samples 
(33 NAP adjacent tissues and 34 PCa) were kept at -80 °C. For protein digestion, samples 
were thawed and 50 µL were transferred to a new microcentrifuge tube and precipitated 
with cold acetone. After spinning down for 10 minutes, the supernatant was removed 
and the pellet was washed twice with cold acetone. Supernatant was removed and 50 
µL 0.1% RapiGest (Waters Corporation, Milford, MA) 50 mM NH4HCO3 were added to 
the protein pellet. The protein pellet was dissolved by external sonication for 5 min at 
70% amplitude at a maximum temperature of 25 °C (Digital Sonifier model 450, Branson, 
Danbury, CT). The proteins were reduced with 10 mM dithiothreitol (DTT) at 60 °C for 
30 min. After the mixture was cooled down to room temperature, it was alkylated in 
the dark with 50 mM iodoacetamide at ambient temperature for 30 min, and digested 
overnight with 8 µL trypsin 0.1 ug/mL (Promega, Madison, WI). To inactivate trypsin and 
to degrade the RapiGest, 6 µL of 5% TFA was added and samples were incubated for 30 
minutes at 37 °C. Samples were centrifuged at maximum speed for 60 minutes at 4 °C 
and the supernatant was transferred to a new Eppendorf tube. A fraction of 5 µL was 
then diluted 40 times and subsequently transferred to LC vials for LC-MS analysis.
Chromatography Separation and Mass Spectrometric Analysis
Samples were measured using a nano-LC system (Ultimate 3000, Thermo Fisher Scien-
tific, Amsterdam, the Netherlands) coupled online to Q Exactive plus mass spectrometer 
(Thermo Fisher Scientific, Bremen, Germany). Chromatographic and mass spectrometry 
conditions used are described previously.14,15 Briefly, 2 µL were injected into the nano-LC 
after preconcentrating and washing of the sample on a C18 trap column (1 mm×300 
μm internal diameter) Thermo Fisher Scientific). Peptides were eluted after loading the 
sample on to a C18 column (PepMap C18, 75 μm ID × 500 mm, 2 μm particle and 100 Å 
pore size, Thermo Fisher Scientific) using a linear 90 min gradient (4-25% acetonitrile/
H2O; 0.1% formic acid) at a flow rate of 250 nL/min. The separation of the peptides was 
monitored by a UV detector (absorption at 214 nm). Data was collected in data-depen-
dent acquisition mode (DDA). Full scan MS spectra (m/z 400-1600) in profile mode were 
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acquired in the Orbitrap with a resolution of 70,000 after accumulation of an AGC target 
of 1 x 106 using a maximum fill time of 100 ms. The top 12 peptide signals (charge-state 
2+ and higher) were isolated (1.6 Da window) and fragmented by HCD (Higher-energy 
collision, normalized collision energy 28.0) and measured in the Orbitrap with a AGC 
target of 50,000, a maximum fill time of 60 ms and a resolution of 17,500. Dynamic 
exclusion was activated; after the first time a precursor was selected for fragmentation it 
was excluded for a period of 30 seconds using a relative mass window of 10 ppm. Lock 
mass correction was activated to improve mass accuracy of the survey scan. Technical 
replicates of each sample were randomly analysed within the measurement period and 
no significant changes in the number of identified proteins were observed in time for 
both the replicates and quality control measurements
Orbitrap-MS/MS Data Processing and Analysis
Label free Quantitation was performed using MaxQuant software (version 1.5.5.1).16 
Data was searched against the UniProt-Swiss-Prot 2014-4 database using the Androm-
eda17 search engine incorporated in MaxQuant. Cysteine carbamidomethylation was 
set as fixed modification and methionine oxidation and N-terminal acetylation were set 
as variable modifications. Peptide and protein identifications were set at a maximum 
False Discovery rate of 1%. We used the option “match between runs” option to allow 
matching identifications across measurements and the minimum number of peptides 
per proteins required for quantitation was set to 2.
Parallel Reaction monitoring (PRM)
PRM was performed on a nano-LC Fusion Orbitrap system. We used similar settings to 
the above-mentioned DDA measurements on the nano-LC, with the difference of an 
elution gradient of 60 min. A targeted MS/MS method was developed for 37 peptides, 
as presented in Table 2. A quadrupole isolation window of 1 m/z units, an AGC target of 
2e5 ions, a maximum fill time of 50 ms and an orbitrap resolving power of 240,000 at 
200 m/z were used. A fixed HCD normalized collision energy for all peptides of 27 was 
used, retention times were determined for all peptides, using multiple injections of a 
tissue sample in which a signal for all 27 peptides was present. Based on the determined 
retention times a scheduled method was established using a 3 minutes retention time 
window for each peptide.
Immunohistochemistry
Tissue slides (5 µm) were mounted on aminoacetyl-silane coated glass slides (Statfrost, 
Berlin, Germany), deparaffinised in xylene and dehydrated in ethanol. Endogenous per-
oxidase was blocked by 1% hydrogen peroxide in methanol for 20 min. Samples were 
pretreated by microwave (700 W) in TRIS-EDTA pH 9.0 or in citrate buffer pH 6.0 for 15 
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min. The slides were incubated overnight at 4 °C with the following primary antibod-
ies targeting anterior gradient protein 2 (AGR2; 1:100; HPA007912, Sigma); fatty acid 
synthase (FASN; 1:400; ab22759, Abcam, Cambridge, MA, USA); arachidonate 15-lipoxy-
genase type B (LX15B 1:2000, ab23691, Abcam, Cambridge, MA, USA), and arachidonate 
5-lipoxygenase (LOX5; 1:200 ab169755, Abcam, Cambridge, MA, USA).13 Chromogenic 
visualization was performed with the EnVision DAKO Kit (Dako, Glostrup, Denmark). 
After counterstaining with haematoxylin, slides were thoroughly washed, dehydrated, 
cleared in xylene and mounted in malinol (Chroma-Geselschaft, Körgen, Germany).
In the tissue microarray, immunohistochemical staining for AGR2, 5-LOX and FASN 
was visually examined as described previously.18 Staining intensity was scored as nega-
tive (0; no staining), weak (1+; only visible at high magnification), moderate (2+; visible 
at low magnification), and strong (3+; striking at low magnification). If there was het-
erogeneous expression, the strongest intensity was used for further analyses. For AGR2, 
the percentage of positive tumor cells was counted and used for further analyses. For 
optimization and validation of all immunohistochemical procedures we used appropri-
ate internal and external controls, and omitted first antibodies to exclude non-specific 
binding.19
Statistics
Protein annotation and statistical testing for differences (two-sided Student’s T-test, 
permutation-based FDR 0.05) in the proteomics shotgun experiments was performed in 
Perseus.20 Protein normalised intensities were log2 transformed before testing. The PRM 
data were analysed using Skyline version 3.5.0.9320 MacCoss Lab Software, Seattle, WA; 
fragment ions for each targeted mass were extracted and peak areas were integrated. 
Data matrix from PRM experiment was processed in GraphPad Prism 5 for Windows and 
R version 3.2.3. One-way Analysis of Variance (ANOVA) allowing multiple comparisons 
was used to estimate differences among Gleason score groups.
Associations between clinico-pathologic parameters and protein expression in TMA 
experiments were performed by student t-test or chi-squared test. Survival curves were 
calculated according Kaplan-Meier (KM), and to detect significant survival differences 
the Log-Rank test was used. Univariate and multivariate Cox regression were used to 
determine predictive properties of AGR2, LOX5 and FASN for BCR. A two-sided p- value 
of ≤ 0.05 was considered significant. Statistical analysis for the TMA expression was 
performed in SPSS version 22.
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RESULTS
Proteomics
In this study we aimed to fi nd protein signatures of PCa with potential applicability 
towards prognosis of the disease. To identify diff erentially expressed proteins in PCa, we 
used shotgun proteomics using the protein fraction from RNA-bee isolation of 34 PCa 
and 33 NAP tissues (Figure 1). Using label free quantifi cation (LFQ), a total of 2865 pro-
teins were identifi ed, and 798 proteins were statistically signifi cant (FDR<0.01). Figure 
2a illustrates the LFQ mean ratio between PCa and NAP, also indicating that an elevated 
number of proteins were up-regulated in PCa. The list of identifi ed proteins as well as 
the diff erentially expressed proteins in PCa is presented in Supp. Table 2. Two proteins, 
anterior gradient 2, AGR2, and fatty acid synthase, FASN, were highly up-regulated in 
PCa and their normalised abundances showed also a trend when compared with the 
Gleason score, as shown in Figure 2b-c. These two proteins were considered for further 
analysis.
Figure 1. Schematic representation of the identifi cation of markers associated to biochemical recurrence 
of PCa. Protein fractions from RNA isolation of PCa tissue were digested and analysed by nano-LC-MS/MS 
using both shotgun and PRM modes. Four selected proteins were validated by immunohistochemistry and 
three proteins: AGR2, FASN and LOX5, were analysed using TMA staining. Kaplan-Meier were constructed to 
evaluate the prognosis of the markers.
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To analyse whether proteins in the Arachidonic acid (AA) pathway could be used as 
prognostic markers for PCa, we manually searched the list of diff erentially expressed 
proteins and compared this list with the list of 79 proteins in the AA pathway as de-
scribed by Sabidó et al. (Supp Table 3).21 Interestingly, we identifi ed fi fteen proteins of 
the AA pathway in the list of de-regulated proteins, and particularly, prostaglandin E 
synthase 3. TEBP, showed a degree of correlation with the Gleason score, as is shown in 
Figure 2D.
We previously reported high levels of HETE metabolites in serum from PCa patients. 
In our shotgun proteomics dataset, we only identifi ed one lipoxygenase-type enzyme 
deregulated in PCa tissue: LX15B, but its expression is higher in NAP and the statistical 
test is signifi cant (p<0.05), as shown in Figure 2E. The deregulated proteins in PCa which 
are part of the AA pathway are presented in Figure 2A.
Gleason score, pT Stage and ERG oncogene status have been associated with poor 
prognosis of PCa. To evaluate whether proteins identifi ed in PCa tissue could be associ-
ated with these clinical parameters, we performed statistically tests on patients with 
diff erent Gleason scores (GS 6 vs. GS 7), diff erent pT stages (pT2, pT3, pT3) and whether 
ERG is activated or not (ERG oncogene-positive vs. ERG oncogene-negative). We did not 
fi nd statistically signifi cant proteins when comparing Gleason score or pT stage, but we 
Figure 2. A Volcano plot illustrating the proteins identifi ed in the shotgun proteomics approach. Non-dif-
ferentially abundant proteins are colored in blue whereas statistically signifi cant proteins are colored from 
red up to green (lowest p-value) Proteins belonging to the AA pathway are labelled in black letters. B-E Box-
plots of normalized abundances at diff erent Gleason scores for proteins AGR2, FASN, TEBP and LX15B. B-E 
Boxplots of normalized abundances at diff erent Gleason scores for proteins AGR2, FASN, TEBP and LX15B.
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found that 15 proteins were statistically significant when comparing ERG activation. In-
terestingly, three of these proteins belonging to the AA pathway and were up-regulated 
(FDR<0.01): phospholipase A2, PA2GA, arachidonate 15-lipoxygenase B, LX15B, and 
prostaglandin reductase 1, PTGR1. The list of differentially expressed proteins when ERG 
is activated is presented in Supp. Table 4. These results indicate that the AA pathway 
might play a role in ERG activation.
Table 1. A. Clinico-pathologic correlations in the PCa-TMA and AGR2 (percentage of positive tumor cells). 
Positive =100% positive cells, Negative = less than 100% positive tumor cells.
Negative Positive Total p-value
PSA at diagnosis
≤10 ng/ml 88 (21.8%) 264 (65.3%) 352 (87.1%) 0.141
>10 ng/ml 18 (4.4%) 34 (8.5%) 52 (12.9%)
Total 106 (26.2%) 298 (73.8%) 404
Gleason score
<7 44 (10.9%) 170 (42.0%) 214 (52.9%) 0.017
7 51 (12.6%) 112 (27.6%) 163 (40.2%)
>7 11 (2.7%) 17 (4.2%) 28 (6.9%)
Total 106 (26.2%) 299 (73.8%) 405
pT-stage
pT2 68 (16.8%) 212 (52.3%) 280 (69.1%) 0.121
pT3/4 38 (9.4%) 87 (21.4%) 125 (30.9%)
Total 106 (26.2%) 299 (73.8%) 405
B. Intensity of positive tumor cells, Negative = weak or no staining, Positive = strong staining intensity.
Negative Positive Total p-value
PSA at diagnosis
≤10 ng/ml 9 (2.2%) 343 (84.9%) 352 (87.1%) 0.203
>10 ng/ml 3 (0.8%) 49 (12.1%) 52 (12.9%)
Total 12 (3.0%) 392 (97.0%) 404
Gleason score
<7 2 (0.5%) 212 (52.3%) 214 (52.8%) 0.032
7 8 (2.0%) 155 (38.3%) 163 (40.3%)
>7 2 (0.5%) 26 (6.4%) 28 (6.9%)
Total 12 (3.0%) 393 (97.0%) 405
pT-stage
pT2 9 (2.3%) 271 (66.9%) 280 (69.2%) 0.465
pT3/4 3 (0.7%) 122 (30.1%) 125 (30.8%)
Total 12 (3.0%) 393 (97.0%) 405
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To validate the results obtained in the shotgun proteomics experiment, we performed 
parallel reaction monitoring measurements (PRM) on the same samples described 
above, and we included other proteins not identifi ed by shotgun approach in order 
to evaluate their potential as prognostic markers for PCa. We selected these proteins 
(Table 2) because they are involved in the metabolism of small molecules and fatty acids 
(polyamines, eicosanoids and phospholipids), as well as in the so-called Warburg eff ect, 
which also involves metabolic enzymes of metabolites present in the TCA cycle.22,23 
In total we analysed 18 proteins and each protein was quantifi ed using two peptides. 
Table 2. Predictive value of protein marker expression for biochemical recurrence (BCR) after radical pros-
tatectomy (RP).
Univariate Analysis Multivariate Analysis
HR (95% CI) P-Value HR (95% CI) p-value
Age 1.06 (1.01-1.10) 0.02 0.97 (0.91-1.04I) 0.46
PSA concentration 3.38 (2.22-5.16) <0.01 1.38 (0.68-2.82) 0.38
Gleason Score 2.66 (2.00-3.54) <0.01 2.39 (1.47-3.85) <0.01
pT-Stage 1.74 (1.47-2.05) <0.01 1.30 (0.99-1.72) 0.06
Surgical Margins 3.09 (2.12-4.50) <0.01 1.70 (0.90-3.17) 0.10
AGR2 Percentage of positive tumor cells 0.61 (0.43-0.93) 0.02 1.10 (0.60-2.01) 0.77
LOX5 Percentage of positive tumor cells 2.53 (1.23-5.22) 0.01 2.30 (1.08-4.98) 0.03
FASN intensity 0.84 (0.47-1.47) 0.55 - - -
Figure 3. Immunohistochemical staining in PCa tissue for A. Anterior Gradient 2 (AGR2) in Gleason score 6 
and Gleason score 9, B. Fatty Acid Synthase (FASN) in Gleason 7 and Gleason 9, C. 15-lipoxygenase-2 (15LXB) 
in Gleason score 8 and Gleason 9 and D: 5-lipoxygenase (LOX5) Gleason 6 and Gleason 8. Arrows indicate 
stating in positive cells.
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We included two peptides for PARK7, a protein recently described for normalisation 
of proteomics experiments,24 and as expected, peak areas between samples were not 
statistically signifi cant (p>0.05) diff erent.
AMACR, a known marker for PCa, and one of the proteins with the highest fold change 
and statistically signifi cant diff erent in the shotgun experiments, was included as posi-
tive control for the PRM measurements. ANOVA comparison between NAP and PCa at 
diff erent Gleason Scores indicated a high up-regulation in PCa (p<0000.1) for AMACR, 
confi rming the validity of our PRM set up. We could also confi rm the shotgun results of 
AGR2 and FASN proteins using PRM, in both cases the peak area and the Gleason score 
correlated well. A summary of the statistical calculations performed for the 18 proteins 
analysed by PRM is presented in Supplementary Table 5.
To validate the importance of the AA pathway in PCa and its possible application in 
prognosis, we analysed seven AA pathway proteins by PRM. We included LOX5 as it is 
involved in the production of eicosanoid-like compounds, and it was not identifi ed by 
shotgun. Statistical analysis presented in Supp. Table 5 indicated that LOX5 and TEBP are 
highly up-regulated in PCa tissue and they are also correlate with the Gleason score. On 
the other hand, LX15B, HYES, PGH1 were down-regulated (ANOVA, p<0.001) and LKHA4 
and FAAH were not diff erent when compared with the Gleason score.
To identify whether selected proteins involved in metabolic reprogramming (Warburg 
eff ect) are de-regulated in PCa, we included transitions for another seven proteins in the 
PRM setup. Interestingly, the ANOVA test indicated that ACSL3, GLSK, LDHA, LDHB and 
ANM1 proteins are statistically signifi cant (p<0.001). Two proteins involved in polyamine 
metabolism, SMS and SRM, were not diff erent between NAP and PCa, even though this 
pathway is known to be heavily deregulated in PCa.22
Figure 4. Kaplan-Meier curves assessing the probability of PCa biochemical recurrence after radical pros-
tatectomy by A: AGR2 and B: LOX5. Blue lines represent: AGR2: Percentage of tumor cells <100% B: LOX5: 
No staining. Red lines represent: AGR2: 100% of positive tumor cells, LOX5: <10% staining of positive tumor 
cells.
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Immunohistochemistry
Based on the results of the mass spectrometry experiments we selected four proteins 
for immunohistochemical (IHC) validation: AGR2, FASN, LOX5 and LX15B. These proteins 
were selected based on their correlation with the Gleason score and the availability of 
antibodies. In addition, these antibodies ought to work reliably using formalin-fixed 
paraffin-embedded (FFPE) tissue. IHC staining of the selected proteins on PCa FFPE tis-
sue sections is shown in Figure 3.
Figure 3.   Immunohistochemical staining in PCa tissue for A. Anterior Gradient 2 
(AGR2) in Gleason score 6 and Gleason score 9, B. Fatty Acid Synthase (FASN) in Gleason 
7 and Gleason 9, C. 15-lipoxygenase-2 (15LXB) in Gleason score 8 and Gleason 9 and D: 
5-lipoxygenase (LOX5) Gleason 6 and Gleason 8. Arrows indicate stating in positive cells.
AGR2 showed heterogeneous expression in normal luminal epithelium and PCa. AGR2 
staining was strikingly positive in cancer and negative in normal (Figure 3A). Expression 
of cytoplasmic FASN was negative to weak and rarely moderate in normal prostate lumi-
nal epithelium. Expression in PCa was stronger (1+/2+) than in adjacent normal tissue 
(0/1+) with locally strong expression (3+) in Gleason grade 7 and 9 areas (Figure 3B).
Expression of LX15B was generally moderate to strong (2+/3+) and occurred in both 
cytoplasm and nucleus of both benign luminal cells and PCa. Normal basal epithelium 
and atrophic prostate epithelium generally showed lower expression (0/1+). Stromal 
expression was negative (0) to weak (1+) (Figure 3C).
LOX5 staining was found to be predominantly expressed in the nuclei and cytoplasm 
of benign basal epithelial cells and atrophic luminal epithelial cells (1+ to 3+). Normal 
luminal epithelial cells were generally negative (0) or weakly positive (1+). PCa showed 
enhanced expressions as compared to benign luminal cells varying from weak to strong, 
but no clear association with the Gleason score was observed (Figure 3D).
Tissue Microarray
To determine whether expression of AGR2, FASN, and LOX5 might correlate with clinical 
parameters we analysed these proteins in 481 samples from RP patients. Cytoplasmic 
expression of AGR2 occurred in 84% (404/481) of the patients, with 52% of cores show-
ing strong intensity (3+). 74% (299/404) of the cores exhibited staining in 100% of tumor 
cells. Strong FASN staining occurred in 86% (399/461) of patients. We did not find any 
expression of LOX5 in 54% of the cores, and both the cytoplasmic and the nuclear inten-
sities were weak (1+) in most cases. The percentage of positive tumor cells stained for 
LOX5 was lower than 10% in the 224 positive cores. An association between the Gleason 
score (GS) and the percentage of positive tumor cells and intensity of AGR2 was found 
(p=0.017, and p=0.032, respectively, as described in Table 1A-B). AGR2 expression oc-
curred more often in patients with lower GS (42% in patients with GS <7 when analysing 
percentage of tumor cells, and 52.3% when cytoplasm was analysed). FASN expression 
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was higher in GS <7 and GS=7 (49.0% and 34.6% respectively) than in GS>7 (5.4%), but 
no correlation existed between FASN and PSA, GS or pT stage (Supplementary Table 6). 
A correlation between pT stage and cytoplasm intensity of LOX5 was found (p= 0.044, in 
Supplementary Table 7A). No other correlation was found when analysing cytoplasmic 
intensity, nuclear intensity, or percentage of positive tumor cells for LOX5 (Supplemen-
tary Table 7 B-C).
We constructed Kaplan Meier (KM) curves to identify the role of AGR and LOX5 in 
predicting BCR after surgery. We analysed if the percentage of positive cells of AGR2 
100% (positive) or lower than 100% (any negative) was predictive for BCR. We found that 
a percentage lower than 100% of positive tumor cells (<100%) in AGR2 was predictive 
for BCR (HR (95% CI) = 0.61 (0.43-0.93); p=0.02), as described in Table 2 and Figure 4.
For LOX5, we analysed whether the percentage of positive cells was negative (LOX5 
0%), or it had any expression (LOX5 > 0%). Expression for LOX5 was characterised by only 
a small percentage of positive tumor cells, being at maximum 10%. KM curves indicate 
that low percentage of LOX5 positive tumor cells is a predictor of BCR in comparison with 
negative staining (0%), in a univariate analysis (HR (95% CI) = 2.53 (1.23-5.22); p=0.002), 
as presented in Table 2 and Figure 4.
DISCUSSION
The Gleason score is an effective indicator of aggressiveness of PCa and therefore an 
important parameter to determine prognosis. However, more knowledge of which pa-
tients will relapse after radical prostatectomy and/or which patients will respond better 
to a specific treatment is still needed. AGR2 is a predictor of biochemical recurrence 
after performing TMA immunostaining in the Evaluation set (Figure 4), confirming previ-
ous reports for this protein as biomarker for PCa.25-27 Bu et al., demonstrated that AGR2 
is overexpressed in PCa, particularly in low-grade tumors and also in tumor precursor 
lesions PIN. In addition, high levels of AGR2 transcript were found in urine sediments 
from PCa patients.28 Two distinct splice variants of AGR2 in urine exosomes have been 
identified as effective markers distinguishing NAP and PCa.29 AGR2 has been reported to 
be induced by androgens in PCa,30 and its tumorigenic function is associated with cell 
growth, survival and metastasis, as recently reviewed.31
Fatty acid synthase (FASN) is known to be a key enzyme in the production of long 
chain fatty acids from Acetyl-CoA and Malonyl-CoA.32 Overexpression of this protein in 
PCa tissue has been reported in cell lines33, tissue microarrays34, tissue biopsy cores35 
and exosomes.36 FASN-normalised intensity was high in PCa in our proteomics dataset 
and its expression was independently evaluated by immunohistochemistry and a TMA. 
Although its expression does not predict biochemical recurrence, inhibition of FASN 
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has been proposed as a therapeutic target because of its increased expression and its 
relation to both cell cycle arrest and apoptosis.37 Our results reinforce the theory that 
FASN could be an important target to manipulate the fatty acid and lipid metabolism in 
cancer and therefore control cancer cell behaviour.38-40
The AA pathway is a key inflammatory pathway involved in cellular signalling as 
well as prostate carcinogenesis.41 Arachidonic acid is stored in cell membranes as a 
phospholipid, it is released by the action of phospholipase A2-type enzymes, and then 
metabolised by the action of cyclooxygenases (COX), lipoxygenases (LOX) and P450 
cytochromes to produce biologically active eicosanoids.8
We found that the abundance of lipoxygenase 15 type 2 (LX15B), an enzyme encoded 
by the gene ALOX15B, was lower in PCa than in NAP. Evaluation by immunohistochemis-
try showed a moderate increased abundance in both cytoplasm and nucleus of normal 
luminal cells and PCa when compared to normal basal epithelium. These results do not 
support our hypothesis that the previously reported high serum concentration of HETE 
metabolites could be explained by an up-regulation of this lipoxygenase-type enzyme.6 
Interestingly, low expression of LOX5 in PCa tissue is slightly higher in PCa compared 
to NAP, and this expression can be used to evaluate BCR after surgery (Figure 4). In ad-
dition, we noticed that expression of upstream enzymes, such as the phospholipases 
(PA2PA), is higher in PCa when there is an activation of ERG-oncogene (Supp. Table 4). 
These results highlight the importance of the AA pathway in PCa, and, particularly, when 
ERG is activated. However, functional studies need to be performed in order to analyse 
the link between ERG activation and the de-regulation of enzymes in the AA pathway, 
as well as the HETE metabolites or other eicosanoid-type fatty acids in the development 
of PCa.
Association of different enzymes of this family with PCa has recently been described 
in literature . Patel et al,42 studied the expression of cytosolic phospholipase A2 in PCa 
cells and they reported that increased levels of this enzyme were observed in androgen-
insensitive PCa cell lines and they suggested that this enzyme plays a role in cancer cell 
proliferation and apoptosis. PAFAH (PLA2G7) enzyme was identified by Vainio et al. in a 
set of 9783 human tissue samples and it was proposed as a potential drug target spe-
cially in ERG positive PCa.43 Validation studies performed by the same group indicated a 
correlation between staining intensity for PAFAH and Gleason Score in 50 % of the cases, 
thus suggesting that both enzymes can be seen as biomarkers for PCa, and the PAFAH 
inhibition by statins as a therapeutic tool for managing the disease.41
We found that the protein TEBP (PTGES3), was up-regulated in PCa tissue, TEBP protein 
is involved in eicosanoid signalling as it produces the Prostaglandin E2, involved in in-
flammation processes. In addition, it is reported to be an enhancer of androgen receptor 
activity. It is involved in AR binding to chromatin, which is a critical step in AR signalling 
and PCa development.44,45 Further validation is still required, using both quantitative 
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mass spectrometry and immunohistochemistry, to confirm a potential role of this pro-
tein in PCa diagnosis and prognosis. In addition, further analysis in-vitro, could address 
the role of the metabolite prostaglandin E, produced by TEBP along the AA pathway in 
PCa development and progression.
Cancer cells demand energy for proliferation and therefore there might be a metabolic 
reprograming in the cancer progression process (Warburg effect). By using both shotgun 
and PRM experiments, we noticed that some metabolic enzymes are de-regulated in PCa 
(Supp. Table 5). It is of interest that the expression of lactate dehydrogenase-A protein 
(LDHA) was significantly (p<0.0001) lower in PCa than in NAP, and it is also de-regulated 
when ERG is activated (Supp. Table 4). This result might be associated to previous reports 
for this protein indicating a key role in PCa oncogenesis.46 LDHA executes the final step 
of aerobic glycolysis and has been reported to be involved in tumor progression.47 It 
was recently demonstrated that LDHA overexpression is highly linked to local relapse 
of PCa.48
In conclusion, the experiments in this study allowed the identification of proteins and 
pathways associated to PCa. We identified a relationship between proteins in the AA 
pathway and PCa, and we have shown that expression of LOX5 and AGR2 in tissue pre-
dict biochemical recurrence after radical prostatectomy. Further validation studies on 
independent cohorts using different antibodies are needed to analyse the role of TEBP 
in PCa progression, as well as their clinical applicability. In addition, functional analyses 
are still required to fully understand their role in cancer cell proliferation, apoptosis and 
senescence.
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ABSTRACT
Introduction
Extracellular vesicles (including the subclass exosomes) secreted by cells contain spe-
cific proteins and RNA that could be of interest in determining new markers. Isolation/
characterization of PCa-derived exosomes from bodily fluids enables us to discover new 
markers for this disease. Unfortunately, isolation with current techniques (ultracentrifu-
gation) is labor intensive and other techniques are still under development. The goal of 
this study was to develop a highly sensitive time resolved-fluorescence immunoassay 
(TR-FIA) for capture/detection of PCa-derived exosomes.
Material and methods
In our assay, biotinylated capture antibodies against human CD9 or CD63 were incu-
bated on Streptavidin-coated wells. After application of exosomes, Europium-labeled 
detection antibodies (CD9 or CD63), were added. Cell medium from 37 cell lines was 
taken to validate this TR-FIA. Urine was collected (after digital rectal exam) from patients 
with PCa (n=67), men without PCa (n=76). As a control, urine was collected from men 
after radical prostatectomy (n=13), women (n=16) and patients with prostate cancer 
without digital rectal exam (n=16). Signal intensities were corrected for urinary PSA and 
creatinine.
Results
This TR-FIA can measure purified exosomes with high sensitivity and minimal back-
ground signals. Exosomes can be measured in medium from 37 cell lines and in urine. 
DRE resulted in a pronounced increase in CD63-signals. After DRE and correction for 
urinary PSA, CD9 and CD63 were significantly higher in men with PCa. 
Conclusions
This TR-FIA enabled us to measure exosomes with high sensitivity directly from urine 
and cell medium. This TR-FIA forms the basis for testing different antibodies directed 
against exosome membrane markers to generate disease-specific detection assays.
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INTRODUCTION:
Prostate specific antigen (PSA, KLK3) is a protein that is commonly used in daily practice 
to aid urologists in diagnosing prostate cancer (PCa). Although PSA has a high sensitiv-
ity, it lacks specificity and therefore causes unnecessary biopsies. Furthermore, PSA is a 
poor prognostic marker.1 In order to increase specificity and distinguish between the 
clinically insignificant cancers and the ones that are clinically relevant, novel markers 
have to be identified. Recent studies have shown that extracellular vesicles and par-
ticularly the vesicles from endosomal origin, referred to as exosomes, could help us in 
identifying novel tissue-specific markers. Moreover, also their presence and number 
might be indicative of disease.2-4
Quantifying the number of exosomes and characterizing them on single particle level 
remains challenging. To determine the number of exosomes in body fluids or measure 
an exosomal marker of interest, purification and concentration steps are often needed. 
Isolation of exosomes is most commonly performed by ultracentrifugation, filtration, 
precipitation or antibody-based capture technologies. Most of these protocols are still 
under development, labor intensive and limited with respect to efficient isolation or 
purity of the final exosomal preparation.5 Measuring the number and size distribution 
of the exosomes is a next challenge and technologies such as nanoparticle tracking 
analysis, tunable resistive pulse sensing and flow cytometry (FACS) are utilized, although 
again, each with their own set of limitations.6
In order to count exosomes or measure an exosomal protein marker in bodily fluids in 
a clinical setting, novel or optimized assays have to be developed. One technique that is 
of special interest is an immunoaffinity assay (e.g. ELISA or TR-FIA) directed against exo-
somal transmembrane proteins. With a sandwich-structure, exosomes can be captured 
without cumbersome preprocessing from body fluids (e.g. plasma, serum or urine) and 
characterized with antibodies directed against disease-specific markers. Although the 
quantity of the protein of interest is reliably measured, the immunoassays in this format 
do not provide an exact number for the concentration of exosomes.
Current efforts to establish such an immunoassay have room for improvement.7-9 
Published reports have shown a sandwich ELISA (CD9-based) with which it is possible 
to isolate and detect exosomes from plasma.7 Exosomes had to be purified first and the 
minimum amount of exosomes that could be detected was 3-10 µg exosomal protein. 
We developed a TR-FIA (time resolved-fluorescence immunoassay) against the trans-
membrane proteins CD9 and CD63. Both proteins are known to be commonly expressed 
on the membrane of exosomes derived from different cell types. Antibodies against 
these proteins were biotinylated for optimal capture and another batch labeled with a 
Europium-chelate for time resolved fluorescence detection. As compared to ELISA, the 
TR-FIA typically has a higher sensitivity and dynamic range and does not require an en-
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zymatic reaction.10 With this TR-FIA we showed that extracellular vesicles can directly be 
measured in cell medium and urine and can be used as a marker for the presence of PCa.
MATERIAL AND METHODS
Cell Culture
Prostate cancer cell lines (DU145, VCaP, PC3 and LNCaP), two immortalized prostate 
epithelial cell lines (PNT2C2 and BPH-1) and the hepatocellular carcinoma cell line 
(Hep3B) were used for exosome isolation. All cell lines were cultured in ten T175 (175 
cm2) culture flasks (Greiner Bio-One, Frickenhause, Germany) up to 80-100% conflu-
ency. DU145 (androgen independent)11, LNCaP (androgen dependent)12, PC3 (androgen 
independent)13 and PNT2C214 were cultured in RPMI 1640 (Lonza, Verviers, Belgium) and 
supplemented with 5% fetal calf serum (FCS) and 500 U penicillin/ 500 U streptomycin 
(P/S). BPH-115 and VCaP16 (androgen dependent) were cultured in the same medium and 
supplements, only with 10% FCS. Hep3B17 was cultured in Alpha MEM (Lonza) supple-
mented with 5% FCS and P/S. When 80-100% confluency was reached, cells were 48 h 
incubated with FCS-free medium. Cell medium was collected for exosomes isolation. All 
other cell lines tested were cultured under their optimal conditions in regular medium, 
containing various concentrations of serum. When 80-100% confluency was reached, 
cell medium was centrifuged 3000 x g and the supernatant stored for short term at 4˚C 
or long term at -80˚C.
Urine collection
Whole urine from men with PCa (n=67) and without PCa (n=76) was collected at the 
out patients clinic from the Erasmus Medical Center Rotterdam after written consent 
(Medical Ethics Approval number 2005-077 and 2010-176). Urine samples from men 
were collected after digital rectal exam (DRE) at the time of day most convenient to 
the person. DRE was performed to increase prostate fluid secretion and therefore the 
number of prostate-derived vesicles in the urine. From another 16 men with prostate 
cancer, urine was collected without DRE. From each prostate cancer patient, PSA-levels 
and prostate biopsy results (Gleason score) are known. Gleason scores varied from 6 
(3+3) up to 9 (5+4). Furthermore, whole urine from women (n=16) and men after radi-
cal prostatectomy (n=12) was collected at the person’s convenience and were used as 
controls. Patient characteristics are shown in Table 1. All urine samples were centrifuged 
at 3,000 x g (20 min) in order to remove cellular debris. Subsequently, urine samples 
were stored in 1.5 mL aliquots at -80 0C.
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Isolation of exosomes
Exosomes were isolated according to a protocol that was previously described.4,18 Briefly, 
cell culture medium was subjected to consecutive centrifugation steps (3,000 x g and 
10,000 x g) to remove cellular debris and large vesicles. Exosomes were then pelleted 
with ultra-centrifugation at 64,000 x g (2 h) and at 100,000 x g (1 h, in a 0.32 M sucrose 
solution). Sucrose supernatant was removed and pellets resuspended in 100 µL PBS and 
stored at -80 0C. Total amount and concentration of exosomal proteins was measured 
with a BCA-assay (Pierce, Rockford, IL, USA).
Time resolved fluorescence immunoassay (TR-FIA)
Biotinylation of capture antibodies
A streptavidin-coated 96-well plate (KaiSA96, Kaivogen, Turku, Finland) was used to bind 
biotinylated capture antibodies. CD9 (mouse monoclonal against human CD9, clone 
MAB1880, R&D systems, Abingdon, UK) and CD63 (mouse monoclonal against human 
CD63, clone 556019, BD Bioscience, Breda, Netherlands) antibodies were biotinylated.19 
Biotin isothiocyanate (BITC) was dissolved in ethanol to a final concentration of 10 mM. 
Before adding biotin, the antibody solution had to be adjusted with 0.5 M carbonate 
buffer to a pH of 9.8. For the most optimal final concentration of 2 mg/ml biotinylated 
antibodies, a 40-fold excess of biotin was used. Antibodies and BITC were incubated for 
4 hours at room temperature. Unreacted BITC was removed by gel filtration with a NAP-5 
column (GE-Illustra, Diegem, Belgium).
MaxiSorp plates (Thermo Scientific, Amsterdam, Netherlands) were used to bind exo-
somes directly to the plate (without capture antibodies) or to capture exosomes with 
unbiotinylated antibodies (CD9/CD63).
Labeling detection antibodies with Europium (Eu)
Antibodies used for Eu-labeling were CD9 (same as above), CD63 (same as above), and 
Human Kallikrein 2 (KLK2). 2 mg Eu-chelate (Perkin-Elmer, Turku, Finland) was dissolved 
in 200 µL sterile water and filtered through a 0.22 µm filter. From this, 100 nM Eu-chelate 
was dissolved in Enhancement solution (Product number 1244-105, Perkin-Elmer) to 
reach 1 nM. For optimal results the final concentration of labeled antibodies should be 
2 mg/ml. A 100-fold excess of Eu-chelates was added to the antibody. pH was adjusted 
to 9.8 with 0.5 M carbonate buffer. The antibodies and Eu-chelates were incubated 
overnight at 4 0C. Purification of the labeled antibodies was performed by gel filtration 
(FPLC), using a Superdex 200 column (GE Healthcare Europe, Helsinki, Finland) with a 
flow rate of 30 ml/h. Fractions containing the protein were pooled. BSA was added to a 
final concentration of 0.1% and filtered through a 0.22 um filter and stored at 4 0C.
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TR-FIA protocol
The streptavidin-coated plates were incubated with 200 ng biotinylated CD9 or CD63 in 
100 µL per well for 1 h with shaking (750 rpm) at room temperature. Supernatant was 
removed and the plates were washed with Wash buffer (Product nr 42-02, Kaivogen, 
Turku, Finland) three times with an automatic plate washer (TECAN Columbus). Sub-
sequently, samples (in triplicate) were diluted in the sample buffer and added to the 
wells and incubated for 1 h with shaking at room temperature. The plates were washed 
again three times. 25 ng of Eu-labeled antibodies was added per well (suspended in 
100 µL sample buffer) and incubated for 1 hour at room temperature. Excess antibody 
was removed and the plates washed again three times. 100 µL Enhancement solution 
(Perkin-Elmer) was added and incubated for 15 min at room temperature with slow shak-
ing. Europium (time resolved fluorescence) was measured by the Wallac Victor 2, 1420 
multilabel counter (Perkin-Elmer) at a wavelength of 615 nm. For analysis of the patient 
samples the assay was constructed with either biotinylated CD9 with Europium-labeled 
CD9 (CD9-assay) or the combination of biotinylated CD63 with Europium-labeled CD63 
(CD63-assay).
LNCaP cell culture medium was collected in a large batch, centrifuged at 3000 x g, 
aliquoted and stored at -80˚C for the 0, 25, 50 and 100 µL control concentration series for 
each 96-well plate we performed. These concentration series were used to correct signal 
level variability between plates.
Urinary PSA and creatinine
As a measure for the amount of prostate fluid present in the urine sample and abnormal 
kidney function, urinary total PSA and creatinine were used for normalization. Both 
urinary proteins were measured in urine with Roche-developed assays for creatinine 
(CRE2U, ACN 8152) and PSA (total-PSA, 04491734 016) by the Erasmus MC Department 
of Clinical Chemistry using a Roche Cobas 8000 Modular Analyzer (Roche, Woerden, the 
Netherlands).
Statistical analyses
GraphPad Prism 6 was used to visualize results and for statistical analyses. Unpaired 
T-tests were used to calculate p-values of expression values between different patient 
groups. Furthermore, this software was used to calculate correlation coefficients (r2) and 
ROC-curves.
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RESULTS
For optimization of the assay, several experiments were conducted. First, capturing exo-
somes via biotinylated antibodies to a streptavidin-coated plate versus direct exosome 
coating to a MaxiSorp 96-well plate was compared. Using biotinylated antibodies on 
streptavidin-coated plates increased signal intensity and lowered background signals 
(Figure 1A). Second, unconjugated CD9 or CD63 antibodies were directly coated on 
MaxiSorp plates. This resulted in up to 3 times higher background signals and limited 
signal increase when an increasing amount of exosomal proteins was added (Figure 
1B). Third, we tested whether the detergent/emulsifier Tween-20 could reduce back-
ground TR-FIA signals. Despite the theory that detergent might dissolve exosomal lipid 
membranes and impair the TR-FIA exosome detection, washing with Tween-20 0.05% 
improved Europium signal intensity (Figure 1C). Fourth, as a negative control for Eu-
ropium labeling, exosome-specificity was tested using Europium-labeled KLK2 which 
is not present on exosomal membranes. As expected, no signals were observed above 
background (Figure 1D). Fifth, FCS is rich in proteins and bovine-derived exosomes and 
therefore could interfere with the capture and detection of cell-derived exosomes. We 
spiked purified VCaP exosome samples (1 µg protein) in culture medium containing dif-
ferent concentrations (0-40%) of FCS. We observed no statistical difference, indicating 
that our assay does not detect exosomes in FCS and that FCS does not affect human-
specific detection of vesicles (Figure 1E).
The conditions we chose for the capture and detection of exosomes included a 
sandwich assay with streptavidin coated plates, biotinylated CD9/CD63 antibodies and 
Europium-labelled CD9/CD63 antibodies. Tween 20, at a concentration of 0.05%, was 
added to wash buffers to reduce background and increase CD9/CD63 signals.
Sensitivity analysis of the TR-FIA with purified exosomes
After optimization of the TR-FIA, sensitivity was tested with purified exosomes from 
the cell lines PC346C and VCaP. A minimum of 9.39 ng exosomes per well in 100 µL 
(measured by amount of protein present in purified exosome preparation) was enough 
to reliably measure CD9 signal. Capturing with biotinylated CD9 antibody and detec-
tion with the Europium-labeled CD9 antibody (CD9-assay) showed highest sensitivity 
for these samples after background correction (Figure 2). For capture with biotinylated 
CD63 antibody and detection with Europium-labeled CD63 antibody (CD63-assay), the 
lowest measurable amount of protein was 18.75 ng with VCaP exosomes and 37.5 ng 
with PC346C exosomes (Figure 2).
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Figure 1. Development of the TR-FIA (data on the CD63-assay not shown). (A) direct application of PC346C 
exosomes to uncoated plates without the capture antibody (direct) versus using streptavidin-coated plates 
with the biotinylated capture antibody (bCD9). Both exosomes were measured with europium-labelled 
CD9 antibody. (B) MaxiSorp plates were coated with non-biotinylated CD9 antibodies and compared with 
streptavidin plates that were coated with biotinylated capture antibody (bCD9). Both exosomes were mea-
sured with europium-labelled CD9. (C) Addition of 0.05% tween 20 in the wash buffer was tested in the 
CD9-assay. (D) Application of a Europium-labelled KLK2 in our assay as a control for membrane-specific 
binding. KLK2 is a protein secreted in a different cellular pathway and normally not present in exosomal 
membranes. (E) We spiked purified VCaP exosome samples (1 µg exosomal protein) in culture medium with 
0-40% FCS and performed the CD9 TR-FIA. All measurements were performed in triplicate and variance was 
estimated with the standard error of the mean (SEM).
Immuno-based assay for extracellular vesicles 153
TR-FIA with cell culture medium
The next step was to test whether minimally processed (only centrifuged once at 3000 
x g) cell culture medium and urine samples could directly be used for TR-FIA analysis. 
Serum free cell culture medium of the LNCaP cell line was collected after 48 h exposure 
to cells (when 80-100% confluency was reached) and tested in the CD9 and CD63 TR-
FIAs (Figure 3). High Europium signals were found within 100 µL cell culture medium 
and dilution series revealed a high linear correlation. After dilution of LNCaP cell culture 
medium, samples were aliquoted and used as calibration curve in all following experi-
ments. Subsequently, we tested 100 µL cell culture medium from 37 cell lines (Figure 4). 
In almost all cell lines both the CD9 and CD63 assay showed a signal above background, 
but levels varied dramatically. Some human cell lines had extremely low signals for CD9 
but were positive for CD63 (e.g. PNT2C2, TOV21G, H460, H295R and U2OS2-G3) or vice 
versa (e.g. EVSA-T, MOA MB453M and BPH1). Overall, the correlation between CD9 and 
CD63 signals among these cell lines was weak (r2=0.1816).
Figure 2. CD9-assay (A) and CD63-assay (B) on purified exosomes from the PC346C and VCaP cell culture 
medium. The amount of protein in purified exosome preparation is used as a measure for the number of 
exosomes (ng exosomal protein). All measurements were performed in triplicate and variance was esti-
mated with the standard error of the mean (SEM).
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FCS (bovine origin), which is often supplemented in cell culture medium, showed no 
signals in the assay (Figure 4, control medium). Also, no or very low signal was measured 
in non-human (mouse and dog) cell line medium. These findings are in agreement with 
the antibody specificity against human CD9 and human CD63.
TR-FIA with urine samples
A total of 135 patient urine samples (100 µL per well in triplicate) were analyzed with 
the CD9 and CD63 TR-FIA. Urine that was collected after DRE showed significantly 
higher Europium signals (Figure 5). Urine from men without a DRE or treated by radical 
prostatectomy did not significantly differ in CD9 and CD63 levels. Women had the low-
est signals compared to any other group tested. Figure 5 also depicts Europium counts 
between the samples (after DRE) with or without PCa in the two different assays. No 
significant difference was found between men with PCa and without PCa (CD9 p=0.166, 
CD63 p=0.223).
Since variability in DRE and urine volume will result in fluctuating concentrations of 
prostate (cancer) fluid in the voided urine, a correction factor is needed. We have chosen 
the urinary prostate-specific antigen PSA (UPSA) as a measure for the contribution of 
prostate fluid in the urine. In addition, urinary creatinine (UCr) was measured in each 
sample to analyze potential effects of differences in renal function. Distribution of 
UPSA (mean 3446.2, range 0.16-57100) and UCr (mean 10.4, range 1.7-30.2) is shown 
in supplemental Figure 1. No significant difference was observed in UPSA and UCr be-
tween men with and without PCa. UCr was lower in women, which is well known (data 
not shown).20 As expected, UPSA was much higher in urine from men that underwent 
DRE (on average 6171.3 ng/ml) and significantly lower in urine from men without DRE 
Figure 3. Dilution-assays with CD9 (A) and CD63 (B) of LNCaP cell culture medium. 100 µL cell culture 
medium was two-fold diluted for 4 times. As a control (0) medium was taken that was not exposed to cells. 
This control was used to correct for background signals. All measurements were performed in triplicate and 
variance was estimated with the standard error of the mean (SEM).
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(on average 317.2 ng/ml (p=0.032). Men treated by radical prostatectomy and women 
mostly had undetectable UPSA levels (data not shown).
After normalization for UCr the CD9 and CD63 assay showed no significant difference 
(Figure 6) between urine from men with and without PCa (both after DRE). However, 
when normalized for UPSA, the CD9 and CD63 signals were significantly higher in urine 
from PCa patients (p=0.0006; p<0.0001). The mean of the Eu-signal/UPSA ratio increased 
from 6.6 to 18.1 for CD9, whereas the mean ratio for CD63 increased from 16.1 to 58.2. 
The Receiver operating characteristic (ROC) curve for the CD63 assays showed an Area 
under curve (AUC) of 0.68 (Figure 7), indicating that within this small cohort, the TR-FIA 
has higher diagnostic accuracy in detecting prostate cancer than CD9 (AUC = 0.58) and 
serum PSA (AUC = 0.61).
Figure 4. Cell culture medium from cell lines (n=37) from different human malignancies was tested in the 
CD9 and CD63-TR-FIA. Two mouse cell lines and one dog cell line were taken as control. Cell lines were cul-
tured up to 80-100% confluency. When this was reached, medium was taken and centrifuged at 3000 x g to 
remove cellular debris. Measurements were performed twice with 100 µL independently from each other. 
Individual signal intensities were corrected for background (unexposed medium) and differences between 
measurements was corrected based on the same LNCaP control concentration series that was applied in 
both measurement. All measurements were performed in triplicate and variance was estimated with the 
standard error of the mean (SEM).
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DISCUSSION
The goal of this study was to design a non-invasive, sensitive assay for detection of 
(prostate cancer) exosomes in body fluids, which could be easily implemented in a 
clinical setting. We have reached most of these aims by constructing a TR-FIA using 
streptavidin-coated plates, biotinylated capture antibodies and Europium-labeled 
detection antibodies. This TR-FIA enabled us to detect prostate-derived vesicles with 
high sensitivity and over a broad dynamic range in shortly centrifuged (at low speed) 
post-DRE urine.
Since we use the same monoclonal antibody for capture and detection we do not mea-
sure single CD9 or CD63 molecules but distinct molecules kept together in membrane 
structures of, for example vesicles. Shortly centrifuged urine supernatant will not only 
contain the 30-150 nm (diameter) size exosomes, but also larger extracellular vesicles 
Figure 5. CD9-assay (A) and CD63-assay (B) on 
urine samples after DRE (DRE+) from men with 
(n=67) or without PCa (n=76), men with PCa 
(n=16) without DRE (DRE-), patients after radi-
cal prostatectomy (n=13) and women (n=16). 
Average of triplicate measurements is shown. All 
measurements were performed in triplicate and 
variance was estimated with the standard error 
of the mean (SEM).
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Figure 7. A Receiver-operating curve (ROC) for the CD63 and CD9-assay after correction for urinary PSA 
(UPSA). Serum PSA and urinary PSA from patients were also analyzed with a ROC.
Figure 6. CD9-assay (A and B) and CD63-assay (C and D) on urine samples from men with (n=67) or without 
PCa (n=76), after DRE. Assays were corrected for urinary creatinine (UCr. A and C) or urinary PSA (UPSA, B 
and D). All measurements were performed in triplicate and variance was estimated with the standard error 
of the mean (SEM).
158 Chapter 7
and membrane debris.21,22 As long as multiple CD9 or CD63 molecules are present, any 
membrane fragment can give a positive TR-FIA signal.
The TR-FIA signal measured is determined by the number of exosomes present, the 
number of antigens per vesicle and the affinity of the antibody to the epitope. For 
example, the high CD9 and CD63 signals in medium from COLO205 could mean that 
many exosomes were secreted and/or a high concentration of the antigens on each 
exosome. With the currently available techniques for quantifying exosomes such as flow 
cytometry, nanoparticle tracking analysis and tunable resistive pulse sensing, it is pos-
sible to estimate the number of vesicles. Unfortunately these techniques still have many 
restrictions such as vesicle size detection limits, quantitation accuracy and laborious 
procedures for regular and high throughput use.6 Whether these technologies correlate 
to the TR-FIA outcome, needs to be established. Regarding the clinical use of the TR-FIA 
for detection of prostate cancer, the difficulty to quantify vesicles is not necessarily a 
limiting factor as long as the signal is reliably measured and significant for the presence 
of disease. A complicating factor that arises within our TR-FIA and could influence results 
is the presence of viruses that use outward-budding from host cell membrane to form 
their envelope.23 For the HIV-1 virus it is known that this envelope contain the trans-
membrane proteins CD9 and CD63.24 We used exosomes from the VCaP and PC346C 
cell line that were provided from xenografts, which produce XMRV-like viruses. If these 
viruses also produce envelopes containing CD9 and CD63 is unknown, but if this is the 
case it could produce a signal in the TR-FIA.
In order to be able to check and correct for variability between TR-FIA plates, we 
used the high CD9 and somewhat lower CD63 signals measured in LNCaP cell culture 
medium. A large batch of medium was prepared and stored and new aliquots were used 
for each experiment. In the future, a more robust common universal standard, such as 
synthetic double-epitope peptides, will have to be devised for assay calibration.
One of the major improvements of the described assay over currently available 
conventional ELISAs is the use of Europium chelate used as a label for time resolved 
fluorescence.25 The main advantage of Europium is that the fluorescence emitted after 
excitation is long lived as compared to auto-fluorescence. Therefore, this technique 
reduces background and enables us to measure with high sensitivity. Furthermore, 
Europium can be measured over a much broader dynamic range (signal intensity 50 
– 300,000) as compared to conventional ELISAs (e.g. HRP-based). Other strategies to im-
prove immunoassays include the adapted proximity ligation assay (PLA) and amplified 
luminescent proximity homogeneous assay using photosensitizer-bead.26,27 Also these 
technologies show high sensitivity and the ability to measure vesicles in low volumes of 
bodily fluids but are relatively more labor intensive.
CD9 and CD63 are transmembrane proteins that are 7-10 times enriched in exosomes 
and are used as a general marker for exosomes.28,29 CD9 was shown to be higher ex-
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pressed in exosomes from prostate cancer, but also in other types of malignancies. 
Furthermore, CD9 was reported to have a specific role in metastasis.4,30-32 We showed 
that CD9 and CD63 are present on exosomes from almost all cell lines with varying 
signal intensities. Although CD9 and CD63 are considered common extracellular vesicle 
markers, we showed that these markers are detectable on exosomes from almost all cell 
lines (n=37) but with highly varying expression levels.
Control medium with FCS and animal cell lines such as those derived from mouse and 
dog showed no or very low signals. This demonstrates that our assay based on antibod-
ies against human CD9 and CD63 is indeed human-specific. The spike-in experiments 
revealed that high concentrations of FCS do not interfere in the detection of markers in 
the TR-FIA.
Although CD9 and CD63 are not prostate (cancer)-specific, we could use their pres-
ence as a marker for prostate-derived exosomes in urine, since levels were very low in 
urine from women, men after prostatectomy and men before DRE. This indicates that 
the number of exosomes and/or the levels of CD9 and CD63 on exosomes from kidney 
and bladder are low in urine as compared to prostate-derived exosomes after DRE. This 
is particularly evident for CD63. Initially, no statistical difference was observed in CD9 
and CD63 signals between men with and without PCa. Urinary creatinine, a marker for 
kidney function showed no additional value as a correction factor in our assay. Although 
serum PSA can be elevated in prostate cancer, urinary PSA itself has shown not to be dif-
ferent between healthy men and men with prostate cancer and therefore could function 
as correction factor for DRE in our assay.33-36 After correction for the relative amount of 
prostatic fluid after DRE using UPSA, a statistically significant difference was observed for 
both markers. These observations show that a DRE is currently an essential element of 
the urine collection. One could argue that a DRE is not necessary anymore if the CD9 and 
CD63-assays would be more sensitive. However, as a consequence of not performing a 
DRE, the lower ratio of prostate (cancer) exosomes among other urinary exosomes (from 
bladder and kidney) might result in loss of distinction between men with and without 
PCa. This issue could be resolved by using antibodies that specifically recognize prostate 
(cancer)-derived exosomes. Antibodies against known prostate (cancer)-specific trans-
membrane proteins need to be tested in the TR-FIA. Exosomal transmembrane proteins 
have been identified using mass spectrometry, but so far few of these proteins have 
been found higher expressed in cancer and none to be cancer-specific.4
The assay we developed reveals that measurements of urinary vesicles can indicate 
the presence of PCa. Because we only measured two markers in urine of men with or 
without PCa, it is unclear whether this assay is affected in men with other diseases of 
the urinary tract and in particular in diseases of the prostate such as benign prostate 
hyperplasia or prostatitis. Other steps to take include determining the assay robustness 
and intra-person variability at different time-points. In addition, we will further have to 
160 Chapter 7
select the optimal capture and detection markers as discussed above. The CD63 TR-FIA 
has an AUC of 0.68 and although this is already better than serum PSA alone in our 
cohort, it still does not fully address the clinical needs.
In this study we only assessed this assay as a diagnostic test. The limitations of the 
PSA assay results in taking unnecessary biopsies in approximately 68% of men with 
PSA higher than 3 ng/mL. In addition, with the cutoff of 3 ng/mL, approximately 13% of 
prostate cancers are missed.37 In our cohort, the CD63 TR-FIA outperforms the PSA assay 
in diagnosing prostate cancer. Logistic regression analysis showed no independence 
between the two assays (p>0.05). Even more relevant would be to predict whether the 
identified PCa should be treated or is insignificant and active surveillance is a valid strat-
egy to follow the patient. The main marker for prognosis currently is Gleason score. Since 
our cohort is based on men entering our clinic for their first consult, there is a strong 
bias towards Gleason score 6. In order to determine whether the TR-FIA has diagnostic 
and prognostic value, a larger cohort balanced for different Gleason scores needs to 
be analyzed. In conclusion, the CD63 TR-FIA could influence patient management with 
respect to making decisions on taking biopsies, while a role in tracking patients on ac-
tive surveillance and therapy selection is still to be investigated.
CONCLUSION
The presented TR-FIA enabled us to measure transmembrane proteins on vesicles di-
rectly in urine and cell culture medium with low background signals and high sensitivity. 
CD9 and CD63 are exosomal markers that show higher signals in men with PCa after DRE 
and correction for urinary PSA. More antibodies need to be tested using this TR-FIA to 
discover the most optimal combination of diagnostic and prognostic PCa markers.
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PART 3
 General discussion and appendices
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GENERAL DISCUSSION AND FUTURE PERSPECTIVES
Prostate cancer (PCa) is a heterogeneous disease with a variety in clinical, morphological 
and molecular genetic presentations between patients, within a patient, intertumoral 
and intratumoral.1,2 This heterogeneity causes many different PCa phenotypes with mul-
tiple clinical outcomes. Over the past decades clinical and molecular researchers have 
begun to unravel these different subclasses of PCa for more accurate diagnosis and a 
better estimation of prognosis.3 With this information, clinicians are increasingly able to 
select the most optimal individual treatment options (personal medicine).4
Current markers that enable us to determine diagnosis and prognosis in PCa, such 
as prostate-specific antigen (PSA), have shown to be a useful marker for daily clinical 
use.5 Unfortunately, PSA lacks specificity to distinguish between low risk PCa, high risk 
PCa and benign prostatic diseases. Consequently, the use of PSA with a specific cut-off 
value has shown to be related to a high risk of overdiagnosis and overtreatment.6 Novel 
biomarkers have to be found for better diagnosis and more reliable prognosis.
Despite rapid advances in technology, few biomarkers have made it to (pre-) clinical 
implementation.7 One of the problems with biomarker research is the so-called dynamic 
range problem. Especially regarding mass spectrometry, few high abundant proteins 
(e.g. albumin, immunoglobulins) overshadow low abundant proteins. The most interest-
ing candidate markers are probably among these low abundant serum proteins (concen-
tration of 10-3 ng/mL to 10-5  ng/mL).8 Even with current “state-of-the-art” technologies, 
discovering novel biomarkers remains challenging.9 As stated in the objectives of this 
thesis, we aimed to identify novel biomarkers for PCa that could help us distinguish 
between normal prostate tissue and PCa, but also estimate prognosis more accurately.
DISCOVERY OF BIOMARKERS WITH EXTRACELLULAR VESICLES
Since the beginning of this millennium, small tissue-derived extracellular vesicles (EVs), 
often referred to as exosomes, have been shown to be present in seminal fluid, urine 
(with or without DRE/prostate massage) and serum. Because of their biosynthesis and 
excretion pathway, they contain a wide range of proteins and RNA that represent their 
tissue of origin.10-12 Many different types of vesicles have been described with their own 
distinct characteristics (e.g. content, size and origin). These differences in nomenclature 
lead to confusion and made comparing vesicle research difficult. In order to improve col-
laboration between researchers, the International Society of Extracellular Vesicles (ISEV) 
was officially founded in the beginning of 2012.13 Involving all members of the society 
it was decided that the collective name of any type of vesicle is ‘extracecullar vesicle’ 
(EV). Also, all data from profiling EVs was combined to improve discovery and has led 
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to an extensive online database such as ExoCarta with more than 286 studies included, 
discovering 9769 unique proteins, 3408 mRNAs and 2838 miRNAs.14 Other databases 
that have been compiled and used are EVpedia, VesiclePedia and exRNA.15-17
The advantage of using these EVs for biomarker discovery is our ability to purify 
them from complex biofluids and therefore profiling their content is less hampered by 
high abundant proteins that are present in serum, plasma or urine. Furthermore, these 
vesicles express specific transmembrane proteins that could be used for more specific 
isolation and detection. In 2011 we published an overview of research regarding differ-
ent aspects of biomarker discovery for PCa by using EVs.9 Together with our own efforts, 
in the intervening seven years progress has been made and novel candidate markers 
have been proposed.
Diagnosis
Using MS-MS we identified 866 proteins, from which 263 proteins were differentially 
expressed between EVs from cancerous and non-cancerous prostate cell lines.18 From 
those proteins, 10 were significantly higher expressed in the PCa cell lines. We se-
lected PDCD6IP, FASN and XPO1 as most promising candidate novel EV biomarkers and 
validated their high expression. When we compared our complete list of differentially 
expressed proteins and with Sandvig et al.19 and Hosseini-Beheshti et al.20 only 9 showed 
overlap, where only our candidate marker PDCD6IP was also identified by Sandvig et al. 
Unfortunately, our study was the only one where PDCD6IP was higher in PCa-derived 
EVs. All 9 overlapping proteins where already shown to be identified in many EVs, also 
from non-PCa cells. Sandvig et al. showed CDCP1 and CD151 as candidate protein mark-
ers, whereas Hosseini-Beheshti et al found ANXA2, CLSTN1, FLNC, PSMA and GDF15 to be 
higher expressed in PCa. CLDN3 and GGT were also identified as candidate markers.21,22 
Further in depth proteomic analysis of EVs from clinical samples (prostatic secretions in 
urine) showed PSA, ACPP, TGM4 and PSMA to be higher expressed.23 In urine TMEM256, 
ADIRF, PCYOX1 and LAMTOR1 showed highest correlation with PCa.24 With an immune-
based assay, CD9 and CD63 were shown to be able to differentiate between PCa and a 
benign prostate by applying 100ul unprocessed urine.25 The clinical impact and variety 
of markers is discussed below.
Regarding RNA, PCA3, ERG and the TMPRSS2:ERG fusion gene were also found to be 
higher expressed in EVs in urine from PCa patients.26-29 In urine from PCa patients miR-
21, miR-141, miR-375, miR-483-5p, miR-1275, miR-1290, miR-107 and miR-574-3p were 
shown to be higher expressed.30-32 miR-196a-5p and miR-501-3p were downregulated in 
urinary EVs from PCa patients.33 These findings suggest that microRNA from EVs might 
serve as a marker for PCa.34 These markers need to further studied in large patient co-
horts to elucidate their true potential.
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Many studies profiled EV-content and revealed promising candidate markers for PCa. 
Despite more tissue/disease specific selection of these proteins/miRNA by using EVs and 
therefore bypassing the dynamic range problem, published studies show no overlap 
in their most distinctive markers. One of the explanations could be the variety of tech-
niques used for identification of protein/RNA markers used among the different studies. 
Especially in mass spectrometry, quality and resolution (better accuracy mass-to-charge 
ratio) have been improved over the years and tandem mass spectrometry (MS/MS) for 
de novo protein sequence information was introduced.35,36 A second explanation could 
be that even with these current techniques, there are still too many high abundant 
(most likely less interesting) proteins in EVs. Thirdly, the use of stringent cut-off values 
for selection of most differential expressed proteins could be part of this problem. Every 
study tries to select 3-5 most promising candidates, whereas there probably is more 
overlap when less stringent cut-off values were applied (e.g. top 20). A fourth possible 
problem that could contribute to these differences, is the use of different cell lines and 
patient groups. Even between PCa cell lines there is a difference in specific protein 
expression.25 This difference is probably also present between or within patient groups 
and subsequently could influence identification. Fifth, isolation techniques for EVs and 
their content could introduce variations in concentration and purity.37 Especially in PCa, 
rectal massage or digital rectal exam (DRE) causes more prostatic fluid in the urethra/
urine and major alteration in protein identification.29 In our study (Chapter 7), we 
showed an enormous increase in the number of urinary EVs upon DRE.25 It is expected 
that PCa urinary PCa markers are much more abundant after DRE and therefore remains 
important for future assays.
With improving techniques and increasing sensitivity we should keep on searching 
for new markers (protein and RNA) and profile more samples from well characterized 
patient groups. Besides identification of a single marker, future research should also fo-
cus on a panel of markers that could possibly better predict significant disease and more 
reliable prognosis. Some clinically available tests that already use such a combination to 
predict the chance of high risk PCa prior to biopsy (Table 1).
Regarding our own work and the identification of XPO1 as most promising candidate 
marker for PCa, it would be interesting to test if this protein has any clinical relevance in 
other diagnostic tests besides Gleason score, surgical margins and pT stage. Besides IHC 
on samples after invasive biopsies or radical prostatectomy, currently no non-invasive 
diagnostic tests are available for direct measuring XPO1 in serum or urine, therefore 
direct translation to the clinic remains difficult. It would be interesting to proceed with 
the exploration of the clinical value of XPO1 and subsequently establish a reliable assay 
for this marker.
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Prognosis
Besides markers for diagnostic purposes, it is interesting to know if EV markers could be 
used to determine prognosis to prevent invasive treatment such as radical prostatec-
tomy for insignificant PCa. Also, it is interesting if these markers can be used to predict 
response to therapy. Unfortunately, the number of reports on prognostic markers is lim-
ited. We tried to correlate XPO1-expression to several clinic-pathological parameters but 
did not identify such a correlation. Other studies showed substantial clinical relevance 
regarding decreased expression of miR-34a in PCa progression and poor prognosis in-
vitro.38 In clinical plasma samples miR-1290 and miR-375 were shown to correlate with 
poor survival in castration resistant PCa (CRPC).39 High expression of miR-141 and miR-
375 in plasma was found in patients with metastatic PCa.31 One study found miR-2909 to 
be higher expressed in urine from patients with high risk PCa.40 Yu et al. profiled miRNA 
in serum EVs from a small group PCa patients before they started with radiotherapy.41 
They found a set of miRNAs that could predict therapeutic effect. An in-vitro study by 
Kharaziha et al., showed that MDR-1, MDR-3, Endophilin-A2 and PABP4 to be enriched 
in the docetaxel resistant DU145 cell line.42 Within the docetaxel resistant PC3 cell line, 
but also in clinical samples, P-glycoprotein (P-gp) was higher expressed.43 Interestingly, 
when P-gp was knocked down, the sensitivity to docetaxel increased. Kawakami et al. 
showed ITGB4 and VCL were upregulated in docetaxel resistant PC3 cell line. Silencing of 
these proteins showed no alteration in proliferation and Taxane resistance but showed 
attenuated cell migration and reduced invasion.44
Recently, the AR-V7 mRNA was identified as a predictive marker for response to the 
anti-androgen enzalutamide and the CYP17 inhibitor/anti-androgen abiraterone.45 The 
primary discovery was made using circulating tumor cells, but Del Re et al., showed 
that also plasma EVs contain the AR-V7 splice variant and can also be used a predictive 
biomarker. 46
Table 1. Overview of commercially available blood/urine assays for PCa based on a panel of markers that 
are applicable prior to prostate biopsy.
Test Source Substrate Clinical relevance Reliability
SelectMDx38 Urine (after DRE) mRNA DLX1 and HOXC6 vs KLK3 Probability for high risk PCa AUC 0.87
ExoDx Prostate 
(Intelliscore)39
Urine EV-derived mRNA PCA3, ERG 
and SPDEF
Probability for high risk PCa AUC 0.74
Michigan 
Prostate Score 
(MiPS)40
Urine (after DRE)
and blood
mRNA TMPRSS2:ERG and PCA3 
and serum PSA
Probability for high risk PCa AUC 0.73
Prostate health 
index (PHI)41
Blood Total PSA, free PSA and [-2]
proPSA
Probability for high risk PCa AUC 0.72
4K score42 Blood Total PSA, free PSA, intact PSA 
and human kallikrein-related 
peptidase
Probability for high risk PCa 
+ risk of distant metastases 
within 20 years
AUC 0.80
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VALIDATION OF BIOMARKERS FROM EVS
Validation is an essential step in the process of biomarker assay development. This 
phase verifies the differential expression between samples and gives the opportunity to 
test the candidate marker in an independent validation set (patient cohort). Especially 
with in vitro studies, discovery of potential candidate markers is mostly validated with 
labour intensive techniques (e.g. Western blotting) and with the similar and limited 
number of EV samples. So far, there are very few studies describing the validation of 
EV-derived markers in large independent (patient) cohorts with enough power. Worst 
et al. validated the presence of CLDN3 in serum in 84 patients with a significant higher 
expression in localized high risk PCa (Gleason score ≥ 8).21 Wang et al. showed that their 
mass spectrometry-identified markers also had higher expression in an immunoaffinity-
based assay with urinary EVs from PCa patients (n=16).47 Li et al. showed that miR-141 
was higher in EVs isolate with ExoQuick in patients with PCa (n=20) and even higher in 
metastatic PCa.48 Our group has shown that EV-derived markers (XPO1) could be vali-
dated with a tissue micro-array in a large group of patients (n=481). One urine EV-based 
assay made it into a clinical setting (ExosomeDx Intelliscore). This assay isolates EVs from 
whole urine (non-DRE) and measures the ERG and PCA3 mRNA expression as compared 
to SPDEF. Besides proof of differentiation between groups, it needs to be shown that 
the marker has independent added clinical value. The markers must add to established 
markers (e.g. Gleason score and PSA) or be cheaper or more convenient when as good 
as current practice.
In general, the number of reports that describe the validation and added clinical 
value of candidate markers in patient cohorts are remarkably low. The studies that 
are published use relatively small groups and labour-intensive techniques (isolation 
of EVs via ultracentrifugation or ExoQuick) that are unsuitable for daily practice or 
high-throughput analysis. In order to make a validation assay, it is important to make 
it reproducible, easy to perform and with the possibility to analyse many samples on 
one platform. Also, when analysing EVs from bodily fluids (e.g. serum, urine or semen) 
it is important to choose which material to utilize. The most ideal material has to be 
taken via minimally-invasive techniques. Because discovery of biomarkers from serum 
is hampered by the abundance of many analytes, urine is an interesting and slightly less 
complex source.49
TECHNIQUES FOR ENRICHMENT AND CHARACTERISATION OF EVS
Isolation of EVs is classically performed by ultracentrifugation. This technique has 
been well developed and can be used to process up to 250 mL of a single sample.9 
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Unfortunately ultracentrifugation requires expensive equipment and is time consuming 
(>5 hours) and cannot be performed high throughput. In order to reduce the time for 
isolation, multiple techniques have been developed such as ultrafiltration, precipitation, 
affinity capture and size exclusion chromatography. Although less laborious, each one 
of these techniques have issues with yield, purity, costs and/or isolation of EV subpopu-
lations.50
Furthermore, we are currently not able to absolutely quantify EVs and analyse them 
on a single particle level.25,51 Since the number of exosomes could possibly be useful for 
correction of assay input, but also have diagnostic or predictive value52, quantification 
is an important step. Current techniques that are utilized, such as nanoparticle tracking 
analysis, tunable resistive pulse sensing and flow cytometry show promising results but 
have their own set of limitations.51,53-56 Besides technical restrictions of quantification of 
EVs, a major challenge is the isolation and quantification of subsets of EVs, particular the 
cancer derived EVs because serum or urine contain a heterogeneous pool of EVs, derived 
from various tissues. Flow cytometry is capable of tissue-specific analysis of EVs in a 
complex fluid. An assay that can count or define EV subpopulations is typically based on 
immune-affinity. Antibodies directed against transmembrane proteins expressed on EVs 
(e.g. CD9, CD63, PSMA) can be used for tissue-specific isolation and characterization.57 
Previous reports have shown that EVs can be isolated from cell culture and plasma with 
an ELISA or with (magnetic) beads.58-62 With our own efforts we were able to establish 
a reliable and highly sensitive TR-FIA (time-resolved fluorescence immunoassay) by 
using antibodies against the transmembrane proteins CD9 and CD63.25 With this assay 
we have shown that EVs from urine from PCa patients had higher expression of these 
transmembrane proteins after correction for urinary PSA. Although showing correla-
tion with PCa, these proteins are known as general markers for EVs.63,64 Ideally more 
PCa-preferential transmembrane proteins, such as PSMA, need to be tested that might 
predominantly recognize PCa-derived EVs.65 Immune-affinity isolation seem to be ideal 
for EV-research, but unfortunately as a separate assay it is also time-consuming and 
therefore less attractive for daily clinical use. An assay that highly selectively captures 
EVs from body fluids and directly characterizes or measures its content of interest, would 
be most ideal. So far, our developed TR-FIA sums up most of these needs and seems to 
be promising for future research.
EVS AS BIOMARKER TREASURE CHESTS IN LIQUID BIOPSIES
The concept of personalized medicine is considered a new epoch in cancer manage-
ment, where for each patient, clinical decision support can be provided regarding indi-
vidual treatment. The clinical application of personalized medicine in PCa is broad and 
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compromise early detection, diagnosis, prognosis, prediction of treatment response and 
disease progression.66 An important aspect of this approach is that each patient needs 
to be stratified, according to several individual and cancer characteristics. Currently the 
most important factors for PCa besides easy acquirable PSA and clinical stage (by DRE) 
are Gleason score and signs of metastases (CT-scan, MRI, bone scan and/or PSMA-PET). 
Unfortunately, Gleason score can only be obtained via invasive biopsies (with risk of 
complications) and for evaluation of metastasis a time consuming and expensive 
technique has to be applied. Non-invasive techniques, such as liquid biopsies, could 
be applied more often with low chance of morbidity. Especially for PCa it also has the 
advantage of reflection of many tumor subclones, whereas biopsies only represent one 
specific tumor region.67 The most promising body fluid components as PCa biomarker 
are circulating tumor cells (CTCs), ctDNA and EVs (Table 2). CTCs and ctDNA harbour the 
same potential as EVs in liquid biopsies and have been used to predict clinical stage and 
monitor the course of PCa.68-70 Unfortunately, they tend to be only present in blood in 
advanced stages.71 So far, CTCs are clinically not useful for localized disease. Soekmadji 
et al. showed that CD9 positive EVs are higher expressed in advanced metastatic PCa 
with detectable CTCs.72 Interestingly, the androgen receptor (AR) splice variant 7 (AR-
V7) can be detected in plasma EVs from CRPC patients and seems comparable to AR-V7 
detection in CTCs.45 Resistance to hormonal therapy could potentially be predicted.46 
Although EVs seem to be a promising source of biomarkers, new EV-based assays for 
PCa have to established and evaluated in order to fully elucidate their true potential as 
liquid biopsy.
LIPIDOMICS
Most publications on biomarker discovery using EVs, focus on their intravesicular pro-
teins or RNA and extravesicular (transmembrane) proteins. Based on their biogenesis 
they also contain a bi-lipid membrane reflecting (subdomains of ) the membrane of the 
Table 2. Most promising non-invasive source for PCa biomakers from body fluids (serum/urine)
Protein RNA DNA Advantages Limitations
Circulating 
tumor cells 
(CTC)
+ + + Quantification and analysis of content 
(e.g. AR-V7) helps in predicting 
outcome and treatment respons
Detection of CTC is stage 
dependant, mainly in advanced 
stages
Cell-free 
tumor DNA
- - + Abundant in plasma. Reveal genomic 
alterations, predict outcome and 
treatment response
Only present in advanced stages
Extracellular 
vesicles 
(EVs)
+ + -/+ Present and detectable in all stages 
of prostate cancer. Can be found in 
urine.
Smaller than CTCs and therefore 
could have a subfraction of all 
cellular proteins/RNA
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cell from which they are derived. This lipid aspect of EVs has not obtained sufficient 
attention. Lipid composition has been measured by mass spectrometry, thin layer chro-
matography and gas liquid chromatography.73,74 Several reports have been published 
describing lipid content and their enrichment factors from cells to EVs (2-3 times more 
cholesterol, glycosphingolipids, phosphatidylserine and sphingomyelin).75 How this en-
richment occurs remains relatively unknown. Only few studies described lipid analysis 
from urinary EVs from PCa,76 but only one study compared this lipid content between 
patients compared to healthy individuals.77 High expression of lactocylceramide oc-
curred in PCa patient and phosphatidylserine in samples from healthy individuals. Heav-
ily underexposed, characterization of EV lipids from more PCa patients with different 
clinical stages could contribute to finding new lipid-markers.
EVS AND TUMOR BIOLOGY AND THERAPEUTIC IMPLICATIONS
The biogenesis of EVs has been described previously.9 How this process is organized and 
which factors influence this process is still not fully known. We do know that multiple 
factors play an important role in formation and secretion. Endosomal sorting complexes 
(ESCRT) and multiple Rab-proteins regulate this process. Excretion of EVs has important 
regulatory functions, such as discarding unnecessary content from cells (lysosomal deg-
radation), but also in cell-cell communication. Especially this latter function could be of 
interest in tumor biology. EVs express many transmembrane proteins that interact with 
recipient cells. Malignant cells could theoretically influence their surrounding cells and 
subsequently change their microenvironment to their own advantage. So far, several 
in vitro studies have shown that EVs from malignant cells do alter their microenviron-
ment (e.g. promote angiogenesis) and promote tumor progression.78-82 Also EVs from 
metastatic site-derived cell lines are taken up more efficiently by benign cell lines and 
increased proliferation and migration.83-85 Delivery of the proteins via EVs could even 
could contribute to PCa progression and induce neuro-endocrine differentiation.86-88 
Several studies suggested that EVs from malignant cells  released in the tumor-bone 
interface, are involved in pathological regulation of bone cell formation in the meta-
static site.89-91 An important finding from the last few years, is the role of EVs in acquiring 
chemotherapeutic resistance during therapy.92 Although more and more publications 
report the role of EVs in tumor biology, more research is needed to fully understand 
how they interfere with their microenvironment. Understanding this process could 
potentially lead to novel treatment strategies for malignant diseases.
Multiple studies have shown EV composition and biology have an effect on recipient 
cells. These findings gave rise to the hypothesis that EVs itself or alteration of EV biology 
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could be used a therapeutic option. To date, the number of reports on EV-mediated 
therapy in PCa is limited but is gently increasing.
Alteration of EV biogenesis
Because emerging evidence links the presence of circulating EVs to PCa progression, 
some studies tried to alter exosome production/secretion in order to treat malignant 
diseases. Manumycin-A, a natural microbial metabolite, was shown to inhibit EV bio-
genesis and secretion by CRPC cells, but not in normal prostate cells. Unfortunately, no 
effect was observed on cell growth.93 In breast cancer a similar effect was observed.94 
From pre-clinical data it was shown that EVs from adipose tissue derived stromal cells 
and menstrual stem cells inhibit PCa growth and angiogenesis. Therefore, these EVs 
from these cells could be a novel therapeutic strategy in PCa.95
Alteration of EV immunogenicity
In vivo tracking studies have found that when EVs are administered systemically, most 
of them are taken up by macrophages and do not reach the organ or cells of interest.96 
In order to reduce immunogenicity and improve their therapeutic effect on recipient 
cells, they can be ‘coated’ with a ligand. Ohno et al. showed that EVs can efficiently be 
delivering miRNA to EGFR-expressing breast cancer cells by genetically altering donor 
cells to express the transmembrane domain of platelet derived growth factor receptor 
fused to the GE11 peptide.97 A similar approach was used to express Lamp2b on den-
dritic EVs in therapy for Alzheimer’s disease.98 To avoid genetic manipulation, EVs can 
also be loaded with iron nano-particles and chemotherapeutics.99 By using a magnet 
close to the recipient cells, these EVs could be manipulated by magnetic force and sub-
sequently delivering their drug. Unfortunately, genetic modification and iron loading of 
EV-secreting cells remains challenging and time consuming. A more practical approach 
by Kooijmans et al. is the use of ligand conjugated polyethylene glycol (PEG) to decorate 
EVs after production.100 With this PEG coating they improved cell specificity and pro-
longed circulation time, potentially improving drug delivery. This approach can also be 
used to fuse EVs with functionalized liposomes to create smart biosynthetic hybrid vec-
tors.101 Interestingly, this fusion approach could theoretically enable efficient EV loading 
of pharmaceutical drugs. Regarding PCa, no reports harbouring these techniques have 
been published.
EV-targeted therapy
EVs have been shown to have multiple roles in cancer by interacting with target cells and 
the tumor environment (e.g. creation of pre-metastatic niche). With these abilities EVs 
can also contribute to cancer metastasis.102 An interesting approach in therapy for ma-
lignant diseases is therefore EV-targeted therapy. Nishida-Oaki et al. used anti-CD9 and 
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anti-CD63 antibodies to deplete EVs and achieved a significant reduction in metastasis 
to the lung, lymph nodes and thoracic cavity in mice.103 This effect was also observed 
in pancreatic cancer.104 These results demonstrated the concept of inhibition of EVs as 
prevention of metastasis and could therefore be beneficial for patients by achieving 
longer survival with less comorbidity.
Delivery of biological or pharmaceutical agents
Although the number of reports on this topic in PCa is also very limited, Johnson et al. 
showed that EVs could be loaded with pharmaceutical agents.105. Saari et al. showed that 
when EVs from PCa cell lines were loaded with Paclitaxel and subsequently administered 
to PCa cells, drug delivery into recipient cells was observed and subsequently had an 
effect of cells.106 Another approach could be loading of EVs with small interfering RNA 
(siRNA) by co-incubation and electroporation.107,108 These siRNAs are small RNA and can 
alter gene expression in cells and have a potential beneficial effect. Milk-derived and 
siRNA loaded EVs showed reduction of a target gene in hepatocellular carcinoma.109 The 
number of reports on this method is increasing, but one major limitation of this method 
is its lack of efficiency and scalability for loading siRNA into EVs. More research is needed 
to clarify if this method is suitable for daily clinical use.
The design of future studies and therapeutics should acknowledge the existence and 
role of EVs, and seriously consider strategies for manipulating or circumventing their 
effects in vivo.
From the work presented in this thesis and published by the EV community, it is clear 
that vesicles are highly promising with respect to disease biomarkers and novel therapy 
interventions. The first EV-assays utilized in a clinical setting are on their way and many 
more are expected once robust assays are developed and the EV-markers independently 
validated.
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Prostate cancer (PCa) is the second most common malignancy in men after non-mela-
noma skin cancer. Approximately 11.700 men are diagnosed yearly in the Netherlands, 
from which 2800 men die because of this disease. Current markers for PCa, such as PSA, 
have a good sensitivity but lack specificity. Also, PSA-based screening leads to a high 
risk of overdiagnosis and overtreatment. Therefore, new molecular markers are needed.
Chapter 1 presents the general introduction and objectives of this thesis. This chapter 
gives an explanation on what defines a tumor marker and what types of markers are 
available. Also, the source of biomarkers (tissue/fluid) is discussed with its advantages 
and disadvantages. The process with subsequent steps that are needed for a marker to 
become a clinically useful marker are explained.
When looking for new markers for PCa, it is important to know which markers already 
have been identified. Chapter 2 provides an overview of all the markers that were 
already found when we started our research. The most widely accepted and commonly 
used marker PSA, but also its isoforms and PSA characteristics are discussed. Other 
interesting candidate markers are reviewed and extracellular vesicles (exosomes) are 
introduced.
The search for novel biomarkers has been the focus of many research groups, and the 
studies have become more extensive and sophisticated. Although exciting progress has 
been made with respect to novel technologies, discovery of protein markers in bodily 
fluids such as serum remains difficult. One of these problems is the presence of high 
abundant proteins which make discovery of promising low abundant proteins challeng-
ing (dynamic range problem). Even with current technologies, discovering biomarkers 
is still like searching for a needle in a haystack. This problem can be partially tackled by 
profiling of subfractions of bodily fluids such as extracellular vesicles (EVs, also referred 
to as exosomes). Chapter 3 gives an overview of relevant data that had been published 
at the start of the project regarding EVs, including their biogenesis, function and con-
tent in relation to PCa. The exact biogenesis of exosomes remains unclear, but they are 
formed inside a multi-vesicular body (MVB) and released when the MVB merges with the 
cell membrane. EVs have a wide range of function, mainly in the immune system. By pre-
senting antigens on their membrane they can interact with recipient cells. Furthermore, 
they have been shown to be able to transport proteins and RNAs. In the field of oncology 
much debate is going on about the pro- or antitumor effect. Most important techniques 
for isolation are ultracentrifugation, precipitation and immunoaffinity capture. Reports 
about profiling PCa-derived EVs are limited, but some have been profiled and this has 
led to the identification of some candidate markers. Although the number of publica-
tions is increasing, further investigations are required to assess the exact clinical values 
of EVs in prostate cancer.
Profiling content from PCa-derived EVs could reveal novel biomarkers. In chapter 4 
we report on proteomic profiling of PCa EVs. In collaboration with the Environmental 
188 Summary
Molecular Science Laboratory (EMSL) in Richland, WA, USA, we analysed EVs from two im-
mortalized primary prostate epithelial cells (PNT2C2 and RWPE-1) and two PCa cell lines 
(PC346C and VCaP) by using a nanoLC-LTQ-Orbitrap operated in tandem MS (MS/MS) 
mode. With this approach we identified 52 proteins that were statistically significantly 
different expressed, from which nine more abundant in EVs from PCa cell lines. From 
this list, three candidate markers (FASN, XPO1 and PDCD6IP) were selected. Validation 
by Western blotting confirmed their higher expression in PCa EVs. Interestingly, with 
immunohistochemistry we noticed that when Gleason score increased, the expression 
of XPO1 gradually went from the nucleus to the cytoplasm.
As described in the introduction, in order to elucidate the potential diagnostic and 
prognostic value of identified candidate markers, they need to be tested on patient 
samples. Chapter 5 describes the validation of FASN, XPO1 and PDCD6IP on large 
well-characterized patient cohorts. First, protein fractions from RNA isolations from 
67 samples (33 healthy individuals and 34 PCa patients) were analyzed by nanoLC-MS. 
Only XPO1 showed higher expression in PCa (p>0.0001). Subsequently we used a tissue 
micro array (TMA) containing 481 patient samples and immunohistochemically stained 
them for all three markers. When we correlated expression with multiple clinicopatho-
logical parameters, only high cytoplasmic XPO1 was correlated with high Gleason score 
(p=0.002) and prostate cancer related death (p=0.009). With this study we showed that 
XPO1 remains an interesting candidate marker for PCa.
In chapter 6 we used the same clinical samples as in chapter 5 for discovery of protein 
markers that are able to predict biochemical recurrence (BCR) after radical prostatecto-
my (RP), with a special interest in proteins that are involved in the arachidonic acid (AA) 
pathway. After proteomic profiling, 798 proteins were statistically significant expressed 
between samples from healthy men and men with PCa. From this list four proteins that 
were dysregulated in PCa, were selected for validation (AGR2, FASN, LX15B and LOX15). 
Immunohistochemistry showed that AGR2, LOX5 and LX15B was positive in PCa and 
negative/low positive in normal tissue. FASN showed higher expression when Gleason 
scores increased. When the same markers were validated on the TMA we observed that 
AGR2 expression was correlated with Gleason score (p=0.032). LOX5 expression in the 
cytoplasm was associated with higher pT stage (p=0.044). FASN showed no clinico-
pathological correlation. Kaplan-Meier curves revealed that <100% of positive tumor 
cells for AGR2 (HR (95% CI) = 0.61 (0.43-0.93) and also when LOX5 expression is present 
(HR (95% CI) = 2.53 (1.23-5.22) are predictors of BCR after RP.
Quantifying the number of EVs and characterizing them on single particle level 
remains challenging. Most techniques for isolation and characterization are labour 
intensive and limited with respect to efficient isolation or purity of the final EV prepara-
tion. In order to measure tissue-specific EVs from bodily fluids novel assays have to be 
developed. One technique that is of special interest is an immunoaffinity assay directed 
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against transmembrane proteins on EVs. In chapter 7 we describe the development 
and validation of a highly sensitive TR-FIA (time resolved fluorescence immunoassay) 
against CD9 and CD63. Cell medium from 37 cell lines and urine from patients with PCa 
(n=67), men without PCa (n=76) was analysed. As a control, urine was collected from 
men after radical prostatectomy (n=13), women (n=16) and patients with PCa without 
digital rectal exam (n=16). After optimisation, we showed that this TR-FIA was able to 
measure EVs with very high sensitivity and low background signals. CD9 and CD63 are 
present on EVs from all cell lines with huge variation between them. After correction 
of urinary PSA as surrogate for the amount of prostate fluid in the urine, expression of 
CD9 and CD63 was higher in patients with PCa. More PCa-specific antibodies need to 
be tested using this TR-FIA to discover the most optimal combination of diagnostic and 
prognostic PCa markers.
In this thesis we have shown that EVs, based on their biogenesis, are an interesting 
and valuable source for biomarker discovery. Proteomic profiling of PCa EVs led to the 
identification of three biomarkers. When validated on different independent patient 
sample cohorts, XPO1 and CD63/PSA remained as the most promising candidate 
biomarkers. More research is needed in order to fully elucidate it clinical potential. 
Unfortunately, current techniques for isolation and characterization of EVs are labour 
intensive, interfere with integrity/purity and lack scalability. Therefore, we developed a 
highly sensitive TR-FIA that was able to distinguish PCa from healthy men by applying 
100 uL urine. More PCa specific antibodies need to be tested to create an assay that has 
higher sensitivity and specificity. With such an assay, EVs in urine of serum could be used 
as a diagnostic, prognostic and disease monitoring markers.
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Prostaatkanker (PK) is de op twee na meest voorkomende maligniteit onder mannen. 
Jaarlijks krijgen 11.700 mannen in Nederland deze diagnose, waarvan ongeveer 2.800 
hieraan uiteindelijk overlijden. Huidige markers voor het opsporen van de ziekte, zoals 
bijvoorbeeld PSA, hebben een goede sensitiviteit, maar hebben te weinig specificiteit. 
Hierdoor krijgen te veel mannen onnodig de diagnose en bestaat er een kans op 
overbehandeling. Hierdoor zijn er nieuwe markers nodig die beter in staat zijn om de 
diagnose te stellen en prognose te bepalen.
Hoofdstuk 1 geeft een algemene introductie weer en bespreekt de doelstelling van 
dit proefschrift. Verder geeft dit hoofdstuk uitleg over wat een marker precies is en 
welke types er zijn. Ook de bron van deze marker (urine of bloed) wordt bediscussieerd. 
Stappen in de ontwikkeling van een marker naar de kliniek worden uiteengezet.
Wanneer men zoekt naar een nieuwe marker voor PK, is het belangrijk om te weten 
welke er al zijn beschreven in de literatuur. Hoofdstuk 2 geeft een overzicht van alle 
markers voor PK die tot dat moment bekend waren. In dit hoofdstuk wordt naast PSA 
(inclusief varianten en karakteristieken) en andere beschreven markers, blaasjes ofwel 
‘extracellular vesicles’ (EVs) geïntroduceerd.
Wereldwijd zijn er veel onderzoeksgroepen die zich richten op het ontdekken van 
nieuwe markers voor PK. Ondanks de vooruitgang omtrent technische ontwikkelin-
gen, blijft het ontdekken van deze markers uit bloed of urine een uitdaging. Een van 
de voornaamste problemen is het zogenaamde ‘dynamic range problem’. In urine en 
bloed zitten veel verschillende eiwitten en RNAs in sterk verschillende concentraties. De 
meest interessante markers zijn waarschijnlijk in een zeer lage concentratie aanwezig. 
Hierdoor worden ze overschaduwd door de veel voorkomende eiwitten/RNAs en kan 
men deze interessante markers lastig identificeren. Het is net als zoeken naar een ‘naald 
in een hooiberg’. Eén van de oplossingen zou het onderzoeken van EVs kunnen zijn. 
Hoofdstuk 3 geeft een overzicht van alle publicatie omtrent EVs, inclusief biogenese, 
functie en inhoud in relatie tot PK. Hoe EVs gemaakt worden is nog niet helemaal duide-
lijk, maar wel weten we dat ze worden gemaakt in zogenaamde ‘multi-vesicular bodies 
(MVB)’. Nadat deze MVB op gaat in het celmembraan, komen de EVs vrij. Buiten de cel 
hebben ze allerlei functies, voornamelijk in het afweersysteem. Door het presenteren 
van antilichamen kunnen ze interactie hebben met de ontvangende cel. Daarnaast 
kunnen ze eiwitten en RNA transporteren van de ene naar de andere cel. Binnen de 
oncologie is de rol van EVs nog onduidelijk waarbij ze soms pro- of antitumor effecten 
hebben. De belangrijkste technieken voor isolatie zijn ultracentrifugatie, precipitatie en 
via immuunaffiniteit. Het aantal publicaties over EVs en PK zijn beperkt, echter sommige 
hebben al kandidaat markers gevonden voor deze ziekte. Ook al neemt het aantal pu-
blicaties over dit specifieke onderwerp toe, er is meer onderzoek nodig om de klinische 
waarde van EVs beter te bepalen.
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Omdat EVs door hun biogenese een weergave zijn van de cel waarvan ze afkomstig 
zijn, zou het in kaart brengen van hun inhoud kunnen leiden tot het vinden van nieuwe 
markers. In hoofdstuk 4 hebben we eiwitten in EVs onderzocht. In samenwerking met 
het Environmental Molecular Science Laboratory (EMSL) in Richland, WA, USA, hebben 
we EVs geanalyseerd van twee prostaat epitheel cellijnen (PNT2C2 en RWPE-1) en twee 
PK-cellijnen (PC346C en VCaP) door een nanoLC-LC-LTQ-Orbitrap massaspectrometer 
te gebruiken. Met deze techniek hebben we 52 eiwitten gevonden die verschillend tot 
expressie kwamen, waarvan er negen hoger tot expressie kwamen in PK EVs. Van deze 
lijst werden drie kandidaat markers geselecteerd (FASN, XPO1 en PDCD6IP). Validatie 
met behulp van Western blotting bevestigde de hogere expressie in EVs afkomstig van 
PK. Wanneer we deze markers valideerden middels immuunhistochemie viel het op dat 
wanneer de Gleason score omhoogging, de expressie van XPO1 zich van de kern ver-
plaatste naar het cytoplasma. Dit gaf het idee dat translocatie van XPO1 geassocieerd 
zou kunnen zijn aan een slechtere klinische uitkomst.
Zoals beschreven in de introductie, moet men om de vertaling te maken van ont-
dekking naar een klinisch toepasbare marker, deze getest worden op patiëntmateriaal. 
Hoofdstuk 5 beschrijft de studie waarin we de drie eerder ontdekte kandidaat markers 
(FASN, XPO1 en PDCD6IP) hebben gevalideerd op materiaal van twee onafhankelijke 
grote groepen patiënten. In eerste instantie hebben we eiwitfracties van weefsel (na 
RNA-isolatie) genomen van 67 patiënten (33 gezonde mannen en 34 PK-patiënten) 
en deze geanalyseerd met een nano-LC massaspectrometer. In deze studie liet alleen 
XPO1 een hogere expressie zien in PK (p>0.0001). Hierna hebben we dezelfde markers 
immunohistochemisch getest in een ‘tissue microarray’ (TMA) die weefsel bevatte 
van 481 patiënten na radicale prostatectomie. Wanneer we de expressie vergeleken 
met meerdere klinische en pathologische uitkomsten was alleen XPO1 in cytoplasma 
gecorreleerd aan een hoge Gleason score (p=0.002) en aan PK-gerelateerd overlijden 
(p=0.009). Met deze studie hebben we laten zien dat XPO1 een interessante marker is 
voor PK.
In hoofdstuk 6 hebben we dezelfde klinische validatie sets gebruikt als in hoofdstuk 
5 om zo eiwitten, betrokken binnen het ‘Arachidonic acid pathway’, te valideren ten 
aanzien van een biochemisch recidief na radicale prostatectomie. In totaal werden 798 
eiwitten gevonden die statisch significant verschilden tussen gezond weefsel en PK. Uit 
deze list werden vier eiwitten gekozen die verhoogd tot expressie kwamen in PK (AGR2, 
FASN, LX15B en LOX15). Immuunhistochemie toonde dat AGR2, LOX5 en LX15B positief 
waren in PK en negatief/laag positief in normaal weefsel. FASN kwam hoger tot expres-
sie wanneer de Gleason score toename. Wanneer deze markers werden getest op de 
TMA, was AGR2 gecorreleerd aan een hogere Gleason score (p=0.032). LOX5 expressie in 
het cytoplasma bleek geassocieerd aan een hogere klinisch pT-stadium (p=0.044). FASN 
liet geen relatie zien met klinische of pathologische parameters. Kaplan-Meier analyse 
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toonde dat een laag percentage met positieve tumorcellen (<100%) voor AGR2 (HR (95% 
CI) = 0.61 (0.43-0.93) en ook aanwezige LOX5 expressie (HR (95% CI) = 2.53 (1.23-5.22) 
voorspellers waren voor een biochemisch recidief na radicale prostatectomie.
Kwantificatie van EVs en het karakteriseren op het niveau van een enkel blaasje blijft 
zelfs met nieuwe ontwikkelingen, zeer uitdagend. De meeste technieken die nu worden 
toegepast zijn tijdsintensief en beperkt in hun efficiëntie/behoudt van integriteit van de 
EVs. Om weefselspecifieke EVs uit urine of bloed te meten, moeten nieuwe en betere as-
says ontwikkeld worden. Een interessante techniek waarmee isolatie en karakterisatie in 
één assay gecombineerd zou kunnen worden is een (sandwich)-immuunaffiniteits assay 
gericht tegen transmembraameiwitten die tot expressie komen op EVs. In hoofdstuk 7 
beschrijven we de ontwikkeling en validatie van een hoog-sensitieve TR-FIA (‘time 
resolved fluorescence immunoassay’) tegen de transmembraameiwitten CD9 en CD63. 
Kweekmedium van 37 verschillende cellijnen en urine van PK-patiënten (n=67), mannen 
zonder PK (n=76). Ter controle namen we urine van mannen na een radicale prostatec-
tomie (n=13), vrouwen (n=16) en patiënten met PK, maar dan zonder prostaatmassage 
(n=16). Na optimalisatie toonde we aan dat deze assay met een hoge sensitiviteit en een 
zeer laag achtergrondsignaal, EVs kon meten. De expressie van CD9 en CD63 varieerde 
enorm tussen de verschillende cellijnen. In de klinische samples was de expressie van 
CD9 en CD63 hoger in urine van PK-patiënten (na correctie voor PSA in de urine). Meer 
PK-specifieke moeten in deze assay getest worden om zo de meest ideale combinatie 
voor diagnose en prognose voor PK te bepalen.
In dit proefschrift hebben we laten zien dat EVs, vanwege hun biogenese, een interes-
sante bron zijn voor het zoeken naar nieuwe markers voor PK. Het in kaart brengen van 
PK EVs heeft geleid tot de identificatie van meerdere kandidaat markers, waarvan XPO1 
en CD63/PSA overbleven na validatie op klinische patiënt weefsel. Meer onderzoek is 
nodig om de exacte klinische toepasbaarheid van deze marker vast te stellen. Omdat 
huidige technieken voor het isoleren en karakteriseren van EVs tijdsintensief zijn en niet 
in staat zijn om grote hoeveelheden samples te verwerken, moeten nieuwe technieken 
ontwikkeld worden. Wij hebben succesvol een zeer sensitieve TR-FIA ontwikkeld die in 
staat was om EVs te meten en onderscheid te maken tussen PK en gezonde mannen. 
Meer PK-specifieke antilichamen moeten in deze assay getest worden om een nog 
betrouwbaardere diagnose te stellen en de prognose beter te voorspellen. Met deze 
assay zouden EVs in de toekomst gebruikt kunnen worden als marker voor diagnostiek, 
prognose en ziekte beloop.
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AA Arachidonic acid
AGR2 Anterior gradient 2
AMACR Alpha-methylacyl coenzyme A racemase
AMT Accurate mass and time
APC Antigen presenting cell
AUC Area under curve
BCR Biochemical recurrence
BPH Benign prostate hyperplasia
BSA Bovine serum albumin
CAV1 Caveolin-1
CM Confocal microscopy
CRISP3 Cysteine-rich secretory protein 3
CRM1 Chromosomal maintenance 1
CRPC Castration resistant prostate cancer
DNA Deoxyribonucleic acid
DRE Digital rectal exam
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
EM Electron microscopy
EMSL Environmental and molecular science laboratory
ENO1 Enolase-1
ERSPC European randomized study of screening of prostate cancer
ESCRT Endosomal sorting complex responsible for transport
Eu Europium
EV Extracellular vesicles
FACS Fluorescence-activated cell sorting
FASN Fatty acid synthetase N
FCS Fetal calf serum
FDR False discovery rate
FFPE Formalin-fixed paraffin-embedded
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GOLPH2  Golgi phoshoprotein 2
GSTP1 Glutathione S-transferase pi 1
GWAS Genome wide association studies
HETE Hydroxyeicosatetraenoic acid
HPRD Human protein reference database
HRP Horse radish peroxidase
IHC Immunohistochemistry
IPA Ingenuity pathway analysis
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KLK2 Kallikrein 2
KLK3 Kallikrein 3
LC Liquid chromatography
LDHA Lactate dehydrogenase-A protein
LFQ Label free quantification
LOX5 Lipoxygenase 5
LX15B Arachidonate 15-lipoxygenase type B
MHC Major histocompatibility complex
mRNA Messenger RNA
MS Mass spectrometry
MVB Multivesicular body
MYO6 Myosin 6
NAP Normal adjacent prostate
P/S Penicillin/Streptomycin
PBS Phosphate buffered saline
PSA Prostate specific antigen
PCa Prostate cancer
PCA3 Prostate cancer antigen 3
PDCD6IP Programmed cell death 6 interacting protein
PRM Parallel reaction monitoring
PSCA  Prostate stem cell antigen
PSMA Prostate specific membrane antigen
qPCR  Quantitative polymerase chain reaction
RNA Ribonucleic acid
ROC Receiver operating characteristic
RP Radical prostatectomy
RPLC Reverse phase liquid chromatography
RT-PCR Reverse transcriptase PCR
SNP Single nucleotide polymorphisms
TMA Tissue micro-array
TRF  Time resolved fluorescence
TR-FIA Time resolved fluorescence immunoassay
TURP Transurethral resection of the prostate
UCr Urinary creatinine
UPSA Urinary prostate specific antigen
XPO1 Exportin-1
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Na ruim 10 jaar kan eindelijk de laatste bladzijde van dit proefschrift geschreven worden. 
Het is af. Dit werk heeft zich niet vanzelf geschreven waarbij ik tijdens de jaren in het 
lab, maar ook daarna, veel steun heb gehad. Hierdoor ben ik velen dank verschuldigd. 
Zonder jullie geen proefschrift!
Geachte prof. dr. ir. Jenster, beste Guido, toen ik voor het eerst bij je op bezoek kwam had 
ik helemaal niet de wens om basaal/celbiologisch onderzoek te willen gaan doen. Echter 
vanaf het eerste gesprek werd ik gepakt door jouw enthousiasme. De daaropvolgende 
jaren van intensieve samenwerking waren voor mij een geweldige ervaring waarin ik alle 
ruimte kreeg om mezelf te ontdekken en te ontwikkelen op wetenschappelijk niveau. 
Altijd was er de mogelijkheid tot het stellen van vragen over ons onderzoek, maar je was 
er ook als ik op zoek was naar een sociaal praatje of motivatie. Dank je wel dat je de gok 
hebt genomen om mij te willen begeleiden!
Geachte prof. dr. Bangma, beste Chris, tijdens mijn tijd in het Erasmus MC heb ik veel 
van je mogen leren. Nog steeds verwondert het me dat je een haarfijn gevoel hebt voor 
kliniek, (basaal) wetenschap en de translatie tussen die twee werelden. Jouw openheid, 
toegankelijkheid en kritische blik hebben absoluut bijgedragen aan een betere kwaliteit 
van dit werk. De persoonlijke noot tijdens congressen of op reis ervaarde ik als zeer 
prettig. Dank je wel voor al je tijd!
Geachte dr. Luider, beste Theo, vanaf het begin van mijn tijd in het lab hebben we 
regelmatig contact gehad. Mijn kennis over massaspectrometrie was vrijwel gelijk aan 
nul, maar jij hebt me samen met jouw team hierin begeleidt. Dank je wel voor jouw 
opmerkingen en stimulerende vragen tijdens het gehele proces.
Beste leden van de leescommissie en promotiecommissie, dank voor jullie kritische 
beoordeling van mijn proefschrift en jullie bereidheid plaats te nemen als opponent.
Beste co-auteurs, dank voor jullie samenwerking en input. Met z’n allen hebben we toch 
een fraai stukje werk neergezet.
Lieve mensen van de afdeling experimentele Urologie, dankzij jullie was het op het lab 
altijd bijzonder prettig werken. Mirella, dank je voor de fijne samenwerking, gezellig-
heid en alle tijd die je in mij geïnvesteerd hebt. Het zal niet altijd even gemakkelijk zijn 
geweest om iemand te begeleiden die nog nooit een pipet in zijn handen had gehad. 
Dank jullie voor alle hulp!
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Beste lab-onderzoekers, arts-onderzoekers en (opleidings-)assistenten, dank voor alle 
hulp en steun. Samen met jullie waren de koffie-momentjes (binnen de Nespresso-club 
of bij de SB) en het bezoeken van congressen altijd gezellig. Het was bijzonder om samen 
met jullie deel te nemen aan Alpe d’ Huzes in 2011 met het team ‘high riding prostate’!
Beste collega’s van het Erasmus MC en Amphia ziekenhuis, tijdens mijn opleiding ben 
ik (helaas) niet veel aan wetenschap toegekomen. Daarentegen hebben jullie mij altijd 
positief gestimuleerd om hier wel mee door te gaan en het toch een keer af te maken. 
Jullie hebben mijn opleiding leuk en leerzaam gemaakt.
Beste collega’s van het CWZ, ook al hebben jullie me weinig meegemaakt tijdens mijn 
promotie, toch mijn dank voor de fijne start in Nijmegen. Mijn aandachtsgebied is niet 
meer gerelateerd aan het onderwerp van mijn proefschrift, desalniettemin kijk ik er 
bijzonder veel naar uit om de komende tijd met jullie te mogen samenwerken.
Geachte drs Lock, beste Tycho, jij stond aan de basis van mijn carrière binnen de urolo-
gie. Vanaf dag één heb je mij op veel manieren kennis laten maken met de kliniek, maar 
ook met de beginselen van het onderzoek doen. Dank je wel voor alle tijd die je voor mij 
hebt vrijgemaakt.
Beste Robert, Dennis en Daan, sinds het begin van Geneeskunde trekken we met elkaar 
op en zijn we gelukkig nog steeds goed bevriend. We zien elkaar niet zeer frequent, 
maar de avondjes bier drinken doen mij veel goed. Dank voor jullie vriendschap!
Beste Martijn en Richard, vrienden van het eerste uur. Martijn, jouw voorstel aan mijn 
ouders om het huis te kopen naast jouw ouders, is een gouden zet geweest. Tijdens al 
die jaren is er een vriendschap ontstaan die ik bijzonder veel koester. Richard, het begon 
op de middelbare school, maar onze vriendschap hebben we voortgezet toen we samen 
in het studentenhuis op de Hessenweg in de Bilt gingen wonen. Vele avonden volgden 
met eten, bier en eindeloze (onzinnige) discussies. Nog steeds kan ik hier bijzonder veel 
van genieten. Ik kan me geen fijnere vrienden voorstellen. Voor mij volkomen logisch 
dat jullie mijn paranimfen zijn!
Lieve Hanneke, Pauline, Jurriaan, Sara, Elise, Alejandro, Lianne, Jantine, Nick en Erik, jullie 
zijn zondermeer de fijnste schoonfamilie die ik had kunnen wensen. Zo druk als het is als 
we bij elkaar zijn, zo veel ontspanning geven jullie mij. Gelukkig geen lange gesprekken 
over mijn onderzoek, maar vooral veel plezier en lekker samen zijn.
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Lieve Mama, Ruud, Yasmijn, Bente, Ramon en Erin, jullie zijn en blijven de basis waar 
alles begonnen is. Dank voor jullie support. Het is niet altijd even leuk of gemakkelijk 
geweest, maar met elkaar kunnen we alles aan! Het is een bijzonder prettig gevoel dat 
ik onderdeel ben van ons gezin.
Lieve Christine, zo onzeker als de toekomst is over de bevindingen in dit proefschrift, 
zo zeker ben ik over onze toekomst samen. Jij bent en blijft de beste ‘ontdekking’ die ik 
ooit heb gedaan. Als mooi resultaat van onze liefde hebben Benjamin, Puk en Dex zich 
aangesloten bij ons gezin. Jij geeft me de kracht, energie en ruimte om te zijn wie ik ben. 
Ik ben heel dankbaar dat ik samen met jou mag zijn. Ik hou van je!
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Diederick was born on July 19th 1984 in 
Vlissingen, the Netherlands. He obtained 
his high school diploma (VWO) in 2002 and 
started with his medical training at Utrecht 
University. During medical school he became 
interested in Urology which resulted in multi-
ple (inter)national publications and a clinical 
elective Urology at Groote Schuur Hospital, 
Cape Town, South-Africa. After graduating 
in December 2008 he started his 3-year PhD 
training in January 2009 at the Erasmus Medi-
cal Center under supervision of prof. dr. ir. Jenster. During his PhD training he worked in 
the US and Finland and has given multiple national and international presentations. At 
the end of his PhD training he worked as a medical doctor at the department of Urology 
at the Erasmus Medical Center. Subsequently he was accepted for his Urology training. 
From 2012-2013 he worked at the department of general surgery at the Sint Franciscus 
Gasthuis in Rotterdam (supervisor: dr. G.H. Mannaerts). The academical part of his Urol-
ogy training was performed from 2014-2015 at the department of Urology at the Eras-
mus Medical Center in Rotterdam (supervisor: dr. P.C.M.S Verhagen). From 2016-2017 
he completed his training at the department of Urology at Amphia Hospital in Breda 
(supervisor: dr. D.K. van der Schoot). Throughout his Urology training he has also worked 
as treasurer and secretary of the European Society of Residents in Urology (ESRU). From 
July 1st 2017 he began his career as a Urologist at the Canisius Wilhelmina Hospital in 
Nijmegen, where he focusses on endo-urology, stone treatment and laparoscopy.

 PhD portfolio

PhD portfolio 221
Name PhD student: Diederick Duijvesz
Erasmus MC Department: Urology
Research Schools: Molecular Medicine (MolMed)
PhD period: January 2009 – December 2011
Promoter: prof. dr. ir Jenster
Co-promotor: dr. Luider
Year Workload 
(ECTS)
General courses
Biomedical research techniques 2009 1.6
Course Advanced Medical Imaging (AMIE) for physicians 2009 0.25
Course Scientific English Writing 2010 4.0
Workshop Photoshop CS3 2010 0.25
Course Research Management 2010 1.0
Course Integrity in Research 2010 2.0
Workshop Successful Grant Writing 2010 0.5
Course Introduction to Data-analysis (NIHES) 2010 1.0
Course Basic and Translational Oncology 2010 1.8
Training outside department
3-week training mass spectrometry, EMSL, Richland, Washington VS 2009 3.0
2-week training immune affinity assays, Department Diagnostics Technologies and 
Applications, Turku, Finland
2011 2.0
Seminars and workshops
JNI oncology lectures 2009-2011 2.0
Department Journal Club 2009-2011 2.0
Department research presentation / PhD meeting 2009-2011 2.0
Department refereeravond 2009-2011 2.0
Symposium ‘Multidisciplinaire behandeling prostaatkanker’ 2009-2011 0.25
Urology EAU and AUA review meetings 2009-2011 1.0
NVU voor- en najaarsvergadering 2009-2011 1.0
Presentations
Oral presentation at Josephine Nefkens Institute (JNI), three times 2010-2011 1.0
Oral presentation scientific lab meetings, 12 times 2009-2011 5.0
Oral presentation lecture evening Erasmus MC (for medical doctors), two times 2010-2011 1.0
Oral presentation PhD meeting urology (promovendi-avond), two times 2010-2011 1.0
Oral presentation ‘Wetenschapslunch’ Urology & Gynaecology 2010 0.5
Invited lecturer for course ‘Biomarker Discovery using old and new technologies’, 
Turku, Finland
2010 0.5
International conferences
222 PhD portfolio
Poster presentation, PCTRE, Amsterdam, the Netherlands 2009 0.5
Poster presentation, SBUR, New Orleans, USA  2009 1.0
Poster presentation, MolMed-day, Rotterdam, the Netherlands 2010 0.5
Poster presentation, ESUR, Vilnius, Lithuania 2010 0.5
Micro and nanovesicles, Oxford, UK 2010 0.5
Poster presentation, KWF SOTO, Ede, the Netherland 2010 0.5
Oral presentation, SEOHS, Rotterdam, the Netherland 2010 0.5
Oral Presentation, IWE, Paris, France 2011 0.5
Oral and poster presentation, EAU, Vienna, Austria 2011 1.0
Poster presentation, WBUR, Innsbruck, Austria 2011 1.0
Oral presentation, EAU, Paris, France 2012 1.0
Poster presentation, AUA, Atlanta, USA 2012 1.0
Oral and poster presentation, ISEV, Gothenborg, Sweden 2012 1.0
Poster presentation, ISEV, Rotterdam, the Netherlands 2014 0.5
Oral and poster presentation, EAU, Madrid, Spain 2016 1.0
Teaching activities
Yin Versluis, student master Molecular Science, 1 year 2010 5.0
Nilab Naïma, HLO-student, 7 months 2011 3.0
Saeid Alinezhad, PhD-student, 2 weeks 2011 0.5
Liton Ferdhon, PhD-student, 2 weeks 2011 0.5
Course ‘anatomy of the male urological and reproductive tract’ for medical students 2010-2011 1.5
Course ‘basic research’ for medical students 2010 0.5
Teaching urological procedures to OR staff 2009-2015 2.0
Extra activities
MolMed day, organizing committee 2010-2011 3.0
PhD committee MolMed school 2010-2011 1.0
Educational committee MolMed school 2010-2011 1.0
Board European Society of Residents in urology (ESRU)
Treasurer (2013-2016) and secretary (2017-2018)
2013-2018
JNI party committee 2010
Organization departmental ‘day-out’ 2011
Participation Alpe d’HuZes fundraising activity, Alpe d’Huez, France 2011
Awards
KWF-Travel grant 2009
EMSL 1 year extension award 2009
Rene Vogels Stipendium Travel grant 2010
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EMSL 1 year extension award 2010
Nominated for PhD of the year 2010
Publication of the year EAU – Residents corner
(Duijvesz D. et al, Eur Urol. 2011. 59(5):823-31)
2012
